|
Genscript Biotech Corporation is a biotechnology company operating through three main platforms. GenScript Life Science Group provides life-science services and products, including gene-to-protein solutions, DNA synthesis, and protein expression for global research communities. ProBio offers end-to-end CRDMO services for biologics development, covering drug discovery through commercialization for modalities such as viral vectors, DNA, RNA, antibodies, and proteins. Bestzyme develops and produces industrial enzymes and functional proteins for applications in biofuel, food and beverage, distilling, starch, household care, textile, and animal feed industries. The company serves customers primarily in North America, Europe, the PRC, and other Asia Pacific regions. It holds an investment in Legend Group and generates license revenue from LaNova. Summarised from the company's own disclosures, fiscal year ended Apr 2026 |
Industry Biotechnology | Homepage genscript.com |
| Sector Healthcare | IR page — | |
|
Tags
dna synthesis, crdmo services, industrial enzymes, antibody discovery, protein expression, synthetic biology, biologics development, life science services, GenScript Life Science Group, ProBio, Bestzyme, LaNova, Legend Group
|
Press page genscript.com/special/press-release |
Metrics
| Valuation | |
|---|---|
| Market cap | HK$ 68.88B |
| Market cap (USD) | $ 8.778B |
| P/E | -13.79 |
| PEG | — |
| P/BV | 2.16 |
| P/S | 10.39 |
| P/OCF | 62.89 |
| P/FCF | — |
| Dividend yield | — |
| Turnover / mcap | 0.88% |
| Returns | |
|---|---|
| ROE | -12.9% |
| ROI | -12.8% |
| ROIC | -12.8% |
| Profit margin | -55.5% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | No |
| Revenue up 3y | No |
| Revenue up 5y | No |
| Earnings growth 3y (net profit CAGR) | — |
| Quality | |
|---|---|
| Profitable | No |
| Margin expanding | No |
| Buying back stock | No |
| Diluting (TTM) | Yes |
| Debt/Equity | 5.0% |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 0 |
| Quality score | -75.0% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 959.526M | 594.486M | 839.529M | 304.677M | 511.062M | 390.846M | 273.354M | 231.017M | 152.649M | 114.735M | 86.709M | 69.994M |
| Net profit | -532.83M | 2.962B | -95.477M | -131.202M | -347.865M | -204.945M | -96.912M | 21.216M | 26.123M | 26.17M | 17.504M | 6.175M |
Podcast Mentions
Announcements and reports published on HKEXnews, newest first, monthly and next-day returns, proxy forms and board-meeting notices included. The link opens the announcement on HKEXnews. Press releases from the company's own website, newest first.
This is a voluntary announcement made by Genscript Biotech Corporation (the “Company”). Reference is made to the announcements of the Company dated 14 April 2026 and 15 July 2026 in relation to the preliminary sales of CARVYKTI® for the quarters ended 31 March 2026 and 30 June 2026. The board of directors (the “Board”) of the Company is pleased to announce that Legend Biotech Corporation (“Legend”), an associate of the Company, whose shares are listed by way of American Depositary Shares on the Nasdaq Global Select Market in the United States (“U.S.”), has filed a Form 6K with the United States Securities and Exchange Commission (the “SEC”) on 13 October 2026 (New York time) (after trading hours on 13 October 2026 in Hong Kong) and announced that CARVYKTI® generated approximately US$710 million in net trade sales during the quarter ended 30 September 2026. This is pursuant to the Collaboration and License Agreement dated 21 December 2017 between Legend and Janssen Biotech, Inc. (“Janssen”). The net trade sales figure is based on information provided to Legend by Janssen, and neither Legend nor the Company have independently verified the accuracy of such sales figure. For details, please refer to the full Form 6-K as published on the SEC’s website available at https://www.sec.gov/Archives/edgar/data/1801198/000117184326006593/0001171843-26-006593index.htm. Cautionary Note Regarding Forward-Looking Statements Statements in this announcement about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to CARVYKTI®, including Legend’s expectations for net trade sales and resulting gross profit of CARVYKTI®. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Legend’s expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including as a result of additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays, including 1
requests for additional safety and/or efficacy data or analysis of data, or government regulation generally; unexpected delays as a result of actions undertaken, or failures to act, by Legend’s third party partners; uncertainties arising from challenges to Legend’s patent or other proprietary intellectual property protection, including the uncertainties involved in the U.S. litigation process; competition in general; government, industry, and general public pricing and other political pressures; as well as the other factors discussed in the “Risk Factors” section of the Legend’s Annual Report on Form 20-F filed with the Securities and Exchange Commission on 10 March 2026. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this announcement as anticipated, believed, estimated or expected. Any forward-looking statements contained in this announcement speak only as of the date of this announcement. The Company specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. This announcement has been issued in the English language with a separate Chinese language translation. If there is any inconsistency or ambiguity between the English version and the Chinese version, the English version shall prevail. Shareholders and potential investors of the Company are advised to pay attention to investment risks and exercise caution when they deal or contemplate dealing in the securities of the Company. By order of the Board Genscript Biotech Corporation Robin Meng Chairman and Executive Director Hong Kong, 13 October 2026 As at the date of this announcement, the executive Directors are Mr. Jiange Meng (“Mr. Robin Meng”), Dr. Fangliang Zhang (“Dr. Frank Zhang”), Dr. Li Zhu and Ms. Ye Wang (“Ms. Sally Wang”); and the independent non-executive Directors are Mr. Yiu Leung Andy Cheung (“Mr. Andy Cheung”), Mr. Jiuan Pan (“Mr. Ethan Pan”), Dr. John Quelch, Dr. Ross Grossman and Dr. Chenyang Shi (“Dr. Victor Shi”).
2
GenScript Launches Life Sciences Startup PitchFest with NVIDIA to Accelerate Biotech Innovation
Oct 08, 2026
Inaugural competition will connect emerging AI life sciences platforms with validation expertise, investors, and ecosystem partners during JPM Week
PISCATAWAY, N.J. and SANTA CLARA, Calif., Oct. 8, 2026 - GenScript Biotech Corporation today announced the GenScript and NVIDIA Life Sciences Startup PitchFest , a global competition for startups applying artificial intelligence to therapeutic discovery and life sciences. The program brings together GenScript's wet lab validation and data generation capabilities and NVIDIA's accelerated computing platforms and startup ecosystem to help selected companies advance AI-driven platforms toward biological proof, investor engagement, and industry visibility.

Applications are now open for the GenScript and NVIDIA Life Sciences Startup PitchFest.
Up to six finalists will be selected for a GenScript-hosted pitch event during JPM Week in January before a panel of judges. The winning company will receive GenScript wet lab data credits and Brev credits from NVIDIA to support its development efforts. Applications opened today, and finalists will be confirmed in December.
AI is making therapeutic discovery more expansive than ever, giving scientists new ways to generate hypotheses, identify targets, and design candidates at unprecedented speed. The PitchFest is designed to channel that momentum by connecting emerging AI drug discovery and life science companies with investors, technology leaders, and partners focused on turning computational predictions into biological proof. The competition will feature startups developing technologies such as AI-driven antibody and protein design, as well as technologies that accelerate the design-build-test-learn cycle.
"To harness the true potential of AI in life sciences, we must build an ecosystem where world-class computation meets trusted, scalable biological validation," said Ray Chen, President of GenScript Life Science Group. "Success in this space requires a connected pathway that brings together data, experimental evidence, and investment to help innovators move with confidence from computational promise to therapeutic progress. PitchFest gives digital biology startups integrated support to rapidly test their models, generate evidence, and accelerate breakthrough therapies."
Through the competition, GenScript will contribute sequence-to-data capabilities and experimental validation expertise, while NVIDIA will provide access to NVIDIA Inception , its free program that helps startups build, scale, and connect across the NVIDIA platform and ecosystem. Together, GenScript and NVIDIA will help selected startups move from promising AI-driven concepts toward stronger biological evidence, investor readiness, and potential partnerships.
Finalists will also be invited to GenScript's Biotech Global Forum , where they can engage with biotechnology executives, strategic partners, and industry leaders focused on the future of AI-enabled discovery.
Additional details on judging criteria, speakers, and investor participation will be announced in the coming weeks as the program helps AI-driven life science startups generate evidence, build industry relationships, and accelerate their own commercialization journeys.
About GenScript Biotech Corporation
Founded in 2002 in New Jersey, GenScript Biotech Corporation accelerates innovation in biotech and healthcare by providing researchers and companies with the building blocks needed to develop groundbreaking treatments and products. As a cornerstone of the global life science ecosystem, GenScript actively collaborates with a diverse network of partners – from academic institutions to industry leaders – to co-create cutting-edge solutions that redefine service excellence. Guided by its mission to Make People and Nature Healthier Through Biotechnology, GenScript has become a trusted global partner with a team of 6,100+ employees, supporting over 200,000 customers across 100+ countries and regions, including the world's Top 20 pharma companies. For more information: www.genscript.com .
Media Contacts:
Kate Grusich, GenScript Biotech Corporation
[[email protected]](mailto: [email protected])
Service & Products
Resource
Tools
About us
Company News
About Us
Overview
GenScript Biotech Corporation is the world’s leading technology and service provider of life Science R&D and manufacture. Built upon its solid gene synthesis, we strives to become the most trustworthy biotech company in the world, and to make people and nature healthier through biotechnology.
Read more latest company news, industry conference, and peer-reviewed publications.



Service & Products
Resource
Tools
About us
FF301
Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities For the month ended:
30 September 2026
Status: New Submission
To : Hong Kong Exchanges and Clearing Limited Name of Issuer:
Genscript Biotech Corporation
Date Submitted:
06 October 2026
I. Movements in Authorised / Registered Share Capital
- Class of shares
Ordinary shares
Type of shares
Stock code (if listed)
01548
Description
Not applicable
Number of authorised/registered shares Balance at close of preceding month Increase / decrease (-) Balance at close of the month
Listed on the Exchange (Note 1)
Par value
5,000,000,000 USD 0 5,000,000,000 USD Total authorised/registered share capital at the end of the month: USD
Page 1 of 10
Yes
Authorised/registered share capital 0.001 USD
5,000,000
USD
0
0.001 USD
5,000,000 5,000,000
v 1.2.1
FF301
II. Movements in Issued Shares and/or Treasury Shares and Public Float Sufficiency Confirmation
- Class of shares
Ordinary shares
Type of shares
Stock code (if listed)
01548
Description
Not applicable
Number of issued shares (excluding treasury shares) Balance at close of preceding month Increase / decrease (-) Balance at close of the month
Listed on the Exchange (Note 1)
Number of treasury shares
Yes
Total number of issued shares
2,200,591,697
0
83,079,029
0
2,283,670,726
0
2,200,591,697
2,283,670,726
Public float sufficiency confirmation (Note 4) Pursuant to Main Board Rule 13.32D(1) or 19A.28D(1) / GEM Rule 17.37D(1) or 25.21D(1), we hereby confirm that, in relation to the class of shares as set out above, as at the close of the month: ✔ the applicable public float requirement (see below) has been complied with the applicable public float requirement (see below) has not been complied with The applicable minimum public float requirement for the class of shares as set out above pursuant to Main Board Rule 13.32B or 19A.28B / GEM Rule 17.37B or 25.21B (as the case may be) is: Applicable public float threshold
Initial Prescribed Threshold - 25% of the total number of issued shares in the class to which the listed shares belong (excluding treasury shares)
Additional information
Page 2 of 10
v 1.2.1
FF301
III. Details of Movements in Issued Shares and/or Treasury Shares (A). Share Options (under Share Option Schemes of the Issuer)
- Class of shares
Ordinary shares
Type of shares
Stock code (if listed)
01548
Description
Particulars of share option scheme
1).
Number of share options outstanding at close of preceding month
Post-IPO Share Option Scheme
General Meeting approval date (if applicable)
Not applicable
Number of share options outstanding at close of the month
Movement during the month
15,741,452 Exercised - new shares involved
Listed on the Exchange (Note 1)
9,788,423
-5,953,029
Yes
Number of treasury Number of new shares shares transferred out of issued during the month treasury during the pursuant thereto (A1) month pursuant thereto (A2)
5,953,029
The total number of Number of shares which shares which may be may be issued or issued or transferred out transferred out of of treasury upon treasury pursuant exercise of all share thereto as at close of options to be granted the month under the scheme at close of the month
0
9,788,423
190,403,529
07 December 2015
Increase in issued shares (excluding treasury shares):
5,953,029
Ordinary shares (AA1)
Decrease in treasury shares:
0
Ordinary shares (AA2)
Total funds raised during the month from exercise of options: HKD
Page 3 of 10
85,328,525.85
v 1.2.1
FF301 (B). Warrants to Issue Shares of the Issuer
Not applicable
Page 4 of 10
v 1.2.1
FF301 (C). Convertibles (i.e. Convertible into Shares of the Issuer)
Not applicable
Page 5 of 10
v 1.2.1
FF301 (D). Any other Agreements or Arrangements to Issue Shares of the Issuer, including Options (other than Share Option Schemes)
Page 6 of 10
Not applicable
v 1.2.1
FF301 (E). Other Movements in Issued Shares and/or Treasury Shares
- Class of shares
Ordinary shares
Type of shares
Stock code (if listed)
01548
Description At price (if applicable)
Events Currency 1).
Placing/subscription - new shares involved
HKD
Not applicable
Date of event (Note 2)
Listed on the Exchange (Note 1)
General Meeting approval date (if applicable)
Increase/ decrease (-) in issued shares (excluding treasury shares) during the month pursuant thereto (E1)
05 June 2026
77,126,000
Yes
Increase/ decrease (-) in treasury shares during the month pursuant thereto (E2)
Number of shares redeemed or repurchased for cancellation but not yet cancelled as at close of the month (Note 3)
Amount 30.5 15 September 2026
Increase/ decrease (-) in issued shares (excluding treasury shares): Increase/ decrease (-) in treasury shares:
77,126,000
Ordinary shares (EE1) Ordinary shares (EE2)
Total increase/ decrease (-) in issued shares (excluding treasury shares) during the month (i.e. Total of AA1 to EE1):
83,079,029
Ordinary shares
Total increase/ decrease (-) in treasury shares during the month (i.e. Total of AA2 to EE2):
0
Ordinary shares
Page 7 of 10
v 1.2.1
FF301
IV. Information about Hong Kong Depositary Receipt (HDR)
Not applicable
Page 8 of 10
v 1.2.1
FF301
V. Confirmations
Not applicable
Submitted by:
Jiange MENG
Title:
Director (Director, Secretary or other Duly Authorised Officer)
Page 9 of 10
v 1.2.1
FF301 Notes 1.
The Exchange refers to The Stock Exchange of Hong Kong Limited.
In the case of repurchase of shares (shares repurchased and cancelled) and redemption of shares (shares redeemed and cancelled), "date of event" should be construed as "cancellation date". In the case of repurchase of shares (shares held as treasury shares), "date of event" should be construed as "date on which shares were repurchased and held by the issuer in treasury".
The information is required in the case of repurchase of shares (shares repurchased for cancellation but not yet cancelled) and redemption of shares (shares redeemed but not yet cancelled). Please state the number of shares repurchased or redeemed during the month or in preceding month(s) but pending cancellation as at close of the month as a negative number.
"Initial Prescribed Threshold”, "Alternative Threshold” and "market value" have the meanings ascribed thereto under Main Board Rule 13.32A or 19A.28A / GEM Rule 17.37A or 25.21A. See also Main Board Rule 13.32D(4) or 19A.28D(4) / GEM Rule 17.37D(4) or 25.21D(4) on the basis of the public float disclosure.
Items (i) to (viii) are suggested forms of confirmation. The listed issuer may amend the item(s) that is/are not applicable to meet individual cases. Where the issuer has already made the relevant confirmations in a return published under Main Board Rule 13.25A / GEM Rule 17.27A in relation to the securities issued, or the treasury shares sold or transferred, no further confirmation is required to be made in this return.
“Identical” means in this context: .
the securities are of the same nominal value with the same amount called up or paid up;
.
they are entitled to dividend/interest at the same rate and for the same period, so that at the next ensuing distribution, the dividend/interest payable per unit will amount to exactly the same sum (gross and net); and
.
they carry the same rights as to unrestricted transfer, attendance and voting at meetings and rank pari passu in all other respects.
Page 10 of 10
v 1.2.1
The board (the “Board”) of directors (the “Directors”) of Genscript Biotech Corporation (the “Company”) hereby announces that the board lot size of the Company’s issued ordinary shares (the “Share(s)”) trading on the Main Board of The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) will be changed from 2,000 Shares (the “Existing Board Lot Size”) to 1,000 Shares (the “New Board Lot Size”) with effect from 9:00 a.m. on Wednesday, 14 October 2026 (the “Change in Board Lot Size”). The Change in Board Lot Size will not affect any of the relative rights of the Company’s shareholders (the “Shareholders”). Based on the closing price of HK$41.40 per Share as quoted on the Stock Exchange as at the date of this announcement, the market value of the Existing Board Lot Size is approximately HK$82,800, and the market value of the New Board Lot Size is approximately HK$41,400. The Change in Board Lot Size will directly reduce the value of each board lot by half, thereby lowering the minimum transaction value for trading of the Shares. The Board is of the view that the lower board lot value may make the Shares more accessible to a wider range of investors and facilitate trading of the Shares, which may in turn improve the liquidity of the Shares. Therefore, the Change in Board Lot Size is in the interests of the Company and the Shareholders as a whole. As the New Board Lot Size is an integral divisor of the Existing Board Lot Size, no new odd lots of the Shares will be created as a result of the Change in Board Lot Size. Having consulted with the Share Registrar (as defined below), no odd lot arrangement or matching service for the sales and purchase of odd lots of the Shares will be made by the Company in connection with the Change in Board Lot Size. EXPECTED TIMETABLE The expected timetable for the Change in Board Lot Size is set out below, where all times and dates refer to Hong Kong local times and dates:
1
Event
Time and date
Publication of this announcement on the Change in Board Lot Size .......................................................... Monday, 21 September 2026 First day for free exchange of the existing share certificates in board lots of 2,000 Shares for the new share certificates in board lots of 1,000 Shares ................................... Tuesday, 29 September 2026 Last day for trading in the Shares in board lots of 2,000 Shares in the original counter ............................................ Tuesday, 13 October 2026 Effective date of the Change in Board Lot Size ............................ Wednesday, 14 October 2026 Original counter for trading in the Shares in board lots of 2,000 Shares becomes counter for trading in the Shares in board lots of 1,000 Shares................................9:00 a.m. Wednesday, 14 October 2026 Temporary counter for trading in the Shares in board lots of 2,000 Shares opens ................................................................................... 9:00 a.m. Wednesday, 14 October 2026 First day of parallel trading in the Shares (in board lots of 1,000 Shares and 2,000 Shares) ................................................................9:00 a.m. Wednesday, 14 October 2026 Temporary counter for trading in the Shares in board lots of 2,000 Shares closes .................................................................... 4:10 p.m. Wednesday, 4 November 2026 Last day of parallel trading in the Shares (in board lots of 1,000 Shares and 2,000 Shares) ............................................................ 4:10 p.m. Wednesday, 4 November 2026 Last day for free exchange of the existing share certificates in board lots of 2,000 Shares for the new share certificates in board lots of 1,000 Shares ...................................................... 4:30 p.m. Friday, 6 November 2026 All dates or deadlines specified in the expected timetable above are indicative only and may be varied by the Company. Any consequential changes to this expected timetable will be notified to the Shareholders by way of announcement as and when appropriate.
2
FREE EXCHANGE OF SHARE CERTIFICATES The Shareholders may submit their existing share certificates in board lots of 2,000 Shares to the Company’s branch share registrar and transfer office, Computershare Hong Kong Investor Services Limited, located at Shops 1712–1716, 17/F, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong (the “Share Registrar”) in exchange for new share certificates in board lots of 1,000 Shares free of charge during business hours (i.e. 9:00 a.m. to 4:30 p.m.) from Tuesday, 29 September 2026 to Friday, 6 November 2026 (both days inclusive). After the expiry of the aforesaid period, the existing share certificates will be accepted for exchange only upon payment of a fee of HK$2.50 (or such higher amount as may from time to time be specified by the Stock Exchange) for each new share certificate issued in board lot of 1,000 Shares or each existing share certificate submitted, whichever number of share certificates involved is higher. It is expected that the new share certificates will be available for collection by the Shareholders from the Share Registrar within ten business days after delivery of the existing share certificates to the Share Registrar for exchange purposes. As from Wednesday, 14 October 2026, any new share certificates will be issued in board lots of 1,000 Shares each (except for odd lots of the Shares or where the Share Registrar is otherwise instructed). All the existing share certificates in board lots of 2,000 Shares will continue to be evidence of legal title to such Shares and be valid for transfer, delivery and settlement purposes. Save and except for the change in the number of Shares represented by each board lot and the logo of the Company, the new share certificates will have the same form as the existing share certificates. The new share certificates will retain the same blue colour as the existing share certificates. The Shareholders and potential investors of the Company should exercise caution when dealing in the Shares, and if they are in any doubt about their position, they should consult their professional advisers. This announcement has been issued in the English language with a separate Chinese language translation. If there is any inconsistency or ambiguity between the English version and the Chinese version, the English version shall prevail.
By order of the Board Genscript Biotech Corporation Robin Meng Chairman and Executive Director
Hong Kong, 21 September 2026 As at the date of this announcement, the executive Directors are Mr. Jiange Meng (“Mr. Robin Meng”), Dr. Fangliang Zhang (“Dr. Frank Zhang”), Dr. Li Zhu and Ms. Ye Wang (“Ms. Sally Wang”); and the independent non-executive Directors are Mr. Yiu Leung Andy Cheung (“Mr. Andy Cheung”), Mr. Jiuan Pan (“Mr. Ethan Pan”), Dr. John Quelch, Dr. Ross Grossman, and Dr. Chenyang Shi (“Dr. Victor Shi”).
3
This announcement is made by Genscript Biotech Corporation (the “Company,” together with its subsidiaries, the “Group”) at the request of The Stock Exchange of Hong Kong Limited (the ‘‘Stock Exchange’’) pursuant to Rule 13.10 of the Rules Governing the Listing of Securities on the Stock Exchange. The board of directors of the Company (the “Board”) has noted the increase in the price and trading volume of the shares of the Company (the “Shares”) today. The Board wishes to provide the shareholders of the Company (the “Shareholders”) and potential investors with the following update on recent business developments of the Group. The Company has entered into an agreement to join Lilly TuneLab™ (“TuneLab”) (the “Agreement”), a collaborative AI-enabled (AI/ML) drug discovery platform created by Eli Lilly and Company (“Lilly”), a multinational pharmaceutical company listed on the New York Stock Exchange (stock code: LLY). Under the Agreement, the Group will offer preferred-rate wet lab services to TuneLab member companies to generate experimental data and translate AIgenerated predictions into biological evidence. The Board notes the Agreement further expands the Group’s engagement with the rapidly growing AI-enabled drug discovery ecosystem and is aligned with its strategy of supporting biopharmaceutical innovation through integrated research and development solutions. The Board further confirms that the Agreement does not constitute inside information of the Company under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “SFO”). Having made such enquiries with respect to the Company as are reasonable in the circumstances, the Board confirms that, save as disclosed in this announcement, as of the time of this announcement, it is not aware of any reasons for the movements in the price and trading volume of the Shares, nor is it aware of any inside information that needs to be disclosed under Part XIVA of the SFO.
1
The Shareholders and potential investors of the Company are advised to carefully consider all relevant investment information and exercise caution when they deal or contemplate dealing in the securities of the Company.
By order of the Board Genscript Biotech Corporation Robin Meng Chairman and Executive Director
Hong Kong, 17 September 2026 As at the date of this announcement, the executive Directors are Mr. Jiange Meng (“Mr. Robin Meng”), Dr. Fangliang Zhang (“Dr. Frank Zhang”), Dr. Li Zhu and Ms. Ye Wang (“Ms. Sally Wang”); and the independent non-executive Directors are Mr. Yiu Leung Andy Cheung (“Mr. Andy Cheung”), Mr. Jiuan Pan (“Mr. Ethan Pan”), Dr. John Quelch, Dr. Ross Grossman, and Dr. Chenyang Shi (“Dr. Victor Shi”).
2
The board (the “Board”) of directors (the “Directors”) of Genscript Biotech Corporation (the “Company”) hereby announces with deepest sorrow that Dr. Alphonse Galdes (“Dr. Galdes”), an independent non-executive Director and a member of the audit committee (the “Audit Committee”) of the Company, was confirmed passing away on 13 September 2026 (Hong Kong Time). Dr. Galdes had served the Board as an independent non-executive Director since September 2024. The Board records its profound appreciation for Dr. Galdes’s invaluable guidance and distinguished contributions to the Company throughout his tenure. On behalf of the Company, the Board also conveys its sincere condolences to the family of Dr. Galdes. CHANGE IN COMPOSITION OF BOARD COMMITTEES The Board further announces the following changes in the composition of the committees of the Company: (i) Dr. Victor Shi, an independent non-executive Director, has been appointed as a new member of the Audit Committee with effect from 16 September 2026; and (ii) Dr. Victor Shi has ceased to be a member of the nomination committee (the “Nomination Committee”) and the strategy committee (the “Strategy Committee”) of the Company with effect from the same date. Following the passing away of Dr. Galdes and the above changes in the composition of the committees: (1) the Board comprises nine Directors, including four executive Directors and five independent non-executive Directors, (ii) the Audit Committee comprises three members, namely Mr. Andy Cheung (chairman), Mr. Ethan Pan and Dr. Victor Shi; (iii) the Nomination Committee comprises five members, namely Mr. Robin Meng (chairman), Mr. Andy Cheung, Mr. Ethan Pan, Mr. Ross Grossman and Ms. Sally Wang; and (iv) the Strategy Committee comprises three members, namely Dr. Frank Zhang (chairman), Mr. Ethan Pan and Dr. John Quelch. The Company meets the minimum number of independent non-executive directors as required under Rule 3.10(i) of the Rules Governing the Listing of Securities on The Stock
1
Exchange of Hong Kong Limited (the “Listing Rules”) and the minimum number of members in the Audit Committee as required under Rule 3.21 of the Listing Rules.
By order of the Board Genscript Biotech Corporation Robin Meng Chairman and Executive Director
Hong Kong, 16 September 2026 As at the date of this announcement, the executive Directors are Mr. Jiange Meng (“Mr. Robin Meng”), Dr. Fangliang Zhang (“Dr. Frank Zhang”), Dr. Li Zhu and Ms. Ye Wang (“Ms. Sally Wang”); and the independent non-executive Directors are Mr. Yiu Leung Andy Cheung (“Mr. Andy Cheung”), Mr. Jiuan Pan (“Mr. Ethan Pan”), Dr. John Quelch, Dr. Ross Grossman, and Dr. Chenyang Shi (“Dr. Victor Shi”).
2
The members of the board of directors (the “Board”) of Genscript Biotech Corporation (the “Company”) are set out below: Executive Directors Mr. Jiange Meng (“Mr. Robin Meng”) (Chairman) Dr. Fangliang Zhang (“Dr. Frank Zhang”) Dr. Li Zhu Ms. Ye Wang (“Ms. Sally Wang”) (President) Independent Non-Executive Directors Mr. Yiu Leung Andy Cheung (“Mr. Andy Cheung”) Mr. Jiuan Pan (“Mr. Ethan Pan”) Dr. John Quelch Dr. Ross Grossman Dr. Chenyang Shi (“Dr. Victor Shi”) The Board has established five committees, and the directors of the Company are serving on the respective committees as below:
Board Committee
Audit Committee
Director Mr. Andy Cheung Mr. Ethan Pan Dr. Frank Zhang Dr. John Quelch Dr. Li Zhu Mr. Robin Meng Dr. Ross Grossman Ms. Sally Wang Dr. Victor Shi Notes:
Remuneration Nomination Committee Committee
C M / / / / / / M
C: Chairman of the relevant Board committees M: Member of the relevant Board committees Hong Kong, 16 September 2026
/ / / / / / M M C
M M / / / C M M /
Risk Management and ESG Committee
Strategy Committee
M M C / / / / / /
/ M C M / / / / /
GenScript Joins Lilly TuneLab to Advance AI-Enabled Drug Discovery
September 16, 2026
GenScript to offer wet lab data generation services to biotech companies using the TuneLab drug discovery platform
GenScript Biotech Corporation today announced an agreement with Lilly TuneLab™ , a collaborative AI/ML drug discovery platform created by Eli Lilly and Company (Lilly). Through the agreement, GenScript will offer preferred-rate wet lab services to TuneLab member companies, helping them rapidly generate experimental data and translate AI-generated predictions into biological evidence.

Lilly TuneLab provides participating biotech companies access to AI/ML models trained on decades of Lilly’s research data, including models that predict antibody developability properties and small molecule ADMET properties. Hosted by a third party and using federated learning, the platform allows biotechs to contribute experimental results back to improve the models. GenScript can then help companies turn AI-enabled predictions into wet lab data by expressing, purifying, and characterizing prioritized sequences under standardized, fully documented protocols, helping to accelerate candidate evaluation.
“AI-enabled drug discovery will advance only as fast as the industry can generate reliable biological evidence,” said Ray Chen, President of GenScript Life Science Group. “The industry's next leap requires connecting AI prediction, wet-lab production, and testing at a scale that fragmented solutions simply cannot match. By helping researchers rapidly transform promising sequences into actionable experimental data, we can help close one of the critical gaps between AI insight and therapeutic discovery.”
Lilly TuneLab is part of Lilly Catalyze360, alongside Lilly Ventures, Lilly Gateway Labs, and Lilly ExploR&D, which together support biotech innovation by providing access to strategic capital, lab space and technology, and research and development capabilities.
Backed by more than two decades of drug discovery and biologics experience, GenScript is building the scale and infrastructure needed to make laboratory testing a practical extension of AI-enabled discovery. Its end-to-end sequence-to-data capabilities help researchers identify promising candidates earlier, allocate resources more effectively and, ultimately, move stronger therapeutic programs toward patients.
Service & Products
Resource
Tools
About us
securities in the United States. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), and may not be offered or sold in the United States unless registered under the U.S. Securities Act or pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act. The Company has no intention to register under the U.S. Securities Act any of the securities referred to herein or to conduct a public offering of securities in the United States.
Genscript Biotech Corporation (Incorporated in the Cayman Islands with limited liability) (Stock code: 1548) COMPLETION OF PLACING OF NEW SHARES UNDER THE GENERAL MANDATE Joint Overall Coordinators and Joint Placing Agents (in alphabetical order)
Reference is made to the announcement of Genscript Biotech Corporation (the “Company) dated 11 September 2026 in respect of the placing of new Shares under the general mandate (the “Placing Announcement”). Unless otherwise stated, capitalised terms used herein shall bear the same meanings as those defined in the Placing Announcement. COMPLETION OF THE PLACING The Board is pleased to announce that all the conditions set out in the Placing Agreement have been fulfilled and the Completion took place on 15 September 2026 in accordance with the terms and conditions of the Placing Agreement.
1
A total of 77,126,000 Placing Shares, representing approximately 3.50% of the existing issued share capital of the Company immediately before completion of the Placing, and approximately 3.38% of the issued share capital of the Company as enlarged by the allotment and issue of the Placing Shares immediately after completion of the Placing, have been successfully placed to not less than six Placees at the Placing Price of HK$30.50 per Share. To the best of the Directors’ knowledge, information and belief, having made all reasonable enquiries, each of the Placees and their respective ultimate beneficial owner(s) (where applicable) is an Independent Third Party. Furthermore, as far as the Company is aware, none of the Placees and their ultimate beneficial owners will become a substantial shareholder (as defined in the Listing Rules) of the Company as a result of the Placing. The gross proceeds to the Company from the Placing are approximately HK$2,352.3 million, and the net proceeds from the Placing, after deducting the placing commission and other relevant costs and expenses of the Placing, amounted to approximately HK$2,327.1 million. Please refer to the Placing Announcement for the details of the intended use of proceeds. As disclosed in the Placing Announcement, following the Completion, the Company will make filings with the regulatory authorities in the PRC in accordance with the relevant applicable laws and regulations, including the CSRC Filings. EFFECTS ON THE SHAREHOLDING STRUCTURE OF THE COMPANY AS A RESULT OF THE PLACING The shareholding structure of the Company (i) immediately before the Completion; and (ii) immediately upon the Completion are set out below: Immediately before the Completion Shareholders
Number of issued Shares
Approximate % of issued share capital of the Company
Immediately upon the Completion Number of issued Shares
(%)Note 1
Approximate % of issued share capital of the Company (%)Note 1
GenScript CorporationNote
799,999,123
36.31
799,999,123
35.08
Other nonpublic Shareholders The Placees
4,016,989
0.18
4,016,989
0.18
77,126,000
3.38
Other public Shareholders
1,399,344,351
63.51
1,399,344,351
61.36
Total
2,203,360,463
100.00
2,280,486,463Note 3
100.00
2
Note: 1.
The aggregate of the percentage figures in the table above may not add up to the relevant subtotal or total percentage figures shown due to rounding of the percentage figures to two decimal places.
2
GenScript Corporation is a company incorporated in the State of Delaware in the U.S. and one of the controlling shareholders of the Company. As at the date of this announcement, it was owned as to approximately 10.87%, 20.19%, 4.86%, 0.93%, 0.96%, 2.44%, 22.76%, 22.66%, 2.37%, 8.06%, 1.78%, 1.05%, and 1.07% by Frank Zhang, the Zhang Trust, Weihong Jin, the Jin 2025 Trust, the Jin 2023 Trust, the Jin 2026 Trust, Larry Wang, Karen Wu (in her own name and through certain family trustees), Sally Wang, the Wang Trust, the Wang 2026 Trust, Yingjun Mu and Charity B-Community Foundation of New Jersey, respectively.
Represents the total number of issued Shares immediately upon the Completion, assuming that no new Shares are issued and allotted under the Company’s post-IPO share option scheme approved and adopted by written resolutions of its then sole shareholder on 7 December 2015.
This announcement has been issued in the English language with a separate Chinese language translation. If there is any inconsistency or ambiguity between the English version and the Chinese version, the English version shall prevail. By order of the Board Genscript Biotech Corporation Robin Meng Chairman and Executive Director Hong Kong, 15 September 2026 As at the date of this announcement, the executive Directors are Mr. Robin Meng, Dr. Frank Zhang, Dr. Li Zhu and Ms. Sally Wang; and the independent non-executive Directors are Dr. Alphonse Galdes, Mr. Andy Cheung, Mr. Ethan Pan, Dr. John Quelch, Dr. Ross Grossman and Dr. Victor Shi.
3
(Equity issuer - changes in issued shares or treasury shares, share buybacks and/or on-market sales of treasury shares) Instrument:
Equity issuer
Name of Issuer:
Genscript Biotech Corporation
Date Submitted:
15 September 2026
Status:
New Submission
Section I must be completed by a listed issuer where there has been a change in its issued shares or treasury shares which is discloseable pursuant to rule 13.25A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Exchange”) (the “Main Board Rules”) or rule 17.27A of the Rules Governing the Listing of Securities on GEM of the Exchange (the “GEM Rules”). Section I
- Class of shares
Ordinary shares
Type of shares
Stock code (if listed)
01548
Description
Listed on the Exchange
Not applicable
Yes
A. Changes in issued shares or treasury shares Changes in issued shares (excluding treasury shares) Events
Opening balance as at (Note 1) 1).
31 August 2026
Issue of new shares or transfer of treasury shares in respect of share awards or options granted to a participant (who is not a director of the issuer) under a share scheme - new shares involved
Changes in treasury shares
As a % of existing number of issued shares (excluding treasury shares) before the relevant event (Note 3)
Number of issued shares (excluding treasury shares)
2,200,591,697 702,099
Issue/ selling price per share (Note 4)
Number of treasury shares
0 0.03 %
Total number of issued shares
2,200,591,697 HKD
18.42
Exercise of options under the Post-IPO share option scheme adopted on 7 December 2015 Date of changes
01 September 2026
Page 1 of 7
v 1.3.0
FF305 2).
Issue of new shares or transfer of treasury shares in respect of share awards or options granted to a participant (who is not a director of the issuer) under a share scheme - new shares involved
406,000
0.02 %
HKD
26.35
500,000
0.02 %
HKD
15.39
221,000
0.01 %
HKD
10.07
80,000
0.004 %
HKD
9.55
345,000
0.02 %
HKD
19.01
33,000
0.001 %
HKD
12.03
Exercise of options under the Post-IPO share option scheme adopted on 7 December 2015 Date of changes 3).
02 September 2026
Issue of new shares or transfer of treasury shares in respect of share awards or options granted to a participant (who is not a director of the issuer) under a share scheme - new shares involved Exercise of options under the Post-IPO share option scheme adopted on 7 December 2015 Date of changes
4).
03 September 2026
Issue of new shares or transfer of treasury shares in respect of share awards or options granted to a participant (who is not a director of the issuer) under a share scheme - new shares involved Exercise of options under the Post-IPO share option scheme adopted on 7 December 2015 Date of changes
5).
04 September 2026
Issue of new shares or transfer of treasury shares in respect of share awards or options granted to a participant (who is not a director of the issuer) under a share scheme - new shares involved Exercise of options under the Post-IPO share option scheme adopted on 7 December 2015 Date of changes
6).
07 September 2026
Issue of new shares or transfer of treasury shares in respect of share awards or options granted to a participant (who is not a director of the issuer) under a share scheme - new shares involved Exercise of options under the Post-IPO share option scheme adopted on 7 December 2015 Date of changes
7).
08 September 2026
Issue of new shares or transfer of treasury shares in respect of share awards or options granted to a participant (who is not a director of the issuer) under a share scheme - new shares involved Exercise of options under the Post-IPO share option scheme adopted on 7 December 2015 Date of changes
09 September 2026
Page 2 of 7
v 1.3.0
FF305 8).
Issue of new shares or transfer of treasury shares in respect of share awards or options granted to a participant (who is not a director of the issuer) under a share scheme - new shares involved
25,000
0.001 %
HKD
19.132
40,000
0.002 %
HKD
8.68
416,667
0.02 %
HKD
25.3
10,000
0.0005 %
HKD
19.132
77,126,000
3.5 %
HKD
30.5
Exercise of options under the Post-IPO share option scheme adopted on 7 December 2015 Date of changes 9).
10 September 2026
Issue of new shares or transfer of treasury shares in respect of share awards or options granted to a participant (who is not a director of the issuer) under a share scheme - new shares involved Exercise of options under the Post-IPO share option scheme adopted on 7 December 2015 Date of changes
10).
11 September 2026
Issue of new shares or transfer of treasury shares in respect of share awards or options granted to a participant (who is not a director of the issuer) under a share scheme - new shares involved Exercise of options under the Post-IPO share option scheme adopted on 7 December 2015 Date of changes
11).
14 September 2026
Issue of new shares or transfer of treasury shares in respect of share awards or options granted to a participant (who is not a director of the issuer) under a share scheme - new shares involved Exercise of options under the Post-IPO share option scheme adopted on 7 December 2015 Date of changes
12).
15 September 2026
Placing/subscription - new shares involved Issue and allotment of new Shares on 15 September 2026 pursuant to the Placing Agreement dated 11 September 2026 (details of which are set out in the Company’s announcements dated 11 September 2026 and 15 September 2026) Date of changes
15 September 2026
Closing balance as at (Notes 5 and 6) 15 September 2026
2,280,496,463
B. Shares redeemed or repurchased for cancellation but not yet cancelled as at the closing balance date (Notes 5 and 6)
Page 3 of 7
0
2,280,496,463
Not applicable
v 1.3.0
FF305 Confirmation Pursuant to Main Board Rule 13.25C / GEM Rule 17.27C, we hereby confirm to the best knowledge, information and belief that, in relation to each issue of shares or sale or transfer of treasury shares as set out in Section I, it has been duly authorised by the board of directors of the listed issuer and carried out in compliance with all applicable listing rules, laws and other regulatory requirements and, insofar as applicable: (Note 7) (i)
all money due to the listed issuer in respect of the issue of shares, or sale or transfer of treasury shares has been received by it;
(ii)
all pre-conditions for the listing imposed by the Main Board Rules / GEM Rules under "Qualifications of listing" have been fulfilled;
(iii) all (if any) conditions contained in the formal letter granting listing of and permission to deal in the securities have been fulfilled; (iv) all the securities of each class are in all respects identical (Note 8); (v)
all documents required by the Companies (Winding Up and Miscellaneous Provisions) Ordinance to be filed with the Registrar of Companies have been duly filed and that compliance has been made with all other legal requirements;
(vi) all the definitive documents of title have been delivered/are ready to be delivered/are being prepared and will be delivered in accordance with the terms of issue, sale or transfer; (vii) completion has taken place of the purchase by the issuer of all property shown in the listing document to have been purchased or agreed to be purchased by it and the purchase consideration for all such property has been duly satisfied; and (viii) the trust deed/deed poll relating to the debenture, loan stock, notes or bonds has been completed and executed, and particulars thereof, if so required by law, have been filed with the Registrar of Companies. Notes to Section I: 1.
Please insert the closing balance date of the last Next Day Disclosure Return published pursuant to Main Board Rule 13.25A / GEM Rule 17.27A or Monthly Return pursuant to Main Board Rule 13.25B / GEM Rule 17.27B, whichever is the later.
Please set out all changes in issued shares or treasury shares requiring disclosure pursuant to Main Board Rule 13.25A / GEM Rule 17.27A together with the relevant dates of changes. Each category will need to be disclosed individually with sufficient information to enable the user to identify the relevant category in the listed issuer's Monthly Return. For example, multiple issues of shares as a result of multiple exercises of share options under the same share option scheme or of multiple conversions under the same convertible note must be aggregated and disclosed as one category. However, if the issues resulted from exercises of share options under 2 share option schemes or conversions of 2 convertible notes, these must be disclosed as 2 separate categories.
The percentage change in the number of issued shares (excluding treasury shares) of the listed issuer is to be calculated by reference to the opening balance of the number of issued shares (excluding treasury shares) being disclosed in this Next Day Disclosure Return.
Page 4 of 7
v 1.3.0
FF305 4.
In the case of a share repurchase or redemption, the “issue/ selling price per share” shall be construed as “repurchase price per share” or “redemption price per share”. Where shares have been issued/ sold/ repurchased/ redeemed at more than one price per share, a volume-weighted average price per share should be given.
The closing balance date is the date of the last relevant event being disclosed.
For repurchase or redemption of shares, disclosure is required when the relevant event has occurred (subject to the provisions of Main Board Rules 10.06(4)(a), 13.25A and 13.31 / GEM Rules 13.13(1), 17.27A and 17.35), even if the repurchased or redeemed shares have not yet been cancelled. If repurchased or redeemed shares are to be cancelled upon settlement of such repurchase or redemption after the closing balance date, they shall remain part of the issued shares as at the closing balance date in Part A. Details of these repurchased or redeemed shares shall be disclosed in Part B.
Items (i) to (viii) are suggested forms of confirmation. The listed issuer may amend the item(s) that is/are not applicable to meet individual cases.
“Identical” means in this context:
the securities are of the same nominal value with the same amount called up or paid up;
they are entitled to dividend/interest at the same rate and for the same period, so that at the next ensuing distribution, the dividend/interest payable per unit will amount to exactly the same sum (gross and net); and
they carry the same rights as to unrestricted transfer, attendance and voting at meetings and rank pari passu in all other respects.
Page 5 of 7
v 1.3.0
FF305 Section II must also be completed by a listed issuer where it has made a repurchase of shares which is discloseable under Main Board Rule 10.06(4)(a) / GEM Rule 13.13(1).
Repurchase report
Not applicable
Page 6 of 7
v 1.3.0
FF305 Section III must also be completed by a listed issuer where it has made a sale of treasury shares on the Exchange or any other stock exchange on which the issuer is listed which is discloseable under Main Board Rule 10.06B / GEM Rule 13.14B.
Report of on-market sale of treasury shares
Not applicable
Submitted by: Jiange Meng (Name) Title: Director (Director, Secretary or other Duly Authorised Officer)
Page 7 of 7
v 1.3.0
securities in the United States. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), and may not be offered or sold in the United States unless registered under the U.S. Securities Act or pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act. The Company has no intention to register under the U.S. Securities Act any of the securities referred to herein or to conduct a public offering of securities in the United States.
Genscript Biotech Corporation (Incorporated in the Cayman Islands with limited liability) (Stock code: 1548) PLACING OF NEW SHARES UNDER THE GENERAL MANDATE Joint Overall Coordinators and Joint Placing Agents (in alphabetical order)
THE PLACING The Board hereby announces that on 11 September 2026 (before trading hours), the Company and the Placing Agents entered into the Placing Agreement, pursuant to which the Company agreed to appoint the Placing Agents, and the Placing Agents have conditionally agreed to procure, on a best effort basis, not less than six Placees in aggregate to subscribe for 77,126,000 Placing Shares at the Placing Price of HK$30.50 per Share upon the terms and subject to the conditions set out in the Placing Agreement. It is expected that the Placing Shares will be placed to not less than six Placees who will be professional, institutional, or other investors that are, together with their respective ultimate beneficial owners, Independent Third Parties. It is also expected that none of the Placees will become a substantial shareholder immediately after the completion of the Placing.
1
The Placing Price of HK$30.50 per Share represents: (i)
a discount of approximately 4.7% to the closing price of HK$32.00 per Share as quoted on the Stock Exchange on 10 September 2026 (being the Last Trading Day); and
(ii)
a discount of approximately 6.3% to the average closing price of approximately HK$32.56 per Share as quoted on the Stock Exchange for the last five consecutive trading days immediately preceding the date of the Placing Agreement.
The Placing Price was determined after arm’s length negotiations between the Company and the Placing Agents with reference to the market conditions and the prevailing market price of the Shares. The Placing Shares represent (i) approximately 3.50% of the existing issued share capital of the Company as at the date of this announcement; and (ii) approximately 3.38% of the issued share capital of the Company as enlarged by the allotment and issue of the Placing Shares (assuming that there will be no change to the issued share capital of the Company from the date of this announcement to the Closing Date). Assuming that all Placing Shares are placed, the gross proceeds from the Placing are expected to be approximately HK$2,352.3 million, and the net proceeds from the Placing (after deduction of the placing commission in respect of the Placing and other related expenses including, among others, the professional fees) are expected to be approximately HK$2,327.1 million, representing an estimated net issue price of approximately HK$30.17 per Placing Share. USE OF PROCEEDS The Company intends to use the net proceeds from the Placing as follows: (i) approximately 70% for expansion of capacity and infrastructure for the Group’s AIDD platform, including automated highthroughput wet-lab facilities, related equipment and laboratory upgrades; (ii) approximately 20% for research and development, digital workflow integration and global business development in connection with such AIDD platform; and (iii) approximately 10% for general corporate purposes and working capital. The specific use of the proceeds is subject to the adjustments by the Board or its authorized persons according to the operating conditions and actual needs of the Company or the Group. GENERAL MANDATE The Placing Shares will be allotted and issued by the Company under the General Mandate and will rank pari passu in all respects with the Shares then in issue on the Closing Date. An application will be made by the Company to the Listing Committee of the Stock Exchange for the listing of, and permission to deal in, the Placing Shares on the Stock Exchange. Completion of the Placing is subject to the satisfaction of the conditions precedent set out in the Placing Agreement and may or may not materialize. Further announcement will be made as and when appropriate in accordance with the relevant rules of the Stock Exchange. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the Company’s securities.
2
PLACING OF NEW SHARES UNDER GENERAL MANDATE The Board hereby announces that on 11 September 2026 (before trading hours), the Company and the Placing Agents entered into the Placing Agreement, pursuant to which the Company agreed to appoint the Placing Agents, and the Placing Agents have conditionally agreed to procure, on a best effort basis, not less than six Placees in aggregate to subscribe for 77,126,000 Placing Shares at the Placing Price of HK$30.50 per Share upon the terms and subject to the conditions set out in the Placing Agreement. THE PLACING AGREEMENT The principal terms of the Placing Agreement are set out below: Date:
11 September 2026 (before trading hours)
Parties:
(i)
the Company; and
(ii)
the Placing Agents
To the best of the Directors’ knowledge, information and belief having made all reasonable enquiries, the Placing Agents, and their respective ultimate beneficial owner(s), are Independent Third Parties. Placing Shares A total of 77,126,000 Placing Shares will be placed by the Placing Agents under the Placing. The number of Placing Shares represents: (i)
approximately 3.50% of the existing issued share capital of the Company as at the date of this announcement; and
(ii)
approximately 3.38% of the issued share capital of the Company as enlarged by the allotment and issue of the Placing Shares (assuming that there will be no change to the issued share capital of the Company from the date of this announcement to the Closing Date).
The Placing Shares have a maximum aggregate nominal value of US$77,126. Placing Price The Placing Price of HK$30.50 per Placing Share represents: (i)
a discount of approximately 4.7% to the closing price of HK$32.00 per Share as quoted on the Stock Exchange on 10 September 2026 (being the Last Trading Day); and
(ii)
a discount of approximately 6.3% to the average closing price of approximately HK$32.56 per Share as quoted on the Stock Exchange for the last five consecutive trading days immediately preceding the date of the Placing Agreement.
The Placing Price was determined after arm’s length negotiations between the Company and the Placing Agents with reference to the market conditions and the prevailing market price of the Shares. The net placing price (after deducting the commissions and estimated expenses) is approximately HK$30.17 per Placing Share.
3
The Placees The Placing Agents have agreed, on a best effort basis, to procure not less than six Placees that are professional, institutional or other investors in aggregate to purchase the Placing Shares, upon the terms and subject to the conditions set out in the Placing Agreement. It is expected that (i) the Placees procured by the Placing Agents and their respective ultimate beneficial owners will remain Independent Third Parties on the Closing Date; and (ii) none of the Placees will become a substantial shareholder immediately after the Completion of the Placing. Ranking of the Placing Shares The Placing Shares shall, when fully paid, rank pari passu in all respects with the other Shares in issue or to be issued by the Company on or prior to the Closing Date, including the rights to receive all dividends and other distributions declared, made or paid on or after the date of allotment. Conditions of the Placing Agreement The Completion of the Placing shall be subject to certain conditions (the “Conditions”), including: (i)
the Listing Committee of the Stock Exchange granting the listing of, and permission to deal in, the Placing Shares and such listing and permission not subsequently being revoked prior to the delivery of definitive share certificate(s) representing the Placing Shares as set out in the Placing Agreement;
(ii)
the Placing Agents having received on or prior to the Closing Date an opinion of the U.S. counsel to the Placing Agents, to the effect that the offer and sale of the Placing Shares by the Placing Agents as set forth in the Placing Agreement are not required to be registered under the U.S. Securities Act;
(iii)
the Placing Agents having received on the Closing Date the substantially complete draft of the CSRC Filings and the draft opinion from the counsel to the Company as to PRC laws in relation to the CSRC Filings, such drafts to be in form and substance reasonably satisfactory to the Placing Agents;
(iv)
the Placing Agents having received on or prior to the Closing Date an opinion of the Cayman Islands counsels to the Company, relating to such matters as the Placing Agents shall reasonably request, such opinion to be in the form and substance reasonably satisfactory to the Placing Agents;
(v)
the representations and warranties made by the Company pursuant to the Placing Agreement being true and accurate and not misleading as of the Closing Date; and
(vi)
the Company having complied with all of its undertakings and obligations required to be performed or satisfied under the Placing Agreement on or before the Closing Date.
The Placing Agents in their respective sole discretion may waive any of the Conditions above (except for Condition (i)), in whole or in part. Termination of the Placing Agreement If any of the Conditions is not fulfilled at or prior to 8:00 a.m. (Hong Kong time) on the Closing Date (or such later time and/or date as may be agreed between the Company and the Placing Agents), then: (i) in the case of Condition (i), the Company and the Placing Agents shall have no further obligations or liabilities to each other under the Placing and neither party shall have any claim against the other for costs, damages, compensation or otherwise arising under the Placing Agreement, save for any antecedent breach; and (ii) in the case of Conditions (ii) to (vi), if such Condition is not fulfilled to the satisfaction of the Placing Agents or waived by them, the Placing Agents may terminate the Placing Agreement forthwith.
4
Furthermore, notwithstanding anything contained in the Placing Agreement, if at any time prior to 8:00 a.m. (Hong Kong time) on the Closing Date: (i)
there develops, occurs or comes into force any new law or regulation, any change or development (including a prospective change) in existing laws or regulations or in their interpretation or application, any change or development in financial, political, economic, legal, military, industrial, fiscal, regulatory, currency, securities market or other conditions, which, in the sole opinion of either of the Placing Agents, is or is likely to be materially adverse to the success of the Placing or makes or is likely to make it impracticable, inadvisable or inexpedient to proceed with the Placing, any force majeure event beyond the reasonable control of the Placing Agents, any suspension of dealings in the Shares (other than as a result of the Placing), or any moratorium, suspension or restriction on trading in securities generally on certain major stock exchanges;
(ii)
it comes to the knowledge of the Placing Agents that there is any breach of the representations, warranties or undertakings of the Company in the Placing Agreement (or, where not qualified by materiality, any such breach in any material respect), any event or matter which, had it occurred or arisen before the date of the Placing Agreement, would have rendered any such representations, warranties or undertakings untrue or incorrect, or any breach or failure by the Company to perform the Placing Agreement in any material respect; or
(iii)
there is any change, or any development involving a prospective change, in or affecting the business, general affairs, management, prospects, assets and liabilities, shareholders’ equity, results of operations or position (financial or otherwise) of the Group as a whole (other than as already disclosed to the public on or before the date of the Placing Agreement) which, in the sole and reasonable opinion of either of the Placing Agents, is or is likely to be materially adverse to the success of the Placing or makes or is likely to make it impracticable, inadvisable or inexpedient to proceed with the Placing,
the Placing Agents may terminate the Placing Agreement by written notice to the Company. If the Company fails to deliver the Placing Shares in accordance with the Placing Agreement, the Placing Agents shall also have the right, exercisable at any time by written notice to the Company, to terminate the Placing Agreement. Lock-up Undertakings by the Company The Company undertakes to the Placing Agents that it shall not, without the prior written consent of the Placing Agents, (i) effect or arrange or procure placement of, allot or issue or offer to allot or issue or grant any option, right or warrant to subscribe for, or enter into any transaction which is designed to, or might reasonably be expected to, result in any of the aforesaid (whether by actual disposition or effective economic disposition due to cash settlement or otherwise), directly or indirectly, any equity securities of the Company or any securities convertible into, or exercisable, or exchangeable for, equity securities of the Company, or (ii) enter into any swap or similar agreement that transfers, in whole or in part, the economic risk of ownership of such Shares, whether any such transaction described in (i) or (ii) above is to be settled by delivery of Shares or such other securities, in cash or otherwise, or (iii) publicly announce an intention to effect any such transaction, for a period beginning on the date of the Placing Agreement and ending on the date which is 90 days after the Closing Date. The foregoing shall not apply to (i) the issue of the Placing Shares under the Placing Agreement, (ii) the issue or grant of share options, awards or shares pursuant to the Company’s existing share option or share award schemes, (iii) the issue of Shares on the exercise or vesting of options or awards outstanding at the date of the Placing Agreement, and (iv) any issue of securities which has been publicly announced prior to the date of the Placing Agreement.
5
Completion Subject to the satisfaction the Conditions, Completion is expected to take place on or before 15 September 2026, or such other time and/or date as the Placing Agents and the Company may agree in writing. ISSUE OF NEW SHARES UNDER THE GENERAL MANDATE By resolutions of the Shareholders passed at the AGM held on 5 June 2026, the General Mandate was granted to the Directors to allot and issue up to 437,683,468 Shares, being 20% of the total number of 2,188,417,343 issued Shares (excluding treasury shares, if any) as at the date of the AGM. As at the date of this announcement, no Shares have been allotted and issued under the General Mandate. The allotment and issue of the Placing Shares will fall within the limit of the General Mandate and is not subject to further approval of the Shareholders. LISTING APPLICATION The Company will apply to the Listing Committee for listing of, and permission to deal in, the Placing Shares. FILING WITH REGULATORY AUTHORITIES IN THE PRC After the Placing Shares are issued and listing on the Stock Exchange, the Company will file with the regulatory authorities in the PRC in accordance with the relevant applicable laws and regulations, including the CSRC Filings. REASONS FOR AND BENEFITS OF THE PLACING AND USE OF PROCEEDS The Company is a well-recognized biotechnology company with proprietary DNA synthesis and related lifescience technologies. It is principally engaged in life-science research services and products, end-to-end CRDMO services for biologics and cell and gene therapy, and industrial synthetic biology products, serving global research institutions and biopharmaceutical customers. The Directors believe that AIDD is increasing demand for an integrated infrastructure that combines computational design with automated, high-throughput wet-lab validation on short turnaround times. The Group intends to apply the net proceeds of the Placing to accelerate capital expenditure and expand its dedicated capacity in this area, including automated high-throughput synthesis, screening and assay platforms, with a view to improving scale and delivery cycles. The Group’s existing operations are supported by its current financial position and operating cash flows. The Placing is intended to fund this expansion without drawing on cash reserved for existing businesses, and to broaden the Company’s institutional shareholder base. In view of the above, the Directors consider that the terms of the Placing Agreement and the transactions contemplated thereunder (including the Placing and the Placing Price) are fair and reasonable and with reference to the prevailing market conditions. The Placing and the entry into of the Placing Agreement are in the interest of the Company and its Shareholders as a whole. Assuming that all Placing Shares are placed, the gross proceeds from the Placing are expected to be approximately HK$2,352.3 million, and the net proceeds from the Placing (after deduction of the placing commission in respect of the Placing and other related expenses including, among others, the professional fees) are expected to be approximately HK$2,327.1 million, representing an estimated net issue price of approximately HK$30.17 per Placing Share.
6
The Company presently intends to use the net proceeds from the Placing as follows: (i) approximately 70% for expansion of capacity and infrastructure for the Group’s AIDD platform, including automated highthroughput wet-lab facilities, related equipment and laboratory upgrades; (ii) approximately 20% for research and development, digital workflow integration and global business development in connection with such AIDD platform; and (iii) approximately 10% for general corporate purposes and working capital. The specific use of the proceeds is subject to the adjustments by the Board or its authorized persons according to the operating conditions and actual needs of the Company or the Group. EQUITY FUND RAISING OF THE COMPANY DURING THE PAST TWELVE MONTHS The Company has not carried out any fund-raising activity involving issue of equity securities during the 12 months immediately prior to the date of this announcement. EFFECT OF THE PLACING ON THE SHARE CAPITAL OF THE COMPANY The table below sets out a summary of the shareholding structure of the Company (i) as at the date of this announcement; and (ii) immediately after the Completion of the Placing, assuming that the Placing Shares are fully placed and that except for the Placing Shares allotted and issued, there is no change in the issued Shares of the Company from the date of the Placing Agreement up to the date of the Completion of the Placing: As at the date of this announcement Shareholders
Number of issued Shares
Approximate % of issued share capital of the Company
Immediately upon Completion and the allotment and issuance of the Placing Shares Number of Approximate % issued Shares of issued share capital of the Company
(%)Note 1
GenScript CorporationNote2 Other nonpublic Shareholders The Placees Other public Shareholders Total
(%)Note 1
799,999,123
36.32
799,999,123
35.09
4,016,989
0.18
4,016,989
0.18
1,398,887,684
63.50
77,126,000 1,398,887,684
3.38 61.35
2,202,903,796
100.00
2,280,029,796
100.00
Note: 1.
The aggregate of the percentage figures in the table above may not add up to the relevant subtotal or total percentage figures shown due to rounding of the percentage figures to two decimal places.
GenScript Corporation is a company incorporated in the State of Delaware in the U.S. and one of the controlling shareholders of the Company. As at the date of this announcement, it was owned as to approximately 10.87%, 20.19%, 4.86%, 0.93%, 0.96%, 2.44%, 22.76%, 22.66%, 2.37%, 8.06%, 1.78%, 1.05%, and 1.07% by Frank Zhang, the Zhang Trust, Weihong Jin, the Jin 2025 Trust, the Jin 2023 Trust, the Jin 2026 Trust, Larry Wang, Karen Wu (in her own name and through certain family trustees), Sally Wang, the Wang Trust, the Wang 2026 Trust, Yingjun Mu and Charity B-Community Foundation of New Jersey, respectively.
7
This announcement has been issued in the English language with a separate Chinese language translation. If there is any inconsistency or ambiguity between the English version and the Chinese version, the English version shall prevail. Completion of the Placing is subject to the satisfaction of the conditions precedent set out in the Placing Agreement and may or may not materialize. Further announcement will be made as and when appropriate in accordance with the relevant rules of the Stock Exchange. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the Company’s securities. DEFINITIONS In this announcement, unless the context otherwise requires, the following expressions have the following meanings: “AGM”
the annual general meeting of the Company held on 5 June 2026
“Andy Cheung”
Mr. Yiu Leung Andy Cheung, an independent non-executive Director
“AIDD”
AI-driven drug discovery
“Board”
the Board of Directors
“Closing Date”
expected to take place on 15 September 2026, or such other date as the Company and the Placing Agents may agree in writing
“Company”
Genscript Biotech Corporation, an exempted company incorporated under the laws of the Cayman Islands with limited liability (stock code: 1548)
“Completion”
the completion of the Placing pursuant to the terms and conditions of the Placing Agreement
“connected person(s)”
has the same meaning ascribed thereto under the Listing Rules
“controlling shareholder(s)”
has the meaning ascribed thereto under the Listing Rules
“CSRC”
the China Securities Regulatory Commission
“CSRC Filings”
the filing report (including any amendments, supplements and/or modifications thereof) with the CSRC in relation to the Placing and any transactions contemplated by the Placing Agreement and any relevant supporting materials
“Director(s)”
the director(s) of the Company
“Ethan Pan”
Mr. Jiuan Pan, an independent non-executive Director
“Frank Zhang”
Dr. Fangliang Zhang, an executive Director
“General Mandate”
the general mandate granted by a resolution passed at the AGM to the Directors to allot, issue or otherwise deal with new Shares not exceeding 20% of the total number of Shares in issue (excluding treasury Shares, if any) as at the date of passing of the resolution
“Group”
the Company and its subsidiaries from time to time
8
“HK$”
Hong Kong dollars, the lawful currency of Hong Kong
“Hong Kong”
Hong Kong Special Administrative Region of the PRC
“Independent Third Party(ies)”
third party(ies) independent of and not connected with the Company and its connected person(s)
“Jin 2023 Trust”
Weihong Jin 2023 GRAT Remainder Trust
“Jin 2025 Trust”
Weihong Jin 2025 Grantor Retained Annuity Trust
“Jin 2026 Trust”
Weihong Jin 2026 Grantor Retained Annuity Trust
“Larry Wang”
Dr. Wang Luquan
“Last Trading Day”
10 September 2026, being the last trading day prior to the signing of the Placing Agreement
“Listing Committee”
has the same meaning ascribed thereto under the Listing Rules
“Listing Rules”
the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, as amended, supplemented or otherwise modified from time to time
“Placee(s)”
any professional, institutional or other investors procured by the Placing Agents to subscribe for the Placing Shares pursuant to the Placing Agreement and who are Independent Third Parties
“Placing”
the placing of the Placing Shares by or on behalf of the Placing Agents on the terms and subject to the conditions set out in the Placing Agreement
“Placing Agents”
Citigroup Global Markets Limited and J.P. Morgan Securities (Asia Pacific) Limited, and each a placing agent (in alphabetical order)
“Placing Agreement”
the conditional placing agreement entered into between the Company and the Placing Agents dated 11 September 2026
“Placing Price”
HK$30.50 per Placing Share
“Placing Share(s)”
77,126,000 new Shares to be allotted and issued pursuant to the terms and conditions of the Placing Agreement which will rank pari passu in all respects with the Shares in issue and together with all rights attaching to as at the date of issue of the Placing Shares
“PRC”
the People’s Republic of China which, for the purpose of this announcement, shall exclude Hong Kong, the Macau Special Administrative Region of the PRC and Taiwan
“Robin Meng”
Mr. Jiange Meng, the chairman of the Board and an executive Director
“Sally Wang”
Ms. Ye Wang, an executive Director and the president of the Company
“Share(s)”
ordinary share(s) in the share capital of our Company, with a nominal value of US$0.001 each
9
“Shareholder(s)”
holder(s) of the Share(s) from time to time
“Stock Exchange”
The Stock Exchange of Hong Kong Limited
“substantial shareholder(s)”
has the same meaning ascribed thereto under the Listing Rules
“U.S.”
the United States of America
“US$”
United States dollars
“Victor Shi”
Dr. Chenyang Shi, an independent non-executive Director
“Wang Trust”
2017 Wang Ye Family Trust set up by Sally Wang
“Wang 2026 Trust”
Wang Ye 2026 Grantor Retained Annuity Trust set up by Sally Wang
“Zhang Trust”
2017 Fang Liang Zhang Trust set up by Frank Zhang
“%”
percent.
By order of the Board Genscript Biotech Corporation Robin Meng Chairman and Executive Director Hong Kong, 11 September, 2026 As at the date of this announcement, the executive Directors are Mr. Robin Meng, Dr. Frank Zhang, Dr. Li Zhu and Ms. Sally Wang; and the independent non-executive Directors are Dr. Alphonse Galdes, Mr. Andy Cheung, Mr. Ethan Pan, Dr. John Quelch, Dr. Ross Grossman and Dr. Victor Shi.
10
FIFTH AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION
Genscript Biotech Corporation (adopted by a Special Resolution passed on 5 June 2026)
Table of Contents
SHARES, WARRANTS AND MODIFICATION OF RIGHTS .................................................... 10 REGISTER OF SHAREHOLDERS AND SHARE CERTIFICATES ......................................... 14 LIEN .................................................................................................................................................... 16 CALLS ON SHARES ......................................................................................................................... 16 TRANSFER OF SHARES ................................................................................................................. 18 TRANSMISSION OF SHARES ........................................................................................................ 20 FORFEITURE OF SHARES............................................................................................................. 20 GENERAL MEETINGS .................................................................................................................... 22 PROCEEDINGS AT GENERAL MEETINGS ............................................................................... 23 VOTES OF SHAREHOLDERS ........................................................................................................ 25 APPOINTMENT OF PROXY AND CORPORATE REPRESENTATIVE ................................. 27 REGISTERED OFFICE .................................................................................................................... 29 BOARD OF DIRECTORS................................................................................................................. 29 APPOINTMENT AND ROTATION OF DIRECTORS ................................................................. 34 BORROWING POWERS .................................................................................................................. 35 MANAGING DIRECTORS, ETC. ................................................................................................... 36 MANAGEMENT ................................................................................................................................ 36 MANAGERS ....................................................................................................................................... 37 CHAIRMAN AND OTHER OFFICERS ......................................................................................... 37 PROCEEDINGS OF THE DIRECTORS ........................................................................................ 37 MINUTES AND CORPORATE RECORDS ................................................................................... 39 SECRETARY...................................................................................................................................... 39 GENERAL MANAGEMENT AND USE OF THE SEAL .............................................................. 39 AUTHENTICATION OF DOCUMENTS ....................................................................................... 41 CAPITALISATION OF RESERVES ............................................................................................... 41 DIVIDENDS AND RESERVES ........................................................................................................ 42 RECORD DATE ................................................................................................................................. 47 ANNUAL RETURNS ......................................................................................................................... 47 ACCOUNTS ........................................................................................................................................ 47 AUDITORS ......................................................................................................................................... 48 NOTICES ............................................................................................................................................ 49 INFORMATION ................................................................................................................................ 51 WINDING UP ..................................................................................................................................... 51 INDEMNITY ...................................................................................................................................... 52
UNTRACEABLE SHAREHOLDERS ............................................................................................. 52 DESTRUCTION OF DOCUMENTS ............................................................................................... 53 SUBSCRIPTION RIGHT RESERVE .............................................................................................. 54 STOCK ................................................................................................................................................ 56 UNCERTIFICATED SECURITIES AND ELECTRONIC PROCESS ........................................ 56
THE COMPANIES ACT (AS REVISED) EXEMPTED COMPANY LIMITED BY SHARES FIFTH AMENDED AND RESTATED MEMORANDUM OF ASSOCIATION OF Genscript Biotech Corporation (Company) (adopted by a Special Resolution passed on 5 June 2026) 1.
The name of the Company is Genscript Biotech Corporation.
The registered office is situated at the offices of Ascentium (Cayman) Limited, 4th Floor, Harbour Place, 103 South Church Street, P.O. Box 10240, Grand Cayman KY1-1002, Cayman Islands or at such other place in the Cayman Islands as the Directors may from time to time decide.
The objects for which the Company is established are unrestricted and except as prohibited or limited by the laws of the Cayman Islands, the Company shall have full power and authority to carry out any object and shall have and be capable of from time to time and at all times exercising any and all of the powers at any time or from time to time exercisable by a natural person or body corporate in any part of the world whether as principal, agent, contractor or otherwise.
Without prejudice to the generality of the foregoing, the objects of the Company shall include, but without limitation, the following: 4.1 To carry on the business of an investment company and for that purpose to acquire and hold, either in the name of the Company or in that of any nominee, land and real estate, gold and silver bullion, shares (including shares in the Company), stocks, debentures, debenture stock, bonds, notes, obligations and securities issued or guaranteed by any company wherever incorporated or carrying on business and debentures, debenture stock, bonds, notes, obligations and securities issued or guaranteed by any government, sovereign, ruler, commissioners, public body or authority, supreme, dependent, municipal, local or otherwise in any part of the world. 4.2 To lend money with or without security either at interest or without and to invest money of the Company in such manner as the Directors think fit.
1
4.3 To acquire by purchase, lease, exchange, or otherwise lands, houses, buildings and other property or any interest in the same in any part of the world. 4.4 To carry on the business of a commodity, commodity futures and forward contracts trader and for that purpose to enter into spot, future or forward contracts for the purchase and sale of any commodity including, but without prejudice to the generality of the foregoing, any raw materials, processed materials, agricultural products, produce or livestock, gold and silver bullion, specie and precious or semi- precious stones, goods, articles, services, currencies, rights and interests which may now or in the future be bought and sold in commerce and whether such trading is effected on an organised commodity exchange or otherwise and either to take delivery of, or to sell or exchange any such commodities pursuant to any contract capable of being entered into on any such commodities exchange. 4.5 To carry on whether as principals, agents or otherwise the business of providing and supplying goods, equipment, materials and services of whatsoever nature, and of financiers, company promoters, realtors, financial agents, land owners and dealers in or managers of companies, estates, lands, buildings, goods, materials, services, stocks, leases, annuities and securities of whatsoever type or kind. 4.6 To purchase or otherwise acquire and hold any rights, privileges, concessions, patents, patent rights, licences, secret processes and any real or personal property of any kind whatsoever. 4.7 To build, equip, furnish, outfit, repair, purchase, own, charter and lease steam, motor, sail or other vessels, ships, boats, tugs, barges, lighters or other property to be used in the business of shipping, transportation, chartering and other communication and transport operations for the use of the Company or for others, and to sell, charter, lease, mortgage, pledge or transfer the same or any interest therein to others. 4.8 To carry on the business of importers, exporters and merchants of goods, produce, stores and articles of all kinds both wholesale and retail, packers, customs brokers, ship agents, warehousemen, bonded or otherwise and carriers and to transact every kind of agency, factor and brokerage business or transaction which may seem to the Company directly or indirectly conducive to its interests. 4.9 To carry on the business of consultants in connection with all manner of services and advisers on all matters relating to companies, firms, partnerships, charities, political and non-political persons and organisations, governments, principalities, sovereign and republican states and countries and to carry on all or any of the businesses of financial, industrial, development, architectural, engineering, manufacturing, contracting, management, advertising, professional business and personal consultants and to advise upon the means and methods for extending, developing, marketing and improving all types of projects, developments, businesses or industries and all systems or processes relating to such businesses and the financing, planning, distribution, marketing and sale thereof.
2
4.10 To act as a management company in all branches of that activity and without limiting the generality of the foregoing, to act as managers of investments and hotels, estates, real property, buildings and businesses of every kind and generally to carry on business as managers, consultants or agents for or representatives of owners of property of every kind, manufacturers, funds, syndicates, persons, firms and companies for any purpose whatsoever. 4.11 To carry on any other trade or business which may seem to the Company capable of being carried on conveniently in connection with any business of the Company. 4.12 To borrow or raise money by the issue of ordinary debenture stock or on mortgage or in such other manner as the Company shall think fit. 4.13 To draw, make, accept, endorse, discount, execute and issue all instruments both negotiable and non-negotiable and transferable including promissory notes, bills of exchange, bills of lading, warrants, debentures and bonds. 4.14 To establish branches or agencies in the Cayman Islands and elsewhere and to regulate and to discontinue the same. 4.15 To distribute any of the property of the Company among the members of the Company in specie. 4.16 To acquire and take over the whole or any part of the business, property and liabilities of any person or persons, firm or company or to take or otherwise acquire and hold shares, stock, debentures or other securities of or interest in any other company carrying on any business or possessed of any property or rights. 4.17 To grant pensions, allowances, gratuities and bonuses to employees or ex- employees of the Company or the dependents of such persons and to support, establish or subscribe to any charitable or other institutions, clubs, societies or funds or to any national or patriotic fund. 4.18 To lend and advance moneys or give credit to such persons and on such terms as may be thought fit and to guarantee or stand surety for the obligations of any third party whether such third party is related to the Company or otherwise and whether or not such guarantee or surety is to provide any benefits to the Company and for that purpose to mortgage or charge the Company’s undertaking, property and uncalled capital or any part thereof, on such terms and conditions as may be thought expedient in support of any such obligations binding on the Company whether contingent or otherwise.
3
4.19 To enter into partnership or into any arrangements for sharing profits, union of interests, co-operation, joint venture, reciprocal concession, amalgamation or otherwise with any person or persons or company engaged or interested or about to become engaged or interested in the carrying on or conduct of any business or enterprise from which this Company would or might derive any benefit whether direct or indirect and to lend money, guarantee the contracts of or otherwise assist any such person or company and to take subscribe for or otherwise acquire shares and securities of any such company and to sell, hold, re issue with or without guarantee or otherwise deal with the same. 4.20 To enter into any arrangements with any authorities, municipal or local or otherwise and to obtain from any such authority any rights, privileges or concessions which the Company may think it desirable to obtain and to carry out, exercise and comply with any such arrangements, rights, privileges or concessions. 4.21 To do all such things as are incidental to or which the Company may think conducive to the attainment of the above objects or any of them. 5.
If the Company is registered as an exempted company as defined in the Cayman Islands Companies Act, it shall have the power, subject to the provisions of the Cayman Islands Companies Act and with the approval of a special resolution, to continue as a body incorporated under the laws of any jurisdiction outside of the Cayman Islands and to be de- registered in the Cayman Islands.
The liability of the members of the Company is limited.
The authorised share capital of the Company is US$5,000,000 consisting of 5,000,000,000 shares of US$0.001 each with the power for the Company to increase or reduce the said capital and to issue any part of its capital, original or increased, with or without any preference, priority or special privilege or subject to any postponement of rights or to any conditions or restrictions; and so that, unless the condition of issue shall otherwise expressly declare, every issue of shares, whether declared to be preference or otherwise, shall be subject to the power hereinbefore contained.
The financial year end of the Company is 31 December or such other date as the Directors may from time to time decide and annex to this Memorandum.
4
THE COMPANIES ACT (AS REVISED) EXEMPTED COMPANY LIMITED BY SHARES FIFTH AMENDED AND RESTATED ARTICLES OF ASSOCIATION OF Genscript Biotech Corporation (Company) (adopted by a Special Resolution passed on 5 June 2026)
- (a) Table ‘‘A’’ of the Companies Act (as revised) shall not apply to the Company. (b) Any marginal notes, titles or lead in references to Articles and the index of the Memorandum and Articles of Association shall not form part of the Memorandum or Articles of Association and shall not affect their interpretation. In interpreting these Articles of Association, unless there be something in the subject or context inconsistent therewith: address:
shall have the ordinary meaning given to it and shall include any facsimile number, electronic number or address or website used for the purposes of any communication pursuant to these Articles;
appointor:
means in relation to an alternate Director, the Director who appointed the alternate to act as his alternate;
Articles:
means these Articles of Association in their present form and all supplementary, amended or substituted articles for the time being in force;
ASR Code: means the Code of Conduct for Approved Securities Registrars published by the SFC as amended from time to time; Auditors:
means the persons appointed by the Company from time to time to perform the duties of auditors of the Company;
Board:
means the board of Directors of the Company as constituted from time to time or as the context may require the majority of Directors present and voting at a meeting of the Directors at which a quorum is present;
Call:
shall include any instalment of a call;
Clearing House: means a clearing house recognised by the laws of the jurisdiction in which the Shares of the Company are listed or quoted with the permission of the Company on a stock exchange in such jurisdiction; Central Clearing and Settlement System:
means the Central Clearing and Settlement System operated by the HKSCC;
5
Marginal Notes
Definitions
Close Associate(s):
shall have the meaning as defined in the Listing Rules;
Companies Act: means the Companies Act (as revised) of the Cayman Islands as amended from time to time and every other act, order regulation or other instrument having statutory effect (as amended from time to time) for the time being in force in the Cayman Islands applying to or affecting the Company, the Memorandum of Association and/or the Articles of Association; the time being in force in the Cayman Islands applying to or affecting the Company, the Memorandum of Association and/or the Articles of Association; Companies Ordinance:
means the Companies Ordinance, Cap. 622 of the Laws of Hong Kong as amended from time to time;
Company: means the above named company; corporate communications: Debenture and Debenture Holder:
has the meaning given to it under the Listing Rules; means and includes respectively debenture stock and debenture stockholder;
Director:
means such person or persons as shall be appointed to the Board from time to time;
Dividend:
means dividends, distributions in specie or in kind, capital distributions and capitalisation issues;
electronic communication:
means a communication sent, transmitted, conveyed or otherwise made available to the intended recipients of the communication in electronic format;
electronic facilities:
means, without limitation, website addresses and conference call systems, and any device, system, procedure, method or other facility whatsoever providing attendance at or participation in (or both attendance at and participation in) a general meeting by electronic communication as determined by the Board pursuant to these Articles;
electronic means:
includes sending or otherwise making available to the intended recipients of the communication in electronic format;
Head Office:
means such office of the Company as the Board may from time to time determine to be the principal office of the Company;
HKSCC:
means The Hong Kong Securities Clearing Company Limited;
HK Stock Exchange:
means The Stock Exchange of Hong Kong Limited;
HK$ or Hong Kong dollars:
means Hong Kong dollars, the lawful currency for the time being of Hong Kong
Holding Company:
has the meaning ascribed to it by Section 13 of the Companies Ordinance;
6
Hong Kong: means the Hong Kong Special Administrative Region of the People’s Republic of China; hybrid meeting:
means a general meeting convened for the (i) physical attendance by members and/or authorised representatives at the principal meeting location and where applicable, one or more meeting locations and (ii) virtual attendance and participation by members and/or authorised representatives by means of electronic facilities;
Listing Rules:
shall mean the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (as amended from time to time);
Month:
means a calendar month;
Newspapers: means at least one English language daily newspaper and at least one Chinese language daily newspaper, in each case published and circulating generally in the Relevant Territory and specified or not excluded for this purpose by the stock exchange in the Relevant Territory; Ordinary Resolution: Paid: prescribed securities:
means a resolution as described in Article 1(e) of these Articles; means, as it relates to a Share, paid or credited as paid; has the meaning given to it under the Securities and Future Ordinance;
Register:
means the principal register and any branch register of Shareholders of the Company to be maintained at such place within or outside the Cayman Islands as the Board shall determine from time to time;
register of holders:
has the meaning given to it under the Securities and Future (Uncertificated Securities Market) Rules;
Registered Office:
means the registered office of the Company for the time being as required by the Companies Act;
Registration Office:
means such place or places in the Relevant Territory or elsewhere where the Board from time to time determine to keep a branch register of Shareholders of the Company in respect of that class of share capital and where (except in cases where the Board otherwise agrees) transfers of other documents of title for Shares are to be lodged for registration and are to be registered;
Relevant Period:
means the period commencing from the date on which any of the securities of the Company first become listed on the HK Stock Exchange to and including the date immediately before the day on which none of such securities are so listed (and so that if at any time listing of any such securities is suspended for any reason whatsoever and for any length of time, they shall nevertheless be treated, for the purpose of this definition, as listed);
Relevant Territory:
means Hong Kong or such other territory where any of the securities of the Company is listed on a stock exchange in that territory;
Seal:
means the common seal of the Company and any one or more facsimile seals from time to time of the Company for use in the Cayman Islands or in any place outside the Cayman Islands;
7
Secretary:
means the person for the time being performing the duties of that office of the Company and includes any assistant, deputy, acting or temporary secretary, and where two or more persons are appointed to act as joint secretaries, any one of those persons;
Securities and Futures Ordinance:
means the Securities and Futures Ordinance, Cap. 571 of the laws of Hong Kong, as amended from time to time;
Securities and Futures means the Securities and Futures (Uncertificated Securities Market) Rules made (Uncertificated Securities under the Securities and Futures Ordinance; Market) Rules: SFC: means the Securities and Futures Commission of Hong Kong; Securities Seal:
shall mean a seal for use for sealing certificates for shares or other securities issued by the Company which is a facsimile of the Seal of the Company with the addition on its face of the words Securities Seal;
Share:
means a share in the share capital of the Company and includes stock except where a distinction between stock and Shares is expressed or implied;
Shareholder:
means the person who is duly registered in the Register as holder for the time being of any Share and includes persons who are jointly so registered;
Special Resolution: Subsidiary:
means a resolution as described in Article 1(d) of these Articles; has the meaning ascribed to it by Section 15 of the Companies Ordinance;
Transfer Office:
means the place where the principal register of Shareholders is located for the time being;
treasury share:
means a share held by the Company in its own name as a treasury share in accordance with the Companies Act; and
UNSRT System:
means an uncertificated securities registration and transfer system, and in relation to any shares or securities of the Company, a computer-based system, together with procedures and other facilities, that (a) enables title to the shares and securities to be evidenced and transferred without an instrument; and (b) facilitates supplementary and incidental matters.
8
(c) In these Articles, unless there be something in the subject or context inconsistent herewith: (i)
General
words denoting the singular number shall include the plural number and vice versa;
(ii) words importing any gender shall include every gender and words importing persons shall include partnerships, firms, companies and corporations; (iii) subject to the foregoing provisions of this Article, any words or expressions defined in the Companies Act (except any statutory modification thereof not in force when these Articles become binding on the Company) shall bear the same meaning in these Articles, save that “company” shall where the context permits include any company incorporated in the Cayman Islands or elsewhere; and (iv) references to a document (including, but without limitation, a resolution in writing) being signed or executed include references to it being signed or executed under hand or under seal or by electronic signature or by electronic communication or by any other method and references to a notice or document include a notice or document recorded or stored in any digital, electronic, electrical, magnetic or other retrievable form or medium and information in visible form whether having physical substance or not; (v) sections 8 and 19 of the Electronic Transactions Act (except any statutory modification thereof not in force when these Articles become binding on the Company), shall not apply to these Articles to the extent it imposes obligations or requirements in addition to those set out in these Articles; and (vi) references to any statute or statutory provision shall be construed as relating to any statutory modification or re-enactment thereof for the time being in force.
(d) At all times during the Relevant Period a resolution shall be a Special Resolution when it has been passed by a majority of not less than ¾ of the voting rights held by such Shareholders as, being entitled so to do, vote in person (whether physically or by virtual attendance with the use of electronic facilities) or by proxy or, in the cases of Shareholders which are corporations, by their respective duly authorised representatives at a general meeting of which notice specifying the intention to propose the resolution as a special resolution has been duly given.
Special Resolution
(e) A resolution shall be an Ordinary Resolution when it has been passed by a simple majority of such Shareholders as, being entitled so to do, vote in person (whether physically or by virtual attendance with the use of electronic facilities) or, where proxies are allowed, by proxy or, in the case of any Shareholder being a corporation, by its duly authorised representative at a general meeting held in accordance with these Articles and of which not less than 14 days’ notice has been duly given.
Ordinary Resolution
(f) A resolution in writing signed (in such manner as to indicate, expressly or impliedly, unconditional approval) by or on behalf of all Shareholders for the time being entitled to receive notice of and to attend and vote at general meetings of the Company shall, for the purpose of these Articles, be treated as an Ordinary Resolution duly passed at a general meeting of the Company duly convened and held and, where relevant as a Special Resolution so passed. Any such resolution shall be deemed to have been passed at a meeting held on the date on which it was signed by the last person to sign, and where the resolution states a date as being the date of his signature thereof by any Shareholder the statement shall be prima facie evidence that it was signed by him on that date. Such a resolution may consist of several documents in the like form, and signed by one or more relevant Shareholders.
Resolutions in writing
(g) A Special Resolution shall be effective for any purpose for which an Ordinary Resolution is expressed to be required under any provision of these Articles.
Special Resolution effective as Ordinary Resolution
9
(h) Subject to Article 5(a), the provisions of Special Resolutions and Ordinary Resolutions shall apply mutatis mutandis to any resolutions passed by the holders of any class of Shares. App.3 Para 16
- To the extent that the same is permissible under Cayman Islands law and subject to Article 13, a Special Resolution shall be required to alter the Memorandum of Association of the Company, to approve any amendment of the Articles or to change the name of the Company.
When Special Resolution is required
SHARES, WARRANTS AND MODIFICATION OF RIGHTS
App.3 Para 15
- Without prejudice to any special rights or restrictions for the time being attaching to any Shares or any class of Shares including preference Shares, any Share may be issued upon such terms and conditions and with such preferred, deferred or other qualified or special rights, or such restrictions, whether in regard to Dividend, voting, return of capital or otherwise, as the Company may from time to time by Ordinary Resolution determine (or, in the absence of any such determination or so far as the same may not make specific provision, as the Board may determine) and any Share may be issued on the terms that it is liable to be redeemed upon the happening of a specified event or upon a given date and either at the option of the Company, or at the option of the holder. No Shares shall be issued to bearer.
Issue of Shares
- The Board may issue warrants to subscribe for any class of Shares or other securities of the Company, which warrants may be issued on such terms as the Board may from time to time determine. Where warrants are issued to bearer, no certificate thereof shall be issued to replace one that has been lost unless the Board is satisfied beyond reasonable doubt that the original certificate thereof has been destroyed and the Company has received an indemnity in such form as the Board shall think fit with regard to the issue of any such replacement certificate.
Warrants
- (a) If at any time the share capital of the Company is divided into different classes of Shares, all or any of the special rights attached to any class (unless otherwise provided for by the terms of issue of the Shares of that class) may, subject to the provisions of the Companies Act, be varied or abrogated with the consent in writing of the holders of at least ¾ of the issued Shares of that class, or with the approval of a resolution passed by at least ¾ of the votes cast by the holders of the Shares of that class present and voting in person (whether physically or by virtual attendance with the use of electronic facilities) or by proxy at a separate meeting of such holders. To every such separate general meeting the provisions of these Articles relating to general meetings shall apply mutatis mutandis, but so that the necessary quorum shall be two persons holding (or, in the case of a Shareholder being a corporation, by its duly authorised representative) or representing by proxy at least one-third of the issued Shares of that class and that any holder of Shares of the class present in person (whether physically or by virtual attendance with the use of electronic facilities) (or in the case of the Shareholder being a corporation, by its duly authorised representative) or by proxy may demand a poll.
How rights of shares may be modified
(b) The provisions of this Article shall apply to the variation or abrogation of the rights attached to the Shares of any class as if each group of Shares of the class differently treated formed a separate class the rights whereof are to be varied or abrogated. (c) The special rights conferred upon the holders of any Shares or class of Shares shall not, unless otherwise expressly provided in the rights attaching to the terms of issue of such Shares be deemed to be altered by the creation or issue of further Shares ranking pari passu therewith. 6. The authorised share capital of the Company on the date of the adoption of these Articles is US$5,000,000 divided into 5,000,000,000 Shares of US$0.001 each.
Authorised Share Capital
- The Company in general meeting may from time to time, whether or not all the Shares for the time being authorised shall have been issued and whether or not all the Shares for the time being issued shall have been fully paid up, by Ordinary Resolution increase its share capital by the creation of new Shares, such new capital to be of such amount and to be divided into Shares of such class or classes and of such amounts in Hong Kong dollars or such other currency as the Shareholders may
Power to increase capital
10
think fit and as the resolution may prescribe. 8. Any new Shares shall be issued upon such terms and conditions and with such rights, privileges or restrictions attached thereto as the general meeting resolving upon the creation thereof shall direct, and if no direction be given, subject to the provisions of the Companies Act and of these Articles, as the Board shall determine; and in particular such Shares may be issued with a preferential or qualified right to participate in Dividends and in the distribution of assets of the Company and with a special right or without any right of voting.
On what conditions new shares may be issued
- The Board may, before the issue of any new Shares, determine that the same, or any of them, shall be offered in the first instance, and either at par or at a premium, to all the existing holders of any class of Shares in proportion as nearly as may be to the number of Shares of such class held by them respectively, or make any other provisions as to the allotment and issue such Shares, but in default of any such determination or so far as the same shall not extend, such Shares may be dealt with as if they formed part of the capital of the Company existing prior to the issue of the same.
When to be offered to existing shareholders
- Except so far as otherwise provided by the conditions of issue or by these Articles, any capital raised by the creation of new Shares shall be treated as if it formed part of the original capital of the Company and such Shares shall be subject to the provisions contained in these Articles with reference to the payment of calls and instalments, transfer and transmission, forfeiture, lien, cancellation, surrender, voting and otherwise.
New shares to form part of original capital
- (a) All unissued Shares and other securities of the Company shall be at the disposal of Unissued Shares the Board and it may offer, allot (with or without conferring a right of renunciation), the Directors grant options over or otherwise dispose of them to such persons, at such times, for such consideration and generally on such terms (subject to Article 9) as it in its absolute discretion thinks fit, but so that no Shares shall be issued at a discount. The Board shall, as regards any offer or allotment of Shares, comply with the provisions of the Companies Act, if and so far as such provisions may be applicable thereto.
Unissued Shares at the disposal of the Directors
(b) Neither the Company nor the Board shall be obliged, when making or granting any allotment of, offer of, option over or disposal of Shares or other securities of the Company, to make, or make available, and may resolve not to make, or make available, any such allotment, offer, option or Shares or other securities to Shareholders or others with registered addresses in any jurisdiction outside of the Relevant Territory, or in any particular territory or territories being a territory or territories where, in the absence of a registration statement or other special formalities, this would or might, in the opinion of the Board, be unlawful or impracticable, or the existence or extent of the requirement for such registration statement or special formalities might be expensive (whether in absolute terms or in relation to the rights of the Shareholder(s) who may be affected) or time consuming to determine. The Board shall be entitled to make such arrangements to deal with fractional entitlements arising on an offer of any unissued Shares or other securities as it thinks fit, including the aggregation and the sale thereof for the benefit of the Company. Shareholders who may be affected as a result of any of the matters referred to in this paragraph (b) shall not be, and shall be deemed not to be, a separate class of Shareholders for any purposes whatsoever. 12. (a) The Company may at any time pay commission to any person for subscribing or agreeing to subscribe (whether absolutely or conditionally) for any Shares or procuring or agreeing to procure subscriptions (whether absolute or conditional) for any Shares, but so that the conditions and requirements of the Companies Act shall be observed and complied with, and in each case the commission shall not exceed 10% of the price at which the Shares are issued. (b) If any Shares are issued for the purpose of raising money to defray the expenses of the construction of any works or buildings or the provision of any plant which cannot be made profitable within a period of one year, the Company may pay interest on so much of that share capital as is for the time being paid up for the period and, subject to any 11
Company may pay commission
Defraying of expenses
conditions and restrictions mentioned in the Companies Act, may charge the sum so paid by way of interest to capital as part of the cost of construction of the works or buildings, or the provisions of the plant. 13. The Company may from time to time by Ordinary Resolution: (a) increase its share capital as provided by Article 7; (b) consolidate or divide all or any of its share capital into Shares of a larger or smaller amount than its existing Shares; and on any consolidation of fully paid Shares into Shares of a larger amount, the Board may settle any difficulty which may arise as it thinks expedient and in particular (but without prejudice to the generality of the foregoing) may as between the holders of Shares to be consolidated determine which particular Shares are to be consolidated into a consolidated Share, and if it shall happen that any person shall become entitled to fractions of a consolidated Share or Shares, such fractions may be sold by some person appointed by the Board for that purpose and the person so appointed may transfer the Shares so sold to the purchaser thereof and the validity of such transfer shall not be questioned, and so that the net proceeds of such sale (after deduction of the expenses of such sale) may either be distributed among the persons who would otherwise be entitled to a fraction or fractions of a consolidated Share or Shares rateably in accordance with their rights and interest or may be paid to the Company for the Company’s benefit;
Increase in capital, consolidation and division of capital and subdivision, cancellation of shares and redenomination etc.
(c) divide its unissued Shares into several classes and attach thereto respectively any preferential, deferred, qualified or special rights, privileges or conditions; (d) sub-divide its Shares or any of them into Shares of smaller amount than is fixed by the Memorandum of Association, subject nevertheless to the provisions of the Companies Act, and so that the resolution whereby any Share is sub-divided may determine that, as between the holders of the Shares resulting from such sub-division, one or more of the Shares may have any such preferred or other special rights over, or may have such deferred rights or be subject to any such restrictions as compared with the others as the Company has power to attach to unissued or new Shares; (e) cancel any Shares which at the date of the passing of the resolution have not been taken or agreed to be taken by any person, and diminish the amount of its share capital by the amount of the Shares so cancelled; (f) make provision for the issue and allotment of Shares which do not carry any voting rights; (g) change the currency of denomination of its share capital; and (h) reduce its share premium account in any manner authorised, and subject to any conditions prescribed by law. 14. The Company may by Special Resolution reduce its share capital or undistributable reserve in any manner authorised, and subject to any conditions prescribed, by law.
12
Reduction of capital
- (a) Subject to the Companies Act, or any other law or so far as not prohibited by any law and subject to any rights conferred on the holders of any class of Shares, the Company shall have the power to purchase or otherwise acquire all or any of its own Shares (which expression as used in this Article includes redeemable Shares) provided that the manner and terms of purchase have first been authorised by an Ordinary Resolution of the Shareholders, and to purchase or otherwise acquire warrants and other securities for the subscription or purchase of its own Shares, and shares and warrants and other securities for the subscription or purchase of any shares in any company which is its Holding Company and may make payment therefor in any manner and terms authorised or not prohibited by law, including out of capital, or to give, directly or indirectly, by means of a loan, a guarantee, an indemnity, the provision of security or otherwise howsoever, financial assistance for the purpose of or in connection with a purchase or other acquisition made or to be made by any person of any Shares or warrants or other securities in the Company or any company which is a Holding Company of the Company and should the Company purchase or otherwise acquire its own Shares or warrants or other securities neither the Company nor the Board shall be required to select the Shares or warrants or other securities to be purchased or otherwise acquired rateably or in any other manner and terms as between the holders of Shares or warrants or other securities of the same class or as between them and the holders of Shares or warrants or other securities of any other class or in accordance with the rights as to Dividends or capital conferred by any class of Shares provided always that any such purchase or other acquisition or financial assistance shall only be made in accordance with the relevant code, rules or regulations issued from time to time by the HK Stock Exchange and/or the Securities and Futures Commission of Hong Kong from time to time in force. (b) Subject to the provisions of the Companies Act and the Memorandum of Association of the Company, and to any special rights conferred on the holders of any Shares or attaching to any class of Shares, Shares may be issued on the terms that they may, at the option of the Company or the holders thereof, be liable to be redeemed on such terms and in such manner, including out of capital, as the Board may deem fit. (c) Where the Company purchases for redemption a redeemable Share, purchases not made through the market or by tender shall be limited to a maximum price, and if purchases are by tender, tenders shall be available to all Shareholders alike. (d) The purchase or redemption of any Share shall not be deemed to give rise to the purchase or redemption of any other Share. (e) The holder of the Shares being purchased or redeemed shall be bound to deliver up to the Company at the Head Office or such other place as the Board shall specify the certificate(s) thereof for cancellation or, in the case of shares held in uncertificated form, by such electronic means or process as may be prescribed by the Board or the relevant system operator, and thereupon the Company shall pay to him the purchase or redemption monies in respect thereof. 15A. Subject to the Companies Act, shares that have been purchased or redeemed by the Company or surrendered to the Company may be held as treasury shares in accordance with the Companies Act. In the event the Board does not specify that the relevant shares are to be held as treasury shares, such shares shall be cancelled. 15B. No dividend may be declared or paid, and no other distribution (whether in cash or otherwise) of the Company's assets (including any distribution of assets to members on a winding up) may be declared or paid in respect of a treasury share. 15C. The Company shall be entered in the Register as the holder of the treasury shares provided that: (a) the Company shall not be treated as a member for any purpose and shall not exercise any right in respect of the treasury shares, and any purported exercise of such right shall be void; and 13
(b) a treasury share shall not be voted, directly or indirectly, at any meeting of the Company and shall not be counted as issued shares at any given time, whether for the purposes of these Articles or the Companies Act, save that an allotment of shares as fully paid bonus shares in respect of a treasury share is permitted and shares allotted as fully paid bonus shares in respect of a treasury share shall be treated as treasury shares. 15D. Subject to the Companies Act and the Listing Rules, treasury shares may be disposed of by the Company on such terms and conditions as determined by the Board. REGISTER OF SHAREHOLDERS AND SHARE CERTIFICATES 16. Except as otherwise expressly provided by these Articles or as required by law or as ordered by a court of competent jurisdiction, no person shall be recognised by the Company as holding any Share upon any trust and, except as aforesaid, the Company shall not be bound by or be compelled in any way to recognise (even when having notice thereof) any equitable, contingent, future or partial interest in any Share or any interest in any fractional part of a Share or any other right or claim to or in respect of any Shares except an absolute right to the entirety thereof of the registered holder. 17. (a) The Board shall cause to be kept the Register and there shall be entered therein the particulars required under the Companies Act. (a) Subject to the provisions of the Companies Act, if the Board considers it necessary or appropriate, the Company may establish and maintain a principal or branch register of Shareholders at such location as the Board thinks fit and, during the Relevant Period, the Company shall keep its principal or a branch register of Shareholders in Hong Kong. App.3 Para 20
Local or branch register
(b) During the Relevant Period (except when the Register is closed in accordance with the terms equivalent to the relevant section of the Companies Ordinance), any Shareholder may inspect during business hours any Register maintained in Hong Kong without charg e and require the provision to him of copies or extracts thereof in all respects as if the Company were incorporated under and were subject to the Companies Ordinance. Except when the register of holders is closed on terms equivalent to the relevant sectio n of the Companies Ordinance, the register of holders held in Hong Kong shall during normal business hours (subject to such reasonable restrictions as the Board may impose) be open to inspection by a holder of the prescribed securities without charge. Any holder of the prescribed securities may require a copy of the register of holders, or any part thereof. (c) The Register may be closed in accordance with the terms equivalent to the relevant section of the Companies Ordinance at such time or for such period not exceeding in the whole 30 days in each year as the Board may determine. 18. (a) Every person whose name is entered as a Shareholder in the Register shall be entitled to hold their shares in uncertificated form through the UNSRT System, the Central Clearing and Settlement System or any other system approved under the Securities and Fut ures Ordinance and the Securities and Futures (Uncertificated Securities Market) Rules, as applicable, in compliance with the Listing Rules and other relevant regulations. Where share certificates are issued, every person whose name is entered as a Shareholder in the Register shall be entitled to receive within the relevant time limit as prescribed in the Companies Act, the ASR Code or as the HK Stock Exchange may from time to time determine, whichever is shorter, after allotment or lodgement of a transfer (or within such other period as the conditions of issue shall provide or is required by the applicable rules of the stock exchange of the Relevant Territory) one certificate for all his Shares, or, if he shall so request, in a case where the allotment or transfer is of a number of Shares in excess of the number for the time being forming a stock exchange board lot for the purposes of the stock exchange of the Relevant Territory on which the Shares are listed upon payment of such sum (in the case of a transfer, not exceeding in the case of any share capital listed on a stock exchange in Hong Kong, HK$2.50 or such other sum as may from time to time be allowed or not prohibited under the Listing Rules, and in the 14
Share certificates
case of any other Shares, such sum in such currency as the Board may from time to time determine to be reasonable in the territory in which the relevant Register is situated, or otherwise such other sum as the Company may by Ordinary Resolution determine) for every certificate after the first as the Board may from time to time determine, such number of certificates for Shares in stock exchange board lots or whole multiples thereof as he shall request and one for the balance (if any) of the Shares in question, provided that in respect of a Share or Shares held jointly by several persons the Company shall not be bound to issue a certificate or certificates to each such person, and the issue and delivery of a certificate or certificates to one of the joint holders shall be sufficient delivery to all such holders. The Company shall comply with all applicable laws and regulations to facilitate the holding, transfer and registration of its prescribed securities, including electronic processes for corporate actions, as required by the uncertificated securities market regime or the ASR Code. (b) The Company may, in the event of a change in the form of definitive Share certificate adopted by the Board, issue new definitive certificates to all holders of Shares appearing on the Register in replacement of old definitive certificates issued to such holders. The Board may resolve whether or not to require the return of the old certificates as a condition precedent to the issue of replacement certificates and, as regards any old certificates which have been lost or defaced, to impose such conditions (including as to indemnity) as the Board shall see fit. If the Board elects not to require the return of the old certificates, the same shall be deemed to have been cancelled and of no further effect for all purposes. 19. Where any Shares, warrants, debentures or any form of securities of the Company are issued in certificated form, such certificate shall be issued under the Seal of the Company, which for this purpose may be a duplicate Seal.
Share certificates to be sealed
- Where share certificates are issued, they shall specify the number and class of Shares in respect of which it is issued and the amount paid thereon and may otherwise be in such form as the Board may from time to time prescribe. A share certificate shall relate to only one class of Shares, and where the capital of the Company includes Shares with different voting rights, the designation of each class of Shares, other than those which carry the general right to vote at general meetings, must include the words “restricted voting” or “limited voting” or “non voting” or some other appropriate designation which is commensurate with the rights attaching to the relevant class of Shares.
Share certificate to specify number and class of shares
- (a) The Company shall not be bound to register more than four persons as joint holders of any Share.
Joint holders
(b) If any Shares shall stand in the names of two or more persons, the person first named in the Register shall be deemed to be sole holder thereof as regards service of notice and, subject to the provisions of these Articles, all or any other matter connected with the Company, except the transfer of the Share. 22. If a share certificate is defaced, lost or destroyed, it may be replaced on payment of such fee, if any, (not exceeding, in the case of any share capital listed on a stock exchange in Hong Kong, HK$2.50 or such sum as may from time to time be allowed or not prohibited under the Listing Rules or prescribed by the ASR Code, and, in the case of any other capital, such sum in such currency as the Board may from time to time determine to be reasonable in the territory in which the relevant Register is situated, or such other sum as the Company may by Ordinary Resolution determine) as the Board shall from time to time determine and on such terms and conditions, if any, as to publication of notices, evidence and indemnity as the Board thinks fit and in the case of wearing out or defacement, after delivery up of the old certificate. In the case of destruction or loss, the person to whom such replacement certificate is given shall also bear and pay to the Company all costs and out- of-pocket expenses incidental to the investigation by the Company of the evidence of such destruction or loss and of such indemnity. 15
Replacement of share certificate
LIEN 23. The Company shall have a first and paramount lien on every Share (not being a fully paid Share) for all moneys, whether presently payable or not, called or payable at a fixed time in respect of that Share; and the Company shall also have a first and paramount lien and charge on all Shares (other than fully paid-up Shares) standing registered in the name of a Shareholder, whether singly or jointly with any other person or persons, for all the debts and liabilities of such Shareholder or his estate to the Company and whether the same shall have been incurred before or after notice to the Company of any equitable or other interest of any person other than such Shareholder, and whether the period for the payment or discharge of the same shall have actually arrived or not, and notwithstanding that the same are joint debts or liabilities of such Shareholder or his estate and any other person, whether a Shareholder of the Company or not. The Company’s lien (if any) on a Share shall extend to all Dividends and bonuses declared in respect thereof. The Board may at any time either generally or in any particular case waive any lien that has arisen, or declare any Share to be exempt wholly or partially from the provisions of this Article.
Company’s lien
- The Company may sell, in such manner as the Board thinks fit, any Shares on which the Company has a lien, but no sale shall be made unless some sum in respect of which the lien exists is presently payable or the liability or engagement in respect of which such lien exists is liable to be presently fulfilled or discharged, nor until the expiration of 14 days after a notice in writing, stating and demanding payment of the sum presently payable or specifying the liability or engagement and demanding fulfilment or discharge thereof and giving notice of intention to sell in default, shall have been given, in the manner in which notices may be sent to Shareholders of the Company as provided in these Articles, to the registered holder for the time being of the Shares, or the person entitled by reason of such holder’s death, bankruptcy or winding-up to the Shares.
Sale of shares subject to lien
of 25. The net proceeds of such sale after the payment of the costs of such sale shall be applied in or towards Application proceeds of sale payment or satisfaction of the debt or liability or engagement in respect whereof the lien exists, so far as the same is presently payable, and any residue shall (subject to a like lien for debts or liabilities not presently payable as existed upon the Shares prior to the sale) be paid to the person entitled to the Shares at the time of the sale. For the purpose of giving effect to any such sale, the Board may authorise some person to transfer the Shares sold to the purchaser thereof and may enter the purchaser’s name in the Register as holder of the Shares, and the purchaser shall not be bound to see the application of the purchase money, nor shall his title to the Shares be affected by any irregularity or invalidity in the proceedings relating to the sale.
CALLS ON SHARES 26. The Board may from time to time make such calls as it thinks fit upon the Shareholders in respect of any moneys unpaid on the Shares held by them respectively (whether on account of the nominal value of the Shares or by way of premiums) and not by the conditions of allotment thereof made payable at a fixed time. A call may be made payable either in one sum or by instalments.
Calls/ instalments
- At least 14 days’ notice of any call shall be given to the relevant Shareholders specifying the time and place of payment and to whom such call shall be paid.
Notice of call
- A copy of the notice referred to in Article 27 shall be sent to relevant Shareholders in the manner in which notices may be sent to Shareholders by the Company as herein provided.
Copy of notice to be sent to shareholders
16
- In addition to the giving of notice in accordance with Article 28, notice of the person appointed to receive payment of every call and of the times and places appointed for payment may be given to the relevant Shareholders by notice to be inserted at least once in the Newspapers.
Notice of call may be given
and place 30. Every Shareholder upon whom a call is made shall pay the amount of every call so made on him to Time for payment of call the person and at the time or times and place or places as the Board shall appoint.
- A call shall be deemed to have been made at the time when the resolution of the Board authorising such call was passed.
When call deemed to have been made
- The joint holders of a Share shall be severally as well as jointly liable for the payment of all calls and instalments due in respect of such Share or other moneys due in respect thereof.
Liability of joint holders
- The Board from time to time at its discretion may extend the time fixed for any call, and may extend such time as regards all or any of the Shareholders, whom due to residence outside the Relevant Territory or other cause the Board may deem entitled to any such extension but no Shareholder shall be entitled to any such extension except as a matter of grace and favour.
Board may extend time fixed for call
- If the sum payable in respect of any call or instalment is not paid before or on the day appointed for payment thereof, the person or persons from whom the sum is due shall pay interest on the same at such rate not exceeding 20% per annum as the Board shall fix from the day appointed for the payment thereof to the time of the actual payment, but the Board may waive payment of such interest wholly or in part.
Interest on unpaid calls
of 35. No Shareholder shall be entitled to receive any Dividend or bonus or to be present or vote (save as Suspension privileges while call proxy or authorised representative for another Shareholder) at any general meeting, either personally, unpaid or (save as proxy or authorised representative for another Shareholder) by proxy, or be reckoned in a quorum, or to exercise any other privilege as a Shareholder until all calls or instalments due from him to the Company, whether alone or jointly or jointly and severally with any other person, together with interest and expenses (if any) shall have been paid. Evidence in 36. On the trial or hearing of any action or other proceedings for the recovery of any money due for any action for call call, it shall be sufficient to prove that the name of the Shareholder sued is entered in the Register as the holder, or one of the holders, of the Shares in respect of which such debt accrues; that the resolution of the Board making the call has been duly recorded in the minute book of the Board; and that notice of such call was given to the Shareholder sued, in pursuance of these Articles, and it shall not be necessary to prove the appointment of the Directors who made such call, nor any other matters whatsoever, but the proof of the matters aforesaid shall be conclusive evidence of the debt. payable 37. (a) Any sum which by the terms of allotment of a Share is made payable upon allotment or at any Sums on allotment deemed a call fixed date, whether on account of the nominal value of the Share and/or by way of premium, shall for all purposes of these Articles be deemed to be a call duly made and notified and payable on the date fixed for payment, and in case of non- payment all the relevant provisions of these Articles as to payment of interest and expenses, forfeiture and the like, shall apply as if such sums had become payable by virtue of a call duly made and notified. Shares may be (b) The Board may on the issue of Shares differentiate between the allottees or holders as to the issued subject to different amount of calls to be paid and the time of payment. conditions as to calls, etc
- The Board may, if it thinks fit, receive from any Shareholder willing to advance the same, and either in money or money’s worth, all or any part of the money uncalled and unpaid or instalments payable upon any Shares held by him, and in respect of all or any of the moneys so advanced may pay interest at such rate (if any) not exceeding 20% per annum, as the Board may decide but a payment in advance of a call shall not entitle the Shareholder to receive any Dividend subsequently declared or to exercise any other rights or privileges as a Shareholder in respect of the Share or the due portion of the Shares upon which payment has been advanced by such Shareholder before it is called up. The Board may at any time repay the amount so advanced upon giving to such Shareholder not less than one Month’s notice in writing of its intention on that behalf, unless before the expiration of such notice the amount 17
so advanced shall have been called up on the Shares in respect of which it was advanced. TRANSFER OF SHARES 39. Subject to the Companies Act, all transfers of Shares shall be effected by transfer in writing in the usual or common form or in such other form as the Board may accept provided always that it shall be in such a form prescribed by the HK Stock Exchange and may be under hand only or, if the transferor or transferee is a Clearing House (or its nominee(s)), under hand or by machine imprinted signature or by such other means of execution as the Board may approve from time to time. Notwithstanding the aforesaid but subject to the Companies Act and all applicable laws and regulations, including without limitation the Securities and Futures Ordinance and the Securities and Futures (Uncertificated Securities Market) Rules, transfers of shares may be effected in uncertificated form through the UNSRT System, the Central Clearing and Settlement System or any other system approved by the HK Stock Exchange or the SFC, without the need for a written instrument of transfer.
Form of transfer
- For certificated shares, the instrument of transfer of any Share shall be executed by or on behalf of the transferor and by or on behalf of the transferee provided that the Board may dispense with the execution of the instrument of transfer by the transferor or the transferee or accept mechanically executed transfers in any case in which it in its absolute discretion thinks fit to do so. The transferor shall be deemed to remain the holder of the Share until the name of the transferee is entered in the Register in respect thereof. Nothing in these Articles shall preclude the Board from recognising a renunciation of the allotment or provisional allotment of any Share by the allottee in favour of some other person.
Execution of transfer
registered 41. (a) The Board may, in its absolute discretion at any time and from time to time, remove any Shares on principal Share on the principal Register to any branch Register or any Share on any branch Register register, branch register, etc to the principal Register or any other branch Register.
(b) Unless the Board otherwise agrees (which agreement may be on such terms and subject to such conditions as the Board in its absolute discretion may from time to time stipulate, and which agreement it shall, without giving any reason therefore, be entitled in its absolute discretion to give or withhold) no Shares on the principal Register shall be removed to any branch Register nor shall Shares on any branch Register be removed to the principal Register or any other branch Register and all removals and other documents of title relating to or affecting the title to any share or other securities of the Company shall be lodged for registration, and be registered, in the case of any Shares on a branch Register, at the relevant Registration Office, and, in the case of any Shares on the principal Register, at the Transfer Office. (c) Notwithstanding anything contained in these Articles, the Company shall as soon as practicable and on a regular basis record in the principal Register all removals of Shares effected on any branch Register and shall at all times maintain the principal Register and all branch Registers in all respects in accordance with the Companies Act.
18
- Fully paid Shares shall be free from any restriction with respect to the right of the holder thereof to transfer such Shares (except when permitted by the HK Stock Exchange) and shall also be free from all liens. The Board however, may, in its absolute discretion, refuse to register a transfer of any Share which is not fully paid to a person of whom it does not approve or any Share issued under any share option scheme upon which a restriction on transfer imposed thereby still subsists, and it may also refuse to register a transfer of any Share (whether fully paid up or not) to more than four joint holders or a transfer of any Shares (not being a fully paid up Share) on which the Company has a lien.
Directors may refuse to register a transfer
- The Board may also decline to recognise any instrument of transfer unless: (a) a fee of such maximum as the HK Stock Exchange may from time to time determine to be payable (or such lesser sum as the Board may from time to time require) has been paid to the Company;
Requirement as to transfer
(b) the instrument of transfer is lodged at the relevant Registration Office or, as the case may be, the Transfer Office accompanied by the certificate of the Shares (if one has been issued) to which it relates, and such other evidence as the Board may reasonably require to show the right of the transferor to make the transfer (and, if the instrument of transfer is executed by some other person on his behalf, the authority of that person so to do); (c) the instrument of transfer is in respect of only one class of Share; (d) the Shares concerned are free of any lien in favour of the Company; and (e) if applicable, the instrument of transfer is properly stamped. 44. The Board may refuse to register a transfer of any Share to an infant or to a person of unsound mind or under other legal disability.
No transfer to an infant
- If the Board shall refuse to register a transfer of any Share, it shall, within two months after the date on which the transfer was lodged with the Company, send to each of the transferor and the transferee notice of such refusal and, except where the subject Share is not a fully paid Share, the reason(s) for such refusal.
Notice of refusal
- Upon every transfer of Shares, the certificate in respect thereof (if one has been issued) held by the transferor shall be given up to be cancelled, and shall forthwith be cancelled accordingly, and a new certificate shall, upon request by the transferee and subject to the Board resolving to issue certificate(s), be issued to the transferee in respect of the Shares transferred to him as provided in Article 18, and if any of the Shares included in the certificate so given up shall be retained by the transferor a new certificate in respect thereof shall, upon request by the transferor and subject to the Board resolving to issue share certificate(s), be issued to him as provided in Article 18. The Company shall retain the instrument of transfer. Where shares are transferred in uncertificated form, no certificate shall be required to be surrendered or issued, and the transfer of shares shall be registered in accordance with the applicable uncertificated securities regime.
Certificate to be given up on transfer
When transfer 47. The registration of transfers may be suspended when the Register is closed in accordance with Article books or register is closed 17(d).
19
TRANSMISSION OF SHARES 48. In the case of the death of a Shareholder, the survivor or survivors where the deceased was a joint holder, and the legal personal representatives of the deceased where he was a sole or only surviving holder, shall be the only persons recognised by the Company as having any title to his interest in the Shares; but nothing herein contained shall release the estate of a deceased holder (whether sole or joint) from any liability in respect of any Share solely or jointly held by him.
Deaths of registered holder or of joint holder of shares
- Any person becoming entitled to a Share in consequence of the death or bankruptcy or winding-up of a Shareholder may, upon such evidence as to his title being produced as may from time to time be required by the Board, and subject as hereinafter provided, elect either to be registered himself as holder of the Share or to have some person nominated by him registered as the transferee thereof.
Registration of personal representativ es and trustees in bankruptcy
- If the person becoming entitled to a Share pursuant to Article 49 shall elect to be registered himself as the holder of such Share, he shall deliver or send to the Company a notice in writing signed by him, at (unless the Board otherwise agrees) the Registration Office, stating that he so elects. If he shall elect to have his nominee registered, he shall testify his election by executing a transfer of such Share to his nominee. All the limitations, restrictions and provisions of these Articles relating to the right to transfer and the registration of transfers of Shares shall be applicable to any such notice or transfer as aforesaid as if the death, bankruptcy or winding-up of the Shareholder had not occurred and the notice or transfer were a transfer executed by such Shareholder.
Notice of election to be registered of nominee
- A person becoming entitled to a Share by reason of the death, bankruptcy or winding- up of the holder shall be entitled to the same Dividends and other advantages to which he would be entitled if he were the registered holder of the Share. However, the Board may, if it thinks fit, withhold the payment of any Dividend payable or other advantages in respect of such Share until such person shall become the registered holder of the Share or shall have effectually transferred such Share, but, subject to the requirements of Article 80 being met, such a person may vote at general meetings of the Company.
Retention of dividends, etc. until transmission of shares of a deceased or bankrupt shareholder
FORFEITURE OF SHARES 52. If a Shareholder fails to pay any call or instalment of a call on the day appointed for payment thereof, the Board may, at any time thereafter during such time as any part of the call or instalment remains unpaid, without prejudice to the provisions of Article 34, serve notice on him requiring payment of so much of the call or instalment as is unpaid, together with any interest which may have accrued and which may still accrue up to the date of actual payment.
If call or instalment not paid notice may be given
- The notice shall name a further day (not earlier than the expiration of 14 days from the date of the notice) on or before which the payment required by the notice is to be made, and it shall also name the place where payment is to be made such place being the Registered Office or a Registration Office or another place within the Relevant Territory. The notice shall also state that, in the event of nonpayment at or before the time appointed, the Shares in respect of which the call was made will be liable to be forfeited.
Content of notice of call
- If the requirements of any such notice as aforesaid are not complied with, any Share in respect of which the notice has been given may at any time thereafter, before the payment required by the notice has been made, be forfeited by a resolution of the Board to that effect. Such forfeiture shall include all Dividends and bonuses declared in respect of the forfeited Share and not actually paid before the forfeiture. The Board may accept the surrender of any Share liable to be forfeited hereunder and in such cases references in these Articles to forfeiture shall include surrender.
If notice not complied with shares may be forfeited
- Any Share so forfeited shall be deemed to be the property of the Company, and may be re-allotted, sold or otherwise disposed of on such terms and in such manner as the Board thinks fit and at any time before a sale or disposition, the forfeiture may be cancelled on such terms as the Board thinks fit.
Forfeited shares to become property of Company
20
- A person whose Shares have been forfeited shall cease to be a Shareholder in respect of the forfeited Shares, but shall, nevertheless, remain liable to pay to the Company all moneys which, at the date of forfeiture, were payable by him to the Company in respect of the forfeited Shares, together with (if the Board shall in its discretion so require) interest thereon from the date of forfeiture until the date of actual payment (including the payment of such interest) at such rate not exceeding 20% per annum as the Board may prescribe, and the Board may enforce the payment thereof if it thinks fit, and without any deduction or allowance for the value of the Shares at the date of forfeiture, but his liability shall cease if and when the Company shall have received payment in full of all such moneys in respect of the Shares. For the purposes of this Article any sum which by the terms of issue of a Share, is payable thereon at a fixed time which is subsequent to the date of forfeiture, whether on account of the nominal value of the Share or by way of premium, shall notwithstanding that such time has not yet arrived be deemed to be payable on the date of forfeiture, and the same shall become due and payable immediately upon the forfeiture, but interest thereon shall only be payable in respect of any period between the said fixed time and the date of actual payment. If the relevant shares are held in uncertificated form, the Company shall take such steps as may be required under the applicable uncertificated securities regime to give effect to the forfeiture.
Arrears to be paid not withstanding forfeiture
- A certificate in writing that the declarant is a Director or the Secretary, and that a Share has been duly forfeited or surrendered on a date stated in the certificate, shall be conclusive evidence of the facts therein stated as against all persons claiming to be entitled to the Share. The Company may receive the consideration, if any, given for the Share on any re- allotment, sale or disposition thereof and may execute a transfer of the Share in favour of the person to whom the Share is re-allotted, sold or disposed of and such person shall thereupon be registered as the holder of the Share, and shall not be bound to see to the application of the subscription or purchase money, (if any), nor shall his title to the Share be affected by any irregularity or invalidity in the proceedings in reference to the forfeiture, re-allotment, sale or disposal of such Share.
Evidence of forfeiture and transfer of forfeited share
- When any Share shall have been forfeited, notice of the forfeiture shall be given to the Shareholder in whose name it stood immediately prior to the forfeiture, and an entry of the forfeiture, with the date thereof, shall forthwith be made in the Register, but no forfeiture shall be in any manner invalidated by any omission or neglect to give such notice or make any such entry.
Notice after forfeiture
- Notwithstanding any such forfeiture as aforesaid the Board may at any time, before any Shares so forfeited shall have been re-allotted, sold or otherwise disposed of, cancel the forfeiture on such terms as it thinks fit or permit the Shares so forfeited to be bought back or redeemed upon the terms of payment of all calls and interest due upon and expenses incurred in respect of the Shares, and upon such further terms (if any) as it thinks fit.
Power to redeem forfeited shares
not to 60. The forfeiture of a Share shall not prejudice the right of the Company to any call already made or any Forfeiture prejudice Company’s right instalment payment thereon.
- (a) The provisions of these Articles as to forfeiture shall apply in the case of non- payment of any sum which, by terms of issue of a Share, becomes payable at a fixed time, whether on account of the nominal value of the Share or by way of premium, as if the same had been payable by virtue of a call duly made and notified. (b) In the event of a forfeiture of Shares the Shareholder shall be bound to deliver and shall forthwith deliver to the Company the certificate or certificates held by him for the Shares so forfeited and in any event the certificates representing Shares so forfeited shall be void and of no further effect.
21
to call or instalment Forfeiture for non-payment of any sum due on shares
GENERAL MEETINGS App.3 Para 14(1)
App 3 Para 14(5)
App.3 Para 14(2)
- At all times during the Relevant Period, the Company shall in each financial year hold a general meeting as its annual general meeting in addition to any other meeting in that year and shall specify the meeting as such in the notice calling it, and such annual general meeting shall be held within 6 Months after the end of the Company’s financial year (or such longer period as may be authorised by the HK Stock Exchange). The annual general meeting shall be held in the Relevant Territory or elsewhere as may be determined by the Board and at such time and place as the Board shall appoint. A meeting of the Shareholders or any class thereof may be held physically, as a hybrid meeting or wholly by electronic means using telephone, electronic or other electronic communication facilities as to permit all persons participating in the meeting to communicate with each other, and participation in such a meeting shall constitute presence at such meeting. Unless otherwise determined by the Board, the manner of convening and the proceedings at a general meeting set out in these Articles shall apply, mutatis mutandis, to hybrid or wholly electronic meetings. In the event of any technical difficulties, disruptions, or procedural issues arising during a hybrid or electronic meeting, including but not limited to connectivity problems, platform malfunctions, or disputes regarding the conduct of the meeting, the chairman of the meeting shall have the authority to make any rulings or decisions necessary to address such issues. Any ruling, determination, or decision made by the chairman of the meeting under the scope of this provision shall be final, conclusive, and binding on the Company and all members.
When annual general meeting to be held
- The Board may, whenever it thinks fit, convene an extraordinary general meeting. One or more Shareholders holding, at the date of deposit of the requisition, in aggregate not less than one tenth of the voting rights (on a one vote per share basis) in the share capital of the Company may also make a requisition to convene an extraordinary general meeting and/or add resolutions to the agenda of a meeting. Such requisition shall be made in writing to the Board or the Secretary for the purpose of requiring an extraordinary general meeting to be called by the Board for the transaction of any business specified in such requisition. Such meeting shall be held within two Months after the deposit of such requisition. If within 21 days of such deposit, the Board fails to proceed to convene such meeting, the requisitionist(s) himself (themselves) may do so in the same manner, and all reasonable expenses incurred by the requisitionist(s) as a result of the failure of the Board shall be reimbursed to the requisitionist(s) by the Company.
Extraordinar y general meeting
- An annual general meeting of the Company shall be called by at least 21 days’ notice in writing, and a general meeting of the Company, other than an annual general meeting, shall be called by at least 14 days’ notice in writing. The notice shall be exclusive of the day on which it is served or deemed to be served and of the day for which it is given, and shall specify the place, the day, the hour and the agenda of the meeting and particulars of the resolutions to be considered at that meeting and in case of special business (as defined in Article 67), the general nature of that business, and shall be given, in manner hereinafter mentioned or in such other manner, if any, as may be prescribed by the Company in general meeting, to such persons as are, under these Articles, entitled to receive such notices from the Company, provided that a meeting of the Company shall notwithstanding that it is called by shorter notice than that specified in this Article, if permitted by the Listing Rules, be deemed to have been duly called if it is so agreed:
Convening of extraordinar y general meeting
65.. An annual general meeting of the Company shall be called by at least 21 days’ notice in writing, and a general meeting of the Company, other than an annual general meeting, shall be called by at least 14 days’ notice in writing. The notice shall be exclusive of the day on which it is served or deemed to be served and of the day for which it is given, and shall specify the place, the day, the hour and the agenda of the meeting and particulars of the resolutions to be considered at that meeting and in case of special business (as defined in Article 67), the general nature of that business, and shall be given, in manner hereinafter mentioned or in such other manner, if any, as may be prescribed by the Company in general meeting, to such persons as are, under these Articles, entitled to receive such notices from the Company, provided that a meeting of the Company shall notwithstanding that it is called by shorter notice than that specified in this Article, if permitted by the Listing Rules, be deemed to have been duly called if it is so agreed:
Notice of meetings
22
(a) in the case of a meeting called as the annual general meeting, by all the Shareholders entitled to attend and vote thereat; and (b) in the case of any other meeting, by a majority in number of the Shareholders having a right to attend and vote at the meeting, being a majority together holding not less than 95% of the total voting rights at the meeting of all members of the Company. 66. (a) The accidental omission to give any notice to, or the non-receipt of any notice by, any person entitled to receive notice shall not invalidate any resolution passed or any proceedings at any such meeting.
Omission to give notice
(b) In the case where forms of proxy or notice of appointment of corporate representative are to be sent out with any notice, the accidental omission to send such forms of proxy or notice of appointment of corporate representative to, or the non-receipt of such forms by, any person entitled to receive notice of the relevant meeting shall not invalidate any resolution passed or any proceeding at any such meeting. PROCEEDINGS AT GENERAL MEETINGS 67. (a) All business shall be deemed special that is transacted at an extraordinary general meeting and also all business shall be deemed special that is transacted at an annual general meeting with the exception of the following, which shall be deemed ordinary business: (i)
Special business, business of annual general meeting
the declaration and sanctioning of Dividends;
(ii) the consideration and adoption of the accounts and balance sheets and the reports of the Directors and Auditors and other documents required to be annexed to the balance sheets; (iii) the election of Directors in place of those retiring; (iv) the appointment of Auditors; (v) the fixing of, or the determining of the method of fixing of the remuneration of the Directors and of the Auditors; (vi) the granting of any mandate or authority to the Board to offer, allot, grant options over, or otherwise dispose of the unissued Shares representing not more than 20% (or such other percentage as may from time to time be specified in the Listing Rules) in nominal value of its then existing issued share capital and the number of any securities repurchased pursuant to paragraph (vii) of this Article; and (vii) the granting of any mandate or authority to the Board to repurchase securities of the Company.
- For all purposes the quorum for a general meeting shall be two Shareholders present in person (whether physically or by virtual attendance with the use of electronic facilities) (or, in the case of a Shareholder being a corporation, by its duly authorised representative) or by proxy and entitled to vote. No business shall be transacted at any general meeting unless the requisite quorum shall be present at the time when the meeting proceeds to business and continues to be present until the conclusion of the meeting.
23
Quorum
- If within 15 minutes from the time appointed for the meeting a quorum is not present, the meeting, if convened upon the requisition of Shareholders, shall be dissolved, but in any other case it shall stand adjourned to the same day in the next week and at such time and place as shall be decided by the Board, and if at such adjourned meeting a quorum is not present within 15 minutes from the time appointed for holding the meeting, the Shareholder or the Shareholders present in person (whether physically or by virtual attendance with the use of electronic facilities) (or, in the case of a Shareholder being a corporation by its duly authorised representative) or by proxy and entitled to vote shall be a quorum and may transact the business for which the meeting was called.
When quorum is not present meeting to be dissolved and when to be adjourned
- The chairman (if any) of the Company or if he is absent or declines to take the chair at such meeting, the vice chairman (if any) of the Company shall take the chair at every general meeting, or, if there be no such chairman or vice chairman, or, if at any general meeting neither of such chairman or vice chairman is present within 15 minutes after the time appointed for holding such meeting, or both such persons decline to take the chair at such meeting, the Directors present shall choose one of their number as chairman of the meeting, and if no Director be present or if all the Directors present decline to take the chair or if the chairman chosen shall retire from the chair, then the Shareholders present shall choose one of their number to be chairman of the meeting.
Chairman of general meeting
- The chairman of the meeting may, with the consent of any general meeting at which a quorum is present, and shall, if so directed by the meeting, adjourn any meeting from time to time and from place to place and/or from one form to another (a physical meeting, a hybrid meeting or an electronic meeting) as the meeting shall determine. Whenever a meeting is adjourned for 14 days or more, at least seven clear days’ notice, specifying the place, the day and the hour of the adjourned meeting shall be given in the same manner as in the case of an original meeting but it shall not be necessary to specify in such notice the nature of the business to be transacted at the adjourned meeting. Save as aforesaid, no notice of an adjournment or of the business to be transacted at any adjourned meeting needs to be given nor shall any Shareholder be entitled to any such notice. No business shall be transacted at an adjourned meeting other than the business which might have been transacted at the meeting from which the adjournment took place.
Power to adjourn general meeting, business of adjourned meeting
- At any general meeting a resolution put to the vote of the meeting shall be decided by poll save that the chairman of the meeting may, pursuant to the Listing Rules, allow a resolution to be voted on by a show of hands. Where a show of hands is allowed, before or on the declaration of the result of the show of hands, a poll may be demanded by:
Poll, show of hands and demand for poll
(a) at least two Shareholders present in person (whether physically or by virtual attendance with the use of electronic facilities) (or, in the case of a Shareholder being a corporation, by its duly authorised representative) or by proxy for the time being entitled to vote at the meeting; or (b) any Shareholder or Shareholders present in person (whether physically or by virtual attendance with the use of electronic facilities) (or, in the case of a Shareholder being a corporation, by its duly authorised representative) or by proxy and representing not less than one-tenth of the total voting rights of all the Shareholders having the right to vote at the meeting; or (c) any Shareholder or Shareholders present in person (whether physically or by virtual attendance with the use of electronic facilities) (or, in the case of a Shareholder being a corporation, by its duly authorised representative) or by proxy and holding Shares conferring a right to vote at the meeting being Shares on which an aggregate sum has been paid up equal to not less than one-tenth of the total sum paid up on all the Shares conferring that right.
24
- Where a resolution is voted on by a show of hands (whether physically or by virtual attendance with the use of electronic facilities) as permitted by the Listing Rules, a declaration by the chairman of the meeting that a resolution has on a show of hands been carried or carried unanimously, or by a particular majority, or not carried by a particular majority, or lost, and an entry to that effect made in the minute book of the Company shall be conclusive evidence of the facts without proof of the number or proportion of the votes recorded in favour of or against such resolution.
What is to be evidence of the passing of a resolution
74 A poll shall be taken in such manner (including the use of ballot or voting papers or tickets or electronic means) and at such time and place as the chairman of the meeting directs. No notice need be given of a poll not taken immediately. The result of the poll shall be deemed to be the resolution of the meeting at which the poll was required or demanded. In the event that a poll is demanded after the chairman of the meeting allows a show of hands pursuant to Article 72, the demand for a poll may be withdrawn, with the consent of the chairman of the meeting, at any time before the close of the meeting at which the poll was demanded or the taking of the poll, whichever is the earlier.
Poll
- Any poll on the election of a chairman of a meeting or on any question of adjournment shall be taken at the meeting and without adjournment.
- In the case of an equality of votes, whether on a show of hands or on a poll (whether physically or by virtual attendance with the use of electronic facilities), the chairman of the meeting shall be entitled to a second or casting vote. In case of any dispute as to the admission or rejection of any vote, the chairman of the meeting shall determine the same, and such determination shall be final and conclusive.
Chairman to have casting vote
- The demand for a poll shall not prevent the continuance of a meeting for the transaction of any business other than the question on which a poll has been demanded.
Business may proceed notwithstandi ng demand for poll
- If an amendment shall be proposed to any resolution under consideration but shall in good faith be ruled out of order by the chairman of the meeting, the proceedings shall not be invalidated by any error in such ruling. In the case of a resolution duly proposed as a Special Resolution no amendment thereto (other than a mere clerical amendment to correct a patent error) may in any event be considered or voted upon.
Amendment of resolutions
VOTES OF SHAREHOLDERS 79. Subject to any special rights, privileges or restrictions as to voting for the time being attached to any class or classes of Shares, at any general meeting on a poll every Shareholder present in person (whether physically or by virtual attendance with the use of electronic facilities) (or, in the case of a Shareholder being a corporation, by its duly authorised representative) or by proxy, shall have one vote for every Share of which he is the holder which is fully paid or credited as fully paid (but so that no amount paid or credited as paid on a Share in advance of calls or instalments shall be treated for the purposes of this Article as paid on the Share), and on a show of hands every Shareholder who is present in person (whether physically or by virtual attendance with the use of electronic facilities) (or, in the case of a Shareholder being a corporation, by its duly authorised representative) or by proxy shall (save as provided otherwise in this Article) have one (1) vote. On a poll a Shareholder entitled to more than one vote need not use all his votes or cast all his votes in the same way. Notwithstanding anything contained in these Articles, where more than one proxy is appointed by a Shareholder which is a Clearing House (or its nominee(s)), each such proxy shall have one vote on a show of hands and on a poll, each such proxy is under no obligation to cast all his votes in the same way. For the avoidance of doubt, votes (whether on a show of hands or by way of poll) may be cast by such means, electronic or otherwise, as the Board or the chairman of the meeting may determine.
25
Votes of shareholders
App.3 Para 14(3), 14(4)
79A. All Shareholders of the Company (including a Shareholder which is a Clearing House (or its nominee(s)) shall have the right to (a) speak at a general meeting and (b) vote at a general meeting (whether physically or by virtual attendance with the use of electronic facilities), except where a Shareholder is required by the Listing Rules to abstain from voting to approve the matter under consideration. Where any Shareholder is, under the Listing Rules, required to abstain from voting on any particular resolution or restricted to voting only for or only against any particular resolution, any votes cast by or on behalf of such Shareholder in contravention of such requirement or restriction shall not be counted. 80. Any person entitled under Article 51 to be registered as the holder of any Shares may vote at any general meeting in respect thereof in the same manner as if he were the registered holder of such Shares, provided that at least 48 hours before the time of the holding of the meeting or adjourned meeting (as the case may be) at which he proposes to vote, he shall satisfy the Board of his right to be registered as the holder of such Shares or the Board shall have previously admitted his right to vote at such meeting in respect thereof.
Votes in respect of deceased and bankrupt shareholders
- Where there are joint registered holders of any Share, any one of such persons may vote at any meeting, either personally or by proxy, in respect of such Share as if he were solely entitled thereto; but if more than one of such joint holders be present at any meeting personally or by proxy, that one of the said persons so present whose name stands first on the Register in respect of such Share shall alone be entitled to vote in respect thereof. Several executors or administrators of a deceased Shareholder, and several trustees in bankruptcy or liquidators of a Shareholder in whose name any Share stands shall for the purposes of this Article be deemed joint holders thereof.
Joint holders
- A Shareholder of unsound mind or in respect of whom an order has been made by any court having jurisdiction in lunacy may vote, whether on a poll or on a show of hands, by his committee or receiver, or other person in the nature of a committee or receiver appointed by that court, and any such committee, receiver or other person may vote on a poll by proxy. Evidence to the satisfaction of the Board of the authority of the person claiming to exercise the right to vote shall be delivered to such place or one of such places (if any) as is specified in accordance with these Articles for the deposit of instruments of proxy or, if no place is specified, at the Registration Office, not later than the latest time at which an instrument of proxy must, if it is to be valid for the meeting, be delivered.
Votes of shareholders of unsound mind
- Save as expressly provided in these Articles or otherwise determined by the Board, no person other than a Shareholder duly registered and who shall have paid everything for the time being due from him payable to the Company in respect of his Shares shall be entitled to be present or to vote (save as proxy or authorised representative for another Shareholder) whether personally, by proxy or by attorney or to be reckoned in the quorum, at any general meeting.
Qualification for voting
- No objection shall be raised to the qualification of any person exercising or purporting to exercise a vote or the admissibility of any vote except at the meeting or adjourned meeting at which the vote objected to is given or tendered, and every vote not disallowed at such meeting shall be valid for all purposes. Any such objection made in due time shall be referred to the chairman of the meeting, whose decision shall be final and conclusive.
Objections to votes
26
APPOINTMENT OF PROXY AND CORPORATE REPRESENTATIVE App.3 Para 18
- Any Shareholder entitled to attend and vote at a meeting of the Company shall be entitled to appoint another person as his proxy to attend and vote instead of him. A Shareholder who is the holder of two or more Shares may appoint more than one proxy to represent him and vote on his behalf at a general meeting of the Company or at a class meeting. A proxy need not be a Shareholder of the Company. On a poll or a show of hands votes may be given either personally (or, in the case of a Shareholder being a corporation, by its duly authorised representative) or by proxy. A proxy shall be entitled to exercise the same powers on behalf of a Shareholder who is an individual and for whom he acts as proxy as such Shareholder could exercise. In addition, a proxy shall be entitled to exercise the same powers on behalf of a Shareholder which is a corporation and for which he acts as proxy as such Shareholder could exercise as if it were an individual Shareholder present in person (whether physically or by virtual attendance with the use of electronic facilities) at any general meeting.
Proxies
- No appointment of a proxy shall be valid unless it names the person appointed and his appointor. The Board may, unless it is satisfied that the person purporting to act as proxy is the person named in the relevant instrument for his appointment and the validity and authenticity of the signature of his appointor, decline such person’s admission to the relevant meeting, reject his vote or, in the event that a poll is demanded after the chairman of the meeting allows a show of hands pursuant to Article 72, his demand for a poll and no Shareholder who may be affected by any exercise by the Board of its power in this connection shall have any claim against the Directors or any of them nor may any such exercise by the Board of its powers invalidate the proceedings of the meeting in respect of which they were exercised or any resolution passed or defeated at such meeting.
App.3 Para 14
- The instrument appointing a proxy shall be in writing under the hand of the appointor or of his attorney duly authorised in writing, or if the appointor is a corporation, either under seal or under the hand of an officer or attorney duly authorised.
Instrument appointing proxy to be in writing
- The instrument appointing a proxy and, if requested by the Board, the power of attorney or other authority (if any) under which it is signed or a notarially certified copy of that power or authority shall be deposited at such place or one of such places (if any) as is specified in the notice of meeting or in the instrument of proxy issued by the Company (or, if no place is specified, at the Registration Office) not less than 48 hours before the time for holding the meeting or adjourned meeting (as the case may be) at which the person named in such instrument proposes to vote, and in default the instrument of proxy shall not be treated as valid. No instrument appointing a proxy shall be valid after the expiration of 12 Months from the date of its execution, except at an adjourned meeting where the meeting was originally held within 12 Months from such date. Delivery of an instrument appointing a proxy shall not preclude a Shareholder from attending and voting in person (whether physically or by virtual attendance with the use of electronic facilities) (or in the case of a Shareholder being a corporation, its duly authorised representative) at the meeting concerned and, in such event, the instrument appointing a proxy shall be deemed to be revoked.
Appointmen t of proxy must be deposited
- Every instrument of proxy, whether for a specified meeting or otherwise, shall be in such form as the Board may from time to time approve, provided that it shall not preclude the use of the twoway form. Any form issued to a Shareholder for use by him for appointing a proxy to attend and vote at an extraordinary general meeting or at an annual general meeting at which any business is to be transacted shall be such as to enable the Shareholder, according to his intentions, to instruct the proxy to vote in favour of or against (or, in default of instructions, to exercise his discretion in respect of) each resolution dealing with any such business.
Form of proxy
- The instrument appointing a proxy to vote at a general meeting shall: (i) be deemed to confer authority upon the proxy to demand or join in demanding a poll and to vote on any resolution (or amendment thereto) put to the meeting for which it is given as the proxy thinks fit; and (ii) unless the contrary is stated therein, be valid as well for any adjournment of the meeting as for the meeting to which it relates.
Authority under instrument appointing proxy
27
App.3 Para 19
- A vote given in accordance with the terms of an instrument of proxy or by the duly authorised representative of a corporation shall be valid notwithstanding the previous death or insanity of the principal or revocation of the proxy or power of attorney or other authority under which the proxy was executed or the transfer of the Share in respect of which the proxy is given, provided that no intimation in writing of such death, insanity, revocation or transfer as aforesaid shall have been received by the Company at its Registration Office, or at such other place as is referred to in Article 88, at least two hours before the commencement of the meeting or adjourned meeting at which the proxy is used.
When vote by proxy valid though authority revoked
- (a) Any corporation which is a Shareholder may, by resolution of its directors or other governing body or by power of attorney, authorise such person as it thinks fit to act as its representative at any meeting of the Company or of any class of Shareholders of the Company, and the person so authorised shall be entitled to exercise the same rights and powers on behalf of the corporation which he represents as that corporation could exercise if it were an individual Shareholder of the Company. References in these Articles to a Shareholder present in person (whether physically or by virtual attendance with the use of electronic facilities) at a meeting shall, unless the context otherwise requires, include a corporation which is a Shareholder represented at the meeting by such duly authorised representative.
Appointmen t of multiple corporate representativ es
(b) Where a Shareholder is a Clearing House (or its nominee(s)), it may (subject to Article 93) appoint proxies or authorise such person or persons as it thinks fit to act as its representative or representatives, who enjoy rights equivalent to the rights of other Shareholders, at any meeting of the Company (including but not limited to general meetings and creditors meetings) or at any meeting of any class of Shareholders provided that if more than one person is so authorised, the authorisation shall specify the number and class of Shares in respect of which each such representative is so authorised. A person so authorised pursuant to the provisions of this Article shall be deemed to have been duly authorised without further evidence of the facts and be entitled to exercise the same rights and powers on behalf of the Clearing House (or its nominee(s)) which he represents as that Clearing House (or its nominee(s)) could exercise as if such person were an individual Shareholder, including the right to speak and vote individually (whether physically or by virtual attendance with the use of electronic facilities) on a show of hands or on a poll. 93. Unless the Board agrees otherwise, an appointment of a corporate representative shall not be valid as against the Company unless: (a) in the case of such an appointment by a Shareholder which is a Clearing House (or its nominee(s)), a written notification of the appointment issued by any director, the secretary or any authorised officer(s) of such Shareholder shall have been delivered at such place or one of such places (if any) as is specified in the notice of meeting or in the form of notice issued by the Company, or handed to the chairman of the meeting at the meeting or, if no place is specified, at the principal place of business maintained by the Company in the Relevant Territory from time to time before the time of holding the meeting or adjourned meeting at which the person so authorised proposes to vote or handed to the chairman of the meeting at the meeting; and (b) in the case of such an appointment by any other corporate Shareholder, a copy of the resolution of its directors or other governing body of the Shareholder authorising the appointment of the corporate representative or a form of notice of appointment of corporate representative issued by the Company for such purpose or a copy of the relevant power of attorney, together with an up-to-date copy of the Shareholder’s constitutive documents and a list of directors or members of the governing body of the Shareholder as at the date of such resolution, or, as the case may be, power of attorney, in each case certified by a director, secretary or a member of the governing body of that Shareholder and notarised, or, in the case of a form of notice of appointment issued by the Company 28
Conditions for appointment of corporate representativ es
as aforesaid, completed and signed in accordance with the instructions thereon or in the case of a power of attorney a notarised copy of the relevant authority under which it was signed, shall have been deposited at such place or one of such places (if any) as is specified in the notice of meeting or in the form of notice issued by the Company as aforesaid (or, if no place is specified, at the Registration Office) not less than 48 hours before the time for holding the meeting or adjourned meeting or poll (as the case may be) a t which the corporate representative proposes to vote. 94. No appointment of a corporate representative shall be valid unless it names the person authorised to act as the appointor’s representative and the appointor is also named. The Board may, unless it is satisfied that a person purporting to act as a corporate representative is the person named in the relevant instrument for his appointment, decline such person’s admission to the relevant meeting and/or reject his vote or demand for a poll and no Shareholder who may be affected by any exercise by the Board of its power in this connection shall have any claim against the Board or any of them nor may any such exercise by the Board of its powers invalidate the proceedings of the meeting in respect of which they were exercised or any resolution passed or defeated at such meeting. REGISTERED OFFICE 95. The Registered Office of the Company shall be at such place in the Cayman Islands as the Board shall from time to time decide.
Registered Office
BOARD OF DIRECTORS 96. The number of Directors shall not be less than two (2). The Company shall keep at its Registered Office a register of its directors and officers in accordance with the Companies Act.
Number of Directors
- A Director may at any time, by notice in writing signed by him delivered to the Registered Office or at the Head Office or at a meeting of the Board, appoint any person (including another Director) to act as alternate Director in his place during his absence and may in like manner at any time determine such appointment. If such person is not another Director such appointment unless previously approved by the Board shall have effect only upon and subject to being so approved. The appointment of an alternate Director shall determine on the happening of any event which, were he a Director, would cause him to vacate such office or if his appointor ceases to be a Director. An alternate Director may act as alternate to more than one Director.
Alternate Directors
- (a) An alternate Director shall (subject to his giving to the Company an address, telephone and facsimile number within the territory of the Head Office for the time being for the giving of notices on him and except when absent from the territory in which the Head Office is for the time being situate) be entitled (in addition to his appointor) to receive and (in lieu of his appointor) to waive notices of meetings of the Board and of any committee of the Board of which his appointor is a member and shall be entitled to attend and vote as a Director at any such meeting at which the Director appointing him is not personally present and generally at such meeting to perform all the functions of his appointor as a Director and for the purposes of the proceedings at such meeting the provisions of these Articles shall apply as if he (instead of his appointor) were a Director. If he shall be himself a Director or shall attend any such meeting as an alternate for more than one Director his voting rights shall be cumulative. If his appointor is for the time being absent from the territory in which the Head Office is for the time being situate or otherwise not available or unable to act, his signature to any resolution in writing of the Directors or any such committee shall be as effective as the signature of his appointor. His attestation of the affixing of the Seal shall be as effective as the signature and attestation of his appointor. An alternate Director shall not, save as aforesaid, have power to act as a Director nor shall he be deemed to be a Director for the purposes of these Articles.
Rights of Alternate Directors
29
(b) An alternate Director shall be entitled to contract and be interested in and benefit from contracts or arrangements or transactions and to be repaid expenses and to be indemnified to the same extent mutatis mutandis as if he were a Director, but he shall not be entitled to receive from the Company in respect of his appointment as alternate Director any remuneration except only such part (if any) of the ordinary remuneration otherwise payable to his appointor as such appointor may by notice in writing to the Company from time to time direct. (c) A certificate by a Director (including for the purpose of this paragraph (c) an alternate Director) or the Secretary that a Director (who may be the one signing the certificate) was at the time of a resolution of the Directors or any committee thereof absent from the territory of the Head Office or otherwise not available or unable to act or has not supplied an address, telephone and facsimile number within the territory of the Head Office for the purposes of giving of notice to him shall in favour of all persons without express notice to the contrary, be conclusive of the matter so certified. 99. A Director or an alternate Director shall not be required to hold any qualification Shares but shall nevertheless be entitled to attend and speak at all general meetings of the Company and all meetings of any class of Shareholders of the Company.
Share qualification of Directors or alternate Directors
- The Directors shall be entitled to receive by way of ordinary remuneration for their services as Directors such sum as shall from time to time be determined by the Company in general meeting or by the Board, such sum (unless otherwise directed by the resolution by which it is voted) to be divided amongst the Directors in such proportions and in such manner as they may agree, or failing agreement, equally, except that in such event any Director holding office for less than the whole of the relevant period in respect of which the ordinary remuneration is paid shall only rank in such division in proportion to the time during such period for which he has held office. Such remuneration shall be in addition to any other remuneration to which a Director who holds any salaried employment or office in the Company may be entitled by reason of such employment or office.
Directors’ remuneratio n
- The Directors shall also be entitled to be repaid all travelling, hotel and other expenses reasonably incurred by them respectively in or about the performance of their duties as Directors, including their expenses of travelling to and from Board meetings, committee meetings or general meetings or otherwise incurred whilst engaged on the business of the Company or in the discharge of their duties as Directors.
Directors’ expenses
- The Board may grant special remuneration to any Director who shall perform or has performed any special or extra services at the request of the Company. Such special remuneration may be made payable to such Director in addition to or in substitution for his ordinary remuneration as a Director, and may be made payable by way of salary, commission or participation in profits or otherwise as may be arranged.
Special remuneratio n
30
103 Notwithstanding Articles 100, 101 and 102, the remuneration of a managing director, joint managing director, deputy managing director or an executive director or a Director appointed to any other office in the management of the Company may from time to time be fixed by the Board and may be by way of salary, commission, or participation in profits or otherwise or by all or any of those modes and with such other benefits (including pension and/or gratuity and/or other benefits on retirement) and allowances as the Board may from time to time decide. Such remuneration shall be in addition to his ordinary remuneration as a Director.
Remuneration of managing directors, etc.
- (a) Payments to any Director or past director of the Company of any sum by way of compensation for loss of office or as consideration for or in connection with his compensation for retirement from office (not being a payment to which the director of the Company or past director is contractually or statutorily entitled) must be approved by the Company in general meeting.
Payments for compensation for loss of office
(b) Except as would, if the Company were a company incorporated in Hong Kong, be permitted by the Companies Ordinance as in force at the date of adoption of these Articles, and except as permitted under the Companies Act, the Company shall not directly or indirectly:
Loans to Directors
(i) make a loan to a Director or a director of any Holding Company of the Company or any of their respective Close Associates; (ii) enter into any guarantee or provide any security in connection with a loan made by any person to a Director or a director of any Holding Company of the Company or any of their respective Close Associates; or (iii) if any one or more of the Directors hold (jointly or severally or directly or indirectly) a controlling interest in another company, make a loan to that other company or enter into any guarantee or provide any security in connection with a loan made by any person to that other company. (c) Article 104(a) and (b) shall only apply during the Relevant Period. When office of Director to be vacated
- A Director shall vacate his office: (a) if he becomes bankrupt or has a receiving order made against him or suspends payment or compounds with his creditors generally; or (b) if he dies or becomes of unsound mind as determined pursuant to an order made by any competent court or official on the grounds that he is or may be suffering from mental disorder or is otherwise incapable of managing his affairs and the Board resolves that his office be vacated; or (c) if he absents himself from the meetings of the Board during a continuous period of six months, without special leave of absence from the Board, and his alternate Director (if any) shall not during such period have attended in his stead, and the Board pass a resolution that he has by reason of such absence vacated his office; or (d) if he becomes prohibited by law from acting as a Director, or he ceases to be a Director by virtue of any provision of law or is removed from office pursuant to these Articles; or (e) if he has been validly required by the stock exchange of the Relevant Territory to cease to be a Director and the relevant time period for application for review of or appeal against such requirement has lapsed and no application for review or appeal has been filed or is underway against such requirement; or (f) if by notice in writing delivered to the Company at its Registered Office or at the Head Office or tendered at a meeting of the Board he resigns his office; or
31
(g) if he shall be removed from office by an Ordinary Resolution of the Company under Article 114; or (h) if he shall be removed from the office by notice in writing served on him signed by not less than ¾ in number (or if that is not a round number, the nearest lower round number) of the Directors (including himself) then in office. 106. No Director shall be required to vacate office or be ineligible for re-election or re- appointment as a Director, and no person shall be ineligible for appointment as a Director by reason only of his having attained any particular age. 107. (a) No Director or intended Director shall be disqualified by his office from contracting with the Company either as vendor, purchaser or otherwise nor shall any such contract or any contract or arrangement entered into by or on behalf of the Company with any person, company or partnership of or in which any Director shall be a member or otherwise interested be capable on that account of being avoided, nor shall any Director so contracting or being any member or so interested be liable to account to the Company for any profit so realized by any such contract or arrangement by reason only of such Director holding that office or the fiduciary relationship thereby established, provided that such Director shall, if his interest in such contract or arrangement is material, declare the nature of his interest at the earliest meeting of the Board at which it is practicable for him to do so, either specifically or by way of a general notice stating that, by reason of the facts specified in the notice, he is to be regarded as interested in any contracts of a specified description which may subsequently be made by the Company. (b) Any Director may continue to be or become a director, managing director, joint managing director, deputy managing director, executive director, manager or other officer or member of any other company in which the Company may be interested and (unless otherwise agreed between the Company and the Director) no such Director shall be liable to account to the Company or the Shareholders for any remuneration or other benefits received by him as a director, managing director, joint managing director, deputy managing director, executive director, manager or other officer or member of any such other company. The Directors may exercise the voting powers conferred by the shares in any other company held or owned by the Company, or exercisable by them as directors of such other company in such manner in all respects as they think fit (including the exercise thereof in favour of any resolution appointing themselves or any of them as directors, managing directors, joint managing directors, deputy managing director, executive directors, managers or other officers of such company) and any Director may vote in favour of the exercise of such voting rights in the manner aforesaid notwithstanding that he may be, or is about to be, appointed a director, managing director, joint managing director, deputy managing director, executive director, manager or other officer of such a company, and that as such he is or may become interested in the exercise of such voting rights in the manner aforesaid. (c) A Director may hold any other office or place of profit with the Company (except that of Auditors) in conjunction with his office of Director for such period and upon such terms as the Board may determine, and may be paid such extra remuneration therefor (whether by way of salary, commission, participation in profit or otherwise) as the Board may determine, and such extra remuneration shall be in addition to any remuneration provided for by or pursuant to any other Articles. (d) A Director shall not vote (nor shall he be counted in the quorum) on any resolution of the Board in respect of any contract or arrangement or proposal in which he or any of his Close Associate(s) has/have a material interest, and if he shall do so his vote shall not be counted (nor shall he be counted in the quorum for that resolution), but this prohibition shall not apply to any of the following matters namely: (i)
the giving of any security or indemnity either:
32
Directors’ interests
(A) to the Director or his Close Associate(s) in respect of money lent or obligations incurred or undertaken by him or any of them at the request of or for the benefit of the Company or any of its subsidiaries; or (B) to a third party in respect of a debt or obligation of the Company or any of its subsidiaries for which the Director or his Close Associate(s) has himself/themselves assumed responsibility in whole or in part and whether alone or jointly under a guarantee or indemnity or by the giving of security; (ii) any proposal concerning an offer of shares or debentures or other securities of or by the Company or any other company which the Company may promote or be interested in for subscription or purchase where the Director or his Close Associate(s) is/are or is/are to be interested as a participant in the underwriting or sub-underwriting of the offer; (iii) any proposal or arrangement concerning the benefit of employees of the Company or its subsidiaries including:
(A) the adoption, modification or operation of any employees’ share scheme or any share incentive or share option scheme under which the Director or his Close Associate(s) may benefit; or (B) the adoption, modification or operation of a pension fund or retirement, death or disability benefits scheme which relates both to Directors, his Close Associates and employees of the Company or any of its subsidiaries and does not provide in respect of any Director or his Close Associate(s), as such any privilege or advantage not generally accorded to the class of persons to which such scheme or fund relates; and (iv) any contract or arrangement in which the Director or his Close Associate(s) is/are interested in the same manner as other holders of shares or debentures or other securities of the Company by virtue only of his/their interest in shares or debentures or other securities of the Company.
(e) Where proposals are under consideration concerning the appointment (including fixing or varying the terms of or terminating the appointment) of two or more Directors to offices or employments with the Company or any company in which the Company is interested, such proposals shall be divided and considered in relation to each Director separate ly and in such case each of the Directors concerned (if not prohibited from voting under paragraph (d)) shall be entitled to vote (and be counted in the quorum) in respect of each resolution except that concerning his own appointment. (f) If any question shall arise at any meeting of the Board as to the materiality of the interest of a Director (other than the chairman of the meeting) or his Close Associates or as to the entitlement of any Director (other than the chairman of the meeting) to vote or be counted in the quorum and such question is not resolved by his voluntarily agreeing to abstain from voting or not to be counted in the quorum, such question shall be referred to the chairman of the meeting and his ruling in relation to such other Director shall be final and conclusive except in a case where the nature or extent of the interest of the Director or his Close Associates concerned as known to such Director has not been fairly disclosed to the Board. If any question as aforesaid shall arise in respect of the chairman of the meeting or his Close Associates such question shall be decided by a resolution of the Board (for which purpose such chairman shall not be counted in the quorum and shall not vote thereon) and such resolution shall be final and conclusive except in a case where the nature or extent of the interest of such chairman or his Close Associates as known to him has not been fairly disclosed to the Board.
33
APPOINTMENT AND ROTATION OF DIRECTORS 108. (a) Notwithstanding any other provisions in these Articles, at each annual general meeting onethird of the Directors for the time being, or, if their number is not three or a multiple of three, then the number nearest to but not less than one-third, shall retire from office by rotation provided that every Director (including those appointed for a specific term) shall be subject to retirement by rotation at least once every three years. A retiring Director shall be eligible for re-election. The Company at the general meeting at which a Director retires may fill the vacated office.
Rotation and retirement of Directors
(b) The Directors to retire by rotation shall include (so far as necessary to obtain the number required) any Director who wishes to retire and not to offer himself for re-election. Any Director who has not been subject to retirement by rotation in the three years preceding the annual general meeting shall retire by rotation at such annual general meeting. Any further Directors so to retire shall be those who have been longest in office since their last reelection or appointment and so that as between persons who became or were last re-elected Directors on the same day those to retire shall (unless they otherwise agree among themselves) be determined by lot. (c) A Director is not required to retire upon reaching any particular age. 109. If at any general meeting at which an election of Directors ought to take place, the places of the retiring Directors are not filled, the retiring Directors or such of them as have not had their places filled shall be deemed to have been re-elected and shall, if willing, continue in office until the next annual general meeting and so on from year to year until their places are filled, unless:
Retiring Directors to remain in office until successors appointed
(a) it shall be determined at such meeting to reduce the number of Directors; or (b) it is expressly resolved at such meeting not to fill such vacated offices; or (c) in any such case the resolution for re-election of a Director is put to the meeting and lost; or (d) such Director has given notice in writing to the Company that he is not willing to be reelected. of general 110. The Company in general meeting may from time to time fix and may from time to time by Ordinary Power meeting to increase or Resolution increase or reduce the maximum and minimum number of Directors but so that the reduce number of number of Directors shall not be less than two (2). Directors
App.3 Para 4(2)
- The Company may from time to time in general meeting by Ordinary Resolution elect any person to be a Director (including a managing Director or other executive Director).
Appointment of Directors
- The Board shall have power from time to time and at any time to appoint any person as a Director either to fill a casual vacancy or as an additional Director but so that the number of Directors so appointed shall not exceed the maximum number determined from time to time by the Shareholders in general meeting or these Articles. Any Director appointed by the Board to fill a casual vacancy or as an addition to the existing Board shall hold office only until the first annual general meeting of the Company after his appointment and shall then be eligible for re-election. Any Director appointed under this Article shall not be taken into account in determining the Directors or the number of Directors who are to retire by rotation at an annual general meeting.
Notice of proposed Director to be given
34
-
No person, other than a retiring Director, shall, unless recommended by the Board for election, be eligible for election to the office of Director at any general meeting, unless notice in writing of the intention to propose that person for election as a Director and notice in writing by that person of his willingness to be elected shall have been lodged at the Head Office or at the Registration Office. The period for lodgment of the notices required under this Article will commence no earlier than the day after the despatch of the notice of the general meeting appointed for such election and end no later than seven days prior to the date of such general meeting and the minimum length of the period during which such notices to the Company may be given will be at least seven days. App.3 Para 4(3)
-
The Shareholders may by Ordinary Resolution remove any Director (including a managing director or other executive director) before the expiration of his term of office notwithstanding anything in these Articles or in any agreement between the Company and such Director (but without prejudice to any claim which such Director may have for damages for any breach of any contract between him and the Company) and may by Ordinary Resolution elect another person in his stead. Any Director so appointed shall be subject to retirement by rotation pursuant to Article 108.
Power to remove Director by Ordinary Resolution
BORROWING POWERS 115. The Board may from time to time at its discretion exercise all the powers of the Company to raise or borrow or to secure the payment of any sum or sums of money for the purposes of the Company and to mortgage or charge its undertaking, property and uncalled capital or any part thereof.
Power to borrow
- The Board may raise or secure the payment or repayment of such sum or sums in such manner and upon such terms and conditions in all respects as it thinks fit and in particular but subject to the provisions of the Companies Act, by the issue of debentures, debenture stock, bonds or other securities of the Company, whether outright or as collateral security for any debt, liability or obligation of the Company or of any third party.
Conditions on which money may be borrowed
- Debentures, debenture stock, bonds and other securities (other than Shares which are not fully paid) may be made assignable free from any equities between the Company and the person to whom the same may be issued.
Assignment of debentures etc.
- Any debentures, debenture stock, bonds or other securities (other than Shares) may be issued at a discount, premium or otherwise and with any special privileges as to redemption, surrender, drawings, allotment or subscription of or conversion into Shares, attending and voting at general meetings of the Company, appointment of Directors and otherwise.
Special privileges of debentures
- The Directors shall cause a proper register to be kept, in accordance with the provisions of the Companies Act, of all mortgages and charges specifically affecting the property of the Company and shall duly comply with such provisions of the Companies Act with regard to the registration of mortgages and charges as may be specified or required.
Register of charges to be kept
- If the Company issues a series of debentures or debenture stock not transferable by delivery, the Board shall cause a proper register to be kept of the holders of such debentures.
Register of debentures or debenture stock
- Where any uncalled capital of the Company is charged, all persons taking any subsequent charge thereon shall take the same subject to such prior charge, and shall not be entitled, by notice to the Shareholders or otherwise, to obtain priority over such prior charge.
Mortgage of uncalled capital
35
MANAGING DIRECTORS, ETC. 122. The Board may from time to time appoint any one or more of the Directors to the office of managing director, joint managing director, deputy managing director or other executive director and/or such other office in the management of the business of the Company as it may decide for such period and upon such terms as it thinks fit and upon such terms as to remuneration as it may decide in accordance with Article 103.
Power to appoint managing directors, etc
- Every Director appointed to an office under Article 122 hereof shall, but without prejudice to any claim for damages for breach of any contract of service between himself and the Company, be liable to be dismissed or removed therefrom by the Board.
Removal of managing directors, etc.
- A Director appointed to an office under Article 122 shall be subject to the same provisions as to resignation and removal as the other Directors of the Company, and he shall ipso facto and immediately cease to hold such office if he shall cease to hold the office of Director for any cause.
Cessation of appointment
- The Board may from time to time entrust to and confer upon a chairman, vice chairman, managing director, joint managing director, deputy managing director or executive director all or any of the powers of the Board that it may think fit provided that the exercise of all powers by such Director shall be subject to such regulations and restrictions as the Board may from time to time make and impose, and, subject to the terms thereof, the said powers may at any time be withdrawn, revoked or varied, but no person dealing in good faith and without notice of such withdrawal, revocation or variation shall be affected thereby.
Power may be delegated
- The Board may from time to time appoint any person to an office or employment having a designation or title including the word “director” or attach to any existing office or employment with the Company such a designation or title. The inclusion of the word “director” in the designation or title of any office or employment with the Company (other than the office of managing director or joint managing director or deputy managing director or executive director) shall not imply that the holder thereof is a Director nor shall such holder be empowered in any respect to act as a Director or be deemed to be a Director for any of the purposes of these Articles. MANAGEMENT
- The business of the Company shall be managed by the Board who, in addition to the powers and authorities by these Articles expressly conferred upon it, may exercise all such powers and do all such acts and things as may be exercised or done or approved by the Company and are not hereby or by the Companies Act expressly directed or required to be exercised or done by the Company in general meeting, but subject nevertheless to the provisions of the Companies Act and of these Articles and to any regulations from time to time made by the Company in general meeting not being inconsistent with such provisions or these Articles, provided that no regulation so made shall invalidate any prior act of the Board which would have been valid if such regulation had not been made.
- Without prejudice to the general powers conferred by these Articles, it is hereby expressly declared that the Board shall have the following powers: (a) to give to any person the right or option of requiring at a future date that an allotment shall be made to him of any Share at par or at such premium and on such other terms as may be agreed; and (b) to give to any Directors, officers or employees of the Company an interest in any particular business or transaction or participation in the profits thereof or in the general profits of the Company either in addition to or in substitution for a salary or other remuneration.
36
General powers of Company vested in Directors
MANAGERS 129. The Board may from time to time appoint a general manager, manager or managers of the business of the Company and may fix his or their remuneration either by way of salary or commission or by conferring the right to participation in the profits of the Company or by a combination of two or more of these modes and pay the working expenses of any of the staff of the general manager, manager or managers who may be employed by him or them upon the business of the Company.
Appointment and remuneration of managers
- The appointment of such general manager, manager or managers may be for such period as the Board may decide and the Board may confer upon him or them all or any of the powers of the Board and such title or titles as it may think fit.
Terms of office and powers
- The Board may enter into such agreement or agreements with any such general manager, Terms and manager or managers upon such terms and conditions in all respects as it may in its appointment absolute discretion think fit, including a power for such general manager, manager or managers to appoint an assistant manager or managers or other employees whatsoever under them for the purpose of carrying on the business of the Company.
Terms and conditions of appointment
CHAIRMAN AND OTHER OFFICERS 132. The Board may from time to time elect or otherwise appoint one of the Directors to the office of chairman of the Company and another to be the vice chairman of the Company (or two or more vice Chairmen) and determine the period for which each of them is to hold office. The chairman of the Company or, in his absence, the vice chairman of the Company shall preside as chairman at meetings of the Board, but if no such chairman or vice chairman be elected or appointed, or if at any meeting the chairman or vice chairman is not present within five minutes after the time appointed for holding the same and willing to act, the Directors present shall choose one of their number to be chairman of such meeting. All the provisions of Articles 103, 108, 123, 124 and 125 shall apply mutatis mutandis to any Directors elected or otherwise appointed to any office in accordance with the provisions of this Article.
Chairman, vice chairman and officers
PROCEEDINGS OF THE DIRECTORS 133. The Board may meet together for the despatch of business, adjourn and otherwise regulate its meetings and proceedings as it thinks fit and may determine the quorum necessary for the transaction of business. Unless otherwise determined two Directors shall be a quorum. For the purpose of this Article an alternate Director shall be counted in a quorum separately in respect of himself (if a Director) and in respect of each Director for whom he is an alternate and his voting rights shall be cumulative and he need not use all his votes or cast all his votes in the same way. A meeting of the Board or any committee of the Board may be held by means of such telephone, electronic or other communication facilities as permit all persons participating in the meeting to communicate with each other simultaneously and instantaneously, and participation in such a meeting shall constitute presence in person at such meeting.
Meeting of Directors, quorum, etc.
- A Director may, and on the request of a Director the Secretary shall, at any time summon a meeting of the Board which may be held in any part of the world, but no such meeting shall be summoned to be held outside the territory in which the Head Office is for the time being situate without the prior approval of the Board. Notice thereof shall be given to each Director and alternate Director in person orally or in writing or by telephone or by telex or telegram or facsimile transmission at the telephone or facsimile number or address from time to time notified to the Company by such Director or in such other manner as the Board may from time to time determine. A Director absent or intending to be absent from the territory in which the Head Office is for the time being situate may request the Board or the Secretary that notices of Board meetings shall during his absence be sent in writing to him at his last known address, facsimile or telex number or any other address, facsimile or telex number given by him to the Company for this purpose, but such notices need not be given any earlier than notices given to the other Directors not so absent and in the absence of any such request it shall not be necessary to give notice of a Board meeting to any Director who is for the time being absent from such territory.
Convening of Meetings of Directors
37
- Subject to Article 107, questions arising at any meeting of the Board shall be decided by a majority of votes, and in case of an equality of votes the chairman of the meeting shall have a second or casting vote.
How questions to be decided
- A meeting of the Board for the time being at which a quorum is present shall be competent to exercise all or any of the authorities, powers and discretions by or under these Articles for the time being vested in or exercisable by the Board generally.
Powers of meeting
- The Board may delegate any of its powers to committees consisting of such member(s) of it and such other person(s) as it thinks fit, and it may from time to time revoke such delegation or revoke the appointment of and discharge any such committees either wholly or in part, and either as to persons or purposes, but every committee so formed shall in the exercise of the powers so delegated conform to any regulations that may from time to time be imposed upon it by the Board.
Power to appoint committee and to delegate
- All acts done by any such committee in conformity with such regulations and in fulfilment of the purposes for which it is appointed, but not otherwise, shall have the like force and effect as if done by the Board, and the Board shall have power, with the consent of the Company in general meeting, to remunerate the members of any special committee, and charge such remuneration to the current expenses of the Company.
Act of committee to be of same effect as acts of Directors
- The meetings and proceedings of any such committee consisting of two or more members shall be governed by the provisions herein contained for regulating the meetings and proceedings of the Board so far as the same are applicable thereto and are not replaced by any regulations imposed by the Board pursuant to Article 137.
Proceedings of committee
- All acts bona fide done by any meeting of the Board or by any such committee or by any person acting as a Director shall, notwithstanding that it shall be afterwards discovered that there was some defect in the appointment of such Director or persons acting as aforesaid or that they or any of them were disqualified, be as valid as if every such person had been duly appointed and was qualified to be a Director or member of such committee.
When acts of Directors or committee to be valid
- The continuing Directors may act notwithstanding any vacancy in their body, but, if and so long as their number is reduced below the number fixed by or pursuant to these Articles as the necessary quorum of the Board meeting, the continuing Director or Directors may act for the purpose of increasing the number of Directors to that number of the necessary quorum or of summoning a general meeting of the Company but for no other purpose.
Directors’ powers when vacancies exist
- (a) A resolution in writing signed by all the Directors (or their respective alternate Directors) shall be as valid and effectual as if it had been passed at a meeting of the Board duly convened and held. Any such resolutions in writing may consist of several documents in like form each signed by one or more of the Directors or alternate Directors.
Directors’ resolutions
(b) Where a Director is, on the date on which a resolution in writing is last signed by a Director, absent from the territory in which the Head Office is for the time being situated, or cannot be contacted at his last known address or contact telephone or facsimile number, or is temporarily unable to act through ill-health or disability and, in each case, his alternate (if any) is affected by any of these events, the signature of such Director (or his alternate) to the resolution shall not be required, and the resolution in writing, so long as such a resolution shall have been signed by at least two Directors or their respective alternates who are entitled to vote thereon or such number of Directors as shall form a quorum, shall be deemed to have been passed at a meeting of the Board duly convened and held, provided that a copy of such resolution has been given or the contents thereof communicated to all the Directors (or their respective alternates) for the time being entitled to receive notices of meetings of the Board at their respective last known address, telephone or facsimile number or, if none, at the Head Office and provided further that no Director is aware of or has received from any Director any objection to the resolution.
38
(c) certificate signed by a Director (who may be one of the signatories to the relevant resolution in writing) or the Secretary as to any of the matters referred to in paragraph (a) or (b) of this Article shall in the absence of express notice to the contrary of the person relying thereon, be conclusive of the matters stated on such certificate. MINUTES AND CORPORATE RECORDS 143. (a) The Board shall cause minutes to be made of: (i)
Minutes of proceedings of meetings and Directors
all appointments of officers made by it;
(ii) the names of the Directors present at each meeting of the Board and of committees appointed pursuant to Article 137; and (iii) all resolutions and proceedings at all meetings of the Company and of the Board and of such committees.
(b) Any such minutes shall be conclusive evidence of any such proceedings if they purport to be signed by the chairman of the meeting at which the proceedings were held or by the chairman of the next succeeding meeting. SECRETARY 144. The Secretary shall be appointed by the Board for such term, at such remuneration and upon such conditions as it may think fit, and any Secretary so appointed may, without prejudice to his right under any contract with the Company, be removed by the Board. Anything by the Companies Act or these Articles required or authorised to be done by or to the Secretary, if the office is vacant or there is for any other reason no Secretary capable of acting, may be done by or to any assistant or deputy Secretary, or if there is no assistant or deputy Secretary capable of acting, by or to any officer of the Company authorised generally or specifically on behalf of the Board.
Appointment of Secretary
- The Secretary shall attend all meetings of the Shareholders and shall keep correct minutes of such meetings and enter the same in the proper books provided for the purpose. He shall perform such other duties as are prescribed by the Companies Act and these Articles, together with such other duties as may from time to time be prescribed by the Board.
Duties of the Secretary
- A provision of the Companies Act or of these Articles requiring or authorising a thing to be done by or to a Director and the Secretary shall not be satisfied by its being done by or to the same person acting both as Director and as, or in place of the Secretary.
Same person not to act in two capacities at once
GENERAL MANAGEMENT AND USE OF THE SEAL 147. (a) Subject to the Companies Act, the Company shall have one or more Seals as the Board may determine, and may have a Seal for use outside the Cayman Islands. The Board shall provide for the safe custody of each Seal, and no Seal shall be used without the authority of the Board or a committee authorised by the Board in that behalf.
39
Custody of Seal
(b) Every instrument to which a Seal shall be affixed shall be signed autographically by one Director and the Secretary, or by two Directors, or by any person or persons (including a Director and/or the Secretary) appointed by the Board for the purpose, provided that as regards any certificates for Shares or Debentures or other securities of the Company, the Board may by resolution determine that such signatures or either of them shall be dispensed with or affixed by some method or system of mechanical signature other than autographic or may be printed thereon as specified in such resolution or that such certificates need not be signed by any person.
Use of Seal
(c) The Company may have a Securities Seal for use for sealing certificates for shares or other securities issued by the Company and no signature of any Director, officer or other person and no mechanical reproduction thereof shall be required on any such certificates or other document and any such certificates or other document to which such Securities Seal is affixed shall be valid and deemed to have been sealed and executed with the authority of the Board notwithstanding the absence of any such signature or mechanical reproduction as aforesaid. The Board may by resolution determine that the affixation of Securities Seal on certificates for shares or other securities issued by the Company be dispensed with or be affixed by printing the image of the Securities Seal on such certificates.
Securities Seal
- All cheques, promissory notes, drafts, bills of exchange and other negotiable instruments, and all receipts for moneys paid to the Company shall be signed, drawn, accepted, endorsed or otherwise executed, as the case may be, in such manner as the Board shall from time to time by resolution determine. The Company’s banking accounts shall be kept with such banker or bankers as the Board shall from time to time determine.
Cheques and banking arrangements
- (a) The Board may from time to time and at any time, by power of attorney under the Seal, appoint any company, firm or person or any fluctuating body of persons, whether nominated directly or indirectly by the Board, to be the attorney or attorneys of the Company for such purposes and with such powers, authorities and discretions (not exceeding those vested in or exercisable by the Board under these Articles) and for such period and subject to such conditions as it may think fit, and any such power of attorney may contain such provisions for the protection and convenience of persons dealing with any such attorney as the Board may think fit, and may also authorise any such attorney to sub-delegate all or any of the powers, authorities and discretions vested in him.
Power to appoint at attorney
(b) The Company may, by writing under its Seal, empower any person, either generally or in respect of any specified matter, as its attorney to execute deeds and instruments on its behalf and to enter into contracts and sign the same on its behalf and every deed signed by such attorney on behalf of the Company and under his seal shall bind the Company and have the same effect as if it were under the Seal duly affixed by the Company.
Execution of deeds by attorney
- The Board may establish any committees, regional or local boards or agencies for managing any of the affairs of the Company, either in the Relevant Territory or elsewhere, and may appoint any persons to be members of such committees, regional or local boards or agencies and may fix their remuneration, and may delegate to any committee, regional or local board or agent any of the powers, authorities and discretions vested in the Board (other than its powers to make calls and forfeit Shares), with power to sub-delegate, and may authorise the members of any regional or local board or any of them to fill any vacancies therein and to act notwithstanding vacancies, and any such appointment or delegation may be upon such terms and subject to such conditions as the Board may think fit, and the Board may remove any person so appointed and may annul or vary any such delegation, but no person dealing in good faith and without notice of any such annulment or variation shall be affected thereby.
Regional or local boards
40
- The Board may establish and maintain or procure the establishment and maintenance of any contributory or non-contributory pension or superannuation funds or personal pension plans for the benefit of, or give or procure the giving of donations, gratuities, pensions, allowances or emoluments to, any persons who are or were at any time in the employment or service of the Company, or of any company which is a subsidiary of the Company, or is allied or associated with the Company or with any such subsidiary company, or who are or were at any time directors or officers of the Company or of any such other company as aforesaid, and holding or who have held any salaried employment or office in the Company or such other company, and the spouses, widows, widowers, families and dependants of any such persons. The Board may also establish and subsidise or subscribe to any institutions, associations, clubs or funds calculated to be for the benefit of or to advance the interests and well-being of the Company or of any such other company as aforesaid or of any such persons as aforesaid, and may make payments for or towards the insurance of any such persons as aforesaid, and subscribe or guarantee money for charitable or benevolent objects or for any exhibition or for any public, general or useful object. The Board may do any of the matters aforesaid, either alone or in conjunction with any such other company as aforesaid. Any Director holding any such employment or office shall be entitled to participate in and retain for his own benefit any such donation, gratuity, pension, allowance or employment.
Power to establish pension funds
AUTHENTICATION OF DOCUMENTS 152. (a) Any Director or the Secretary or other authorised officer of the Company shall have power to authenticate any documents affecting the constitution of the Company and any resolutions passed by the Company or the Board or any committee, and any books, records, documents and accounts relating to the business of the Company, and to certify copies thereof or extracts therefrom as true copies of extracts; and where any books, records, documents or accounts are elsewhere than at the Registered Office or the Head Office, the local manager or such other officer of the Company having the custody thereof shall be deemed to be the authorised officer of the Company as aforesaid.
Power to authenticate
(b) A document purporting to be a document so authenticated or a copy of a resolution, or an extract from the minutes of a meeting, of the Company or of the Board or any local board or committee, or of any books, records, documents or accounts or extracts therefrom as aforesaid, and which is certified as aforesaid, shall be conclusive evidence in favour of all persons dealing with the Company upon the faith thereof that the document authenticated (or, if this be authenticated as aforesaid, the matter so authenticated) is authentic or, as the case may be, that such resolution has been duly passed or, as the case may be, that any minute so extracted is a true and accurate record of proceedings at a duly constituted meeting or, as the case may be, that the copies of such books, records, documents or accounts were true copies of their originals or as the case may be the extracts of such books, records, documents or accounts are true and accurate records of the books, records, documents or accounts from which they were extracted. CAPITALISATION OF RESERVES 153. (a) The Company in general meeting may, upon the recommendation of the Board, resolve to capitalise any sum standing to the credit of any of the Company’s reserve accounts which are available for distribution (including its share premium account and capital redemption reserve fund, subject to the Companies Act) and to appropriate such sums to the holders of Shares on the Register at the close of business on the date of the relevant resolution (or such other date as may be specified therein or determined as provided therein) in the proportions in which such sum would have been divisible amongst them had the same been a distribution of profits by way of Dividend and to apply such sum on their behalf in paying up in full unissued Shares for allotment and distribution credited as fully paid-up to and amongst them in the proportion aforesaid.
41
Power to capitalise
(b) Subject to the Companies Act, whenever such a resolution as aforesaid shall have been passed, the Board shall make all appropriations and applications of the reserves or profits and undivided profits resolved to be capitalised thereby, and attend to all allotments and issues of fully paid Shares, debentures, or other securities and generally shall do all acts and things required to give effect thereto. For the purpose of giving effect to any resolution under this Article, the Board may settle any difficulty which may arise in regard to a capitalisation issue as it thinks fit, and in particular may disregard fractional entitlements or round the same up or down and may determine that cash payments shall be made to any Shareholders in lieu of fractional entitlements or that fractions of such value as the Board may determine may be disregarded in order to adjust the rights of all parties or that fractional entitlements shall be aggregated and sold and the benefit shall accrue to the Company rather than to the Shareholders concerned, and no Shareholders who are affected thereby shall be deemed to be, and they shall be deemed not to be, a separate class of Shareholders by reason only of the exercise of this power. The Board may authorise any person to enter on behalf of all Shareholders interested in a capitalisation issue any agreement with the Company or other(s) providing for such capitalisation and matters in connection therewith and any agreement made under such authority shall be effective and binding upon all concerned. Without limiting the generality of the foregoing, any such agreement may provide for the acceptance by such persons of the Shares, debentures or other securities to be allotted and distributed to them respectively in satisfaction of their claims in respect of the sum so capitalised.
Effect of resolution to capitalise
(c) The provisions of paragraph (e) of Article 160 shall apply to the power of the Company to capitalise under this Article as it applies to the grant of election thereunder mutatis mutandis and no Shareholder who may be affected thereby shall be, and they shall be deemed not to be, a separate class of Shareholders by reason only of the exercise of this power. DIVIDENDS AND RESERVES 154. Subject to the Companies Act and these Articles, the Company in general meeting may declare Dividends in any currency but no Dividends shall exceed the amount recommended by the Board.
Power to declare dividends
- (a) The Board may subject to Article 156 from time to time pay to the Shareholders such interim Dividends as appear to the Board to be justified by the financial conditions and the profits of the Company and, in particular but without prejudice to the generality of the foregoing, if at any time the share capital of the Company is divided into different classes, the Board may pay such interim Dividends in respect of those Shares in the capital of the Company which confer to the holders thereof deferred or non-preferential rights as well as in respect of those Shares which confer on the holders thereof preferential rights with regard to Dividend and provided that the Board acts bona fide it shall not incur any responsibility to the holders of Shares conferring any preference for any damage that they may suffer by reason of the payment of an interim Dividend on any Shares having deferred or non-preferential rights.
Board’s power to pay interim dividends
(b) The Board may also pay half-yearly or at other suitable intervals to be settled by it any Dividend which may be payable at a fixed rate if the Board is of the opinion that the financial conditions and the profits of the Company justify the payment. (c) The Board may in addition from time to time declare and pay special Dividends of such amounts and on such dates and out of such distributable funds of the Company as it thinks fit, and the provisions of paragraph (a) of this Article as regards the power and exemption from liability of the Board as relate to the declaration and payment of interim Dividends shall apply, mutatis mutandis, to the declaration and payment of any such special Dividends. 156. (a) No Dividend shall be declared or paid or shall be made otherwise than in accordance with the Companies Act.
42
Dividends not to be paid out of capital
(b) Subject to the provisions of the Companies Act but without prejudice to paragraph (a) of this Article, where any asset, business or property is bought by the Company as from a past date (whether such date be before or after the incorporation of the Company) the profits and losses thereof as from such date may at the discretion of the Board in whole or in part be carried to revenue account and treated for all purposes as profits or losses of the Company, and be available for Dividend accordingly. Subject as aforesaid, if any Shares or securities are purchased cum Dividend or interest, such Dividend or interest may at the discretion of the Board be treated as revenue, and it shall not be obligatory to capitalise the same or any part thereof or to apply the same towards reduction of or writing down the book cost of the asset, business or property acquired. (c) Subject to paragraph (d) of this Article all Dividends and other distributions in respect of Shares shall be stated and discharged, in the case of Shares denominated in Hong Kong dollars, in Hong Kong dollars, and in the case of Shares denominated in any other currency, in such other currency, provided that, in the case of Shares denominated in Hong Kong dollars, the Board may determine in the case of any distribution that Shareholders may elect to receive the same in any other currency selected by the Board, converted at such rate of exchange as the Board may determine. (d) If, in the opinion of the Board, any Dividend or other distribution in respect of Shares or any other payment to be made by the Company to any Shareholder is of such a small amount as to make payment to that Shareholder in the relevant currency impracticable or unduly expensive either for the Company or the Shareholder then such Dividend or other distribution or other payment may, at the absolute discretion of the Board, be, if this be practicable, converted at such rate of exchange as the Board may determine and paid or made in the currency of the country of the relevant Shareholder (as indicated by the address of such Shareholder on the Register). 157. Notice of the declaration of an interim Dividend shall be given in such manner as the Board shall determine.
Notice of interim dividend
- No Dividend or other moneys payable on or in respect of a Share shall bear interest as against the Company.
No interest on dividend
- Whenever the Board or the Company in general meeting has resolved that a Dividend be paid or declared, the Board may further resolve that such Dividend be satisfied wholly or in part by the distribution of specific assets of any kind and in particular of paid up shares, debentures or warrants to subscribe securities of any other company, or in any one or more of such ways, with or without offering any rights to Shareholders to elect to receive such Dividend in cash, and where any difficulty arises in regard to the distribution the Board may settle the same as it thinks expedient, and in particular may disregard fractional entitlements or round the same up or down, and may fix the value for distribution of such specific assets, or any part thereof, and may determine that cash payments shall be made to any Shareholders upon the footing of the value so fixed in order to adjust the rights of all parties and may determine that fractional entitlements shall be aggregated and sold and the benefit shall accrue to the Company rather than to the Shareholders concerned, and may vest any such specific assets in trustees as may seem expedient to the Board and may authorise any person to sign any requisite instruments of transfer and other documents on behalf of all Shareholders interested in the Dividend and such instrument and document shall be effective. The Board may further authorise any person to enter into on behalf of all Shareholders having an interest in any agreement with the Company or other(s) providing for such Dividend and matters in connection therewith and any such agreement made under such authority shall be effective. The Board may resolve that no such assets shall be made available or made to Shareholders with registered addresses in any particular territory or territories being a territory or territories where, in the absence of a registration statement or other special formalities, this would or might, in the opinion of the Board, be unlawful or impracticable or the legality or practicality of which may be time consuming or expensive to ascertain whether in absolute terms or in relation to the value of the holding of Shares of the Shareholder concerned and in any such event the only entitlement of the Shareholders aforesaid shall be to receive cash payments as aforesaid. Shareholders affected as a result of exercise by the Board of its discretion under this
Dividend in specie
43
Article shall not be, and shall be deemed not to be, a separate class of Shareholders for any purposes whatsoever. 160. (a) Whenever the Board or the Company in general meeting has resolved that a Dividend be paid or declared on the share capital of the Company, the Board may further resolve, either:: (i) that such Dividend be satisfied wholly or in part in the form of an allotment of Shares credited as fully paid on the basis that the Shares so allotted shall be of the same class or classes as the class or classes already held by the allottee, provided that the Shareholders entitled thereto will be entitled to elect to receive such Dividend (or part thereof) in cash in lieu of such allotment. In such case, the following provisions shall apply: (A) the basis of any such allotment shall be determined by the Board; (B) the Board, after determining the basis of allotment, shall give not less than 14 clear days’ notice in writing to the Shareholders of the right of election accorded to them and shall send with such notice forms of election and specify the procedure to be followed and the place at which and the latest date and time by which duly completed forms of election must be lodged in order to be effective; (C) the right of election may be exercised in respect of the whole or part of that portion of the Dividend in respect of which the right of election has been accorded; and (D) Dividend (or that part of the Dividend to be satisfied by the allotment of Shares as aforesaid) shall not be payable in cash in respect whereof the cash election has not been duly exercised (“the non-elected Shares”) and in lieu and in satisfaction thereof Shares shall be allotted credited as fully paid to the holders of the non-elected Shares on the basis of allotment determined as aforesaid and for such purpose the Board shall capitalise and apply out of any part of the undivided profits of the Company or any part of any of the Company’s reserve accounts (including any special account, or share premium account (if there be any such reserve)) as the Board may determine, a sum equal to the aggregate nominal amount of the Shares to be allotted on such basis and apply the same in paying up in full the appropriate number of Shares for allotment and distribution to and amongst the holders of the non- elected Shares on such basis; or (ii) that Shareholders entitled to such Dividend will be entitled to elect to receive an allotment of Shares credited as fully paid in lieu of the whole or such part of the Dividend as the Board may think fit on the basis that the Shares so allotted shall be of the same class or classes as the class or classes of Shares already held by the allottee. In such case, the following provisions shall apply: (A) the basis of any such allotment shall be determined by the Board; (B) the Board, after determining the basis of allotment, shall give not less than 14 clear days’ notice in writing to the Shareholders of the right of election accorded to them and shall send with such notice forms of election and specify the procedure to be followed and the place at which and the latest date and time by which duly completed forms of election must be lodged in order to be effective; (C) the right of election may be exercised in respect of the whole or part of that portion of the Dividend in respect of which the right of election has been accorded; and
44
Scrip dividend
(D) the Dividend (or that part of the Dividend in respect of which a right of election has been accorded) shall not be payable on Shares in respect whereof the Share election has been duly exercised (“the elected Shares”) and in lieu thereof Shares shall be allotted credited as fully paid to the holders of the elected Shares on the basis of allotment determined as aforesaid and for such purpose the Board shall capitalise and apply out of any part of the undivided profits of the Company or any part of any of the Company’s reserve accounts (including any special account, contributed surplus account, share premium account and capital redemption reserve fund (if there be any such reserve)) as the Board may determine, a sum equal to the aggregate nominal amount of the Shares to be allotted on such basis and apply the same in paying up in full the appropriate number of Shares for allotment and distribution to and amongst the holders of the elected Shares on such basis. (b) The Shares allotted pursuant to the provisions of paragraph (a) of this Article shall rank pari passu in all respects with the Shares then in issue and held by the allottee in respect of which they were allotted, save only as regards participation: (i) in the relevant Dividend (or the right to receive or to elect to receive an allotment of Shares in lieu thereof as aforesaid); or (ii) in any other distributions, bonuses or rights paid, made, declared or announced prior to or contemporaneously with the payment or declaration of the relevant Dividend unless, contemporaneously with the announcement by the Board of its proposal to apply the provisions of sub-paragraph (i) or (ii) of paragraph (a) of this Article in relation to the relevant Dividend or contemporaneously with its announcement of the distribution, bonus or rights in question, the Board shall have specified that the Shares to be allotted pursuant to the provisions of paragraph (a) of this Article shall rank for participation in such distribution, bonus or rights. (c) The Board may do all acts and things considered necessary or expedient to give effect to any capitalisation pursuant to the provisions of paragraph (a) of this Article with full power to the Board to make such provisions as it thinks fit in the case of Shares becoming distributable in fractions (including provisions whereby, in whole or in part, fractional entitlements are aggregated and sold and the net proceeds distributed to those entitled, or are disregarded or rounded up or down or whereby the benefit of fractional entitlements accrues to the Company rather than to the Shareholders concerned), and no Shareholders who will be affected thereby shall be, and they shall be deemed not to be, a separate class of Shareholders by reason only of the exercise of this power. The Board may authorise any person to enter into on behalf of all Shareholders interested, an agreement with the Company providing for such capitalisation and matters incidental thereto and any agreement made pursuant to such authority shall be effective and binding on all concerned. (d) The Company may upon the recommendation of the Board by Ordinary Resolution resolve in respect of any one particular Dividend that notwithstanding the provisions of paragraph (a) of this Article a Dividend may be satisfied wholly in the form of an allotment of Shares credited as fully paid without offering any right to Shareholders to elect to receive such Dividend in cash in lieu of such allotment. (e) The Board may on any occasion determine that rights of election and the allotment of Shares under paragraph (a) of this Article shall not be made available or made to any Shareholders with registered addresses in any territory where in the absence of a registration statement or other special formalities the circulation of an offer of such rights of election or the allotment of Shares would or might be unlawful or impracticable or the legality or practicability of which may be time consuming or expensive to ascertain whether in absolute terms or in relation to the value of the holding of Shares of the Shareholder concerned, and in such event the provisions aforesaid shall be read and construed subject to such determination and no Shareholder who may be affected by any such determination shall be, and they shall be deemed not to be, a separate class of Shareholders for any purposes whatsoever. 45
- The Board may, before recommending any Dividend, set aside out of the profits of the Company such sums as it thinks fit as a reserve or reserves which shall, at the discretion of the Board, be applicable for meeting claims on or liabilities of the Company or contingencies or for paying off any loan capital or for equalising Dividends or for any other purpose to which the profits of the Company may be properly applied, and pending such application may, at the like discretion, either be employed in the business of the Company or be invested in such investments (including in the repurchase by the Company of its own securities or the giving of any financial assistance for the acquisition of its own securities) as the Board may from time to time think fit, and so that it shall not be necessary to keep any investments constituting the reserve or reserves separate or distinct from any other investments of the Company. The Board may also without placing the same to reserve, carry forward any profits which it may think prudent not to distribute by way of Dividend.
Reserves
- Unless and to the extent that the rights attached to any Shares or the terms of issue thereof otherwise provide, all Dividends shall (as regards any Shares not fully paid throughout the period in respect of which the Dividend is paid) be apportioned and paid pro rata according to the amounts paid or credited as paid on the Shares during any portion or portions of the period in respect of which the Dividend is paid. For the purposes of this Article no amount paid on a Share in advance of calls pursuant to Article 38 shall be treated as paid on the Share.
Dividends to be paid in proportion to paid up capital
- (a) The Board may retain any Dividends or other moneys payable on or in respect of a Share upon which the Company has a lien, and may apply the same in or towards satisfaction of the debts, liabilities or engagements in respect of which the lien exists.
Retention of dividends, etc.
(b) The Board may deduct from any Dividend or other money payable to any Shareholder all sums of money (if any) presently payable by him to the Company on account of calls, instalments or otherwise.
Deduction of debts
- Any general meeting sanctioning a Dividend may make a call on the Shareholders of such amount as the meeting fixes, but so that the call on each Shareholder shall not exceed the Dividend payable to him, and so that the call shall be made payable at the same time as the Dividend, and the Dividend may, if so arranged between the Company and the Shareholder, be set off against the call.
Dividend and call together
- A transfer of Shares shall not, as against the Company but without prejudice to the rights of the transferor and transferee inter se, pass the right to any Dividend or bonus declared thereon before the registration of the transfer.
Effect of transfer
- If two or more persons are registered as joint holders of any Share, any one of such persons may give effectual receipts for any Dividends and other moneys payable and bonuses, rights and other distributions in respect of such Shares.
Receipt for dividends by joint holders of share
- Unless otherwise directed by the Board, any Dividend or other moneys payable or bonuses, rights or other distributions in respect of any Share may be paid or satisfied by cheque or warrant or certificate or other documents or evidence of title sent through the post to the registered address of the Shareholder entitled, or, in the case of joint holders, to the registered address of that one whose name stands first in the Register in respect of the joint holding or to such person and to such address as the holder or joint holders may in writing direct. Every cheque, warrant, certificate or other document or evidence of title so sent shall be made payable to the order of the person to whom it is sent or, in the case of certificates or other documents or evidence of title as aforesaid, in favour of the Shareholder(s) entitled thereto, and the payment on any such cheque or warrant by the banker upon whom it is drawn shall operate as a good discharge to the Company in respect of the Dividend and/or other moneys represented thereby, notwithstanding that it may subsequently appear that the same has been stolen or that any endorsement thereon has been forged. Every such cheque, warrant, certificate or other document or evidence of title as aforesaid shall be sent at the risk of the person entitled to the Dividend, money, bonus, rights and other distributions represented thereby.
Payment by post
46
- All Dividends, bonuses or other distributions or the proceeds of the realisation of any of the foregoing unclaimed for one year after having been declared by the Company until claimed and, notwithstanding any entry in any books of the Company may be invested or otherwise made use of by the Board for the benefit of the Company or otherwise howsoever, and the Company shall not be constituted a trustee in respect thereof. All Dividends, bonuses or other distributions or the proceeds of the realisation of any of the foregoing unclaimed for six years after having been declared may be forfeited by the Board and, upon such forfeiture, shall revert to the Company and, in the case where any of the same are securities of the Company, may be re-allotted or re-issued for such consideration as the Board thinks fit and the proceeds thereof shall accrue to the benefit of the Company absolutely.
Unclaimed Dividend
RECORD DATE 169. Subject to the Listing Rules, any resolution declaring a Dividend or other distribution on Shares of Record dates any class, whether a resolution of the Company in general meeting or a resolution of the Board, may specify that the same shall be payable or made to the persons registered as the holder of such Shares at the close of business on a particular date or at a particular time on a particular date, and thereupon the Dividend or other distribution shall be payable or made to them in accordance with their respective holdings so registered, but without prejudice to the rights inter se in respect of such Dividend or other distribution between the transferors and transferees of any such Shares. The provisions of this Article shall mutatis mutandis apply to determining the Shareholders entitled to receive notice and vote at any general meeting of the Company, bonuses, capitalisation issues, distributions of realised and unrealised capital profits or other distributable reserves or accounts of the Company and offers or grants made by the Company to the Shareholders. 170. The Company in general meeting may at any time and from time to time resolve that any surplus Distribution of realised moneys in the hands of the Company representing capital profits arising from moneys received or capital profits recovered in respect of or arising from the realisation of any capital assets of the Company or any investments representing the same and not required for the payment or provision of any fixed preferential Dividend instead of being applied in the purchase of any other capital assets or for other capital purposes be distributed amongst its Shareholders on the footing that they receive the same as capital and in the Shares and proportions in which they would have been entitled to receive the same if it had been distributed by way of Dividend, provided that no such surplus moneys as aforesaid shall be so distributed unless the Company will remain solvent after the distribution, or the net realisable value of the assets of the Company will after the distribution be greater than the aggregate of its liabilities, share capital and share premium account. ANNUAL RETURNS 171. The Board shall make or cause to be made such annual or other returns or filings as may be required to be made in accordance with the Companies Act.
Annual Returns
ACCOUNTS 172. The Board shall cause proper books of account to be kept of the sums of money received and expended by the Company, and the matters in respect of which such receipts and expenditure take place; and of the assets and liabilities of the Company and of all other matters required by the Companies Act necessary to give a true and fair view of the state of the Company’s affairs and to show and explain its transactions.
Accounts to be kept
Where 173. The books of account shall be kept at the Head Office or at such other place or places as the Board accounts to be kept thinks fit and shall always be open to the inspection of the Directors. by 174. No Shareholder (not being a Director) or other person shall have any right of inspecting any account Inspection shareholders or book or document of the Company except as conferred by the Companies Act or ordered by a court of competent jurisdiction or authorised by the Board or the Company in general meeting.
47
profit 175. (a) The Board shall from time to time cause to be prepared and laid before the Company at its Annual and loss account and annual general meeting profit and loss accounts and balance sheets of the Company and such balance sheet other reports and documents as may be required by law and the Listing Rules. The accounts of the Company shall be prepared and audited based on the generally accepted accounting principles of Hong Kong, the International Accounting Standards, or such other standards as may be permitted by the HK Stock Exchange. report (b) Subject to paragraph (c) below, every balance sheet of the Company shall be signed on behalf Annual of Directors balance of the Board by two of the Directors and a copy of every balance sheet (including every and sheet to be document required by law to be comprised therein or annexed thereto) and profit and loss sent to account which is to be laid before the Company at its annual general meeting, together with a shareholders copy of the Directors’ report and a copy of the Auditors’ report thereon, shall, not less than 21 days before the date of the meeting be delivered or sent together with the notice of annual general meeting to every Shareholder and every Debenture Holder of the Company and every other person entitled to receive notices of general meetings of the Company under the provisions of these Articles, provided that this Article shall not require a copy of those documents to be sent to any person of whose address the Company is not aware or to more than one of the joint holders of any Shares or Debentures, but any Shareholder or Debenture Holder to whom a copy of those documents has not been sent shall be entitled to receive a copy free of charge on application at the Head Office or the Registration Office. If all or any of the Shares or Debentures or other securities of the Company shall for the time being be (with the consent of the Company) listed or dealt in on any stock exchange or market, there shall be forwarded to such stock exchange or market such number of copies of such documents as may for the time being be required under its regulations or practice.
(c) Subject to the Listing Rules, the Company may send summarised financial statements to Shareholders who has, in accordance with the Listing Rules, consented and elected to receive summarised financial statements instead of the full financial statements. The summarised financial statements must be accompanied by any other documents as may be required under the Listing Rules and must be sent to the Shareholders not less than twenty-one days before the general meeting to those Shareholders that have consented and elected to receive the summarised financial statements. AUDITORS App.3 Para 17
- (a) The Shareholders shall at each annual general meeting appoint one or more firms of auditors to Appointment of Auditors hold office by Ordinary Resolution until the conclusion of the next annual general meeting on such terms and with such duties as may be agreed with the Board, but if an appointment is not made, the Auditors in office shall continue in office until a successor is appointed. A Director, officer or employee of any such Director, officer or employee shall not be appointed Auditors of the Company. Subject to compliance with the Listing Rules, the Board may fill any casual vacancy in the office of Auditors, but while any such vacancy continues the surviving or continuing Auditors (if any) may act. The remuneration of the Auditors shall be fixed by or on the authority of the Shareholders in the annual general meeting by Ordinary Resolution or in any other manner specified in such Ordinary Resolution and, subject to compliance with the Listing Rules, the remuneration of any Auditors appointed to fill any casual vacancy may be fixed by the Board. (b) The Shareholders may, at any general meeting convened and held in accordance with these Articles, remove the Auditors by Ordinary Resolution at any time before the expiration of the term of office and shall, by Ordinary Resolution, at that meeting appoint new Auditors in their place for the remainder of the term.
48
Auditors to 177. The Auditors of the Company shall have a right of access at all times to the books and accounts and have right of vouchers of the Company and shall be entitled to require from the Directors and officers of the access to books and Company such information as may be necessary for the performance of his or their duties, and the accounts Auditors shall audit every balance sheet and profit and loss account of the Company in each year and prepare an Auditors’ report thereon to be annexed thereto. Such report shall be laid before the Company in the annual general meeting.
- No person other than the retiring Auditors shall be appointed as Auditors at an annual general Appointment of auditors than meeting unless notice of an intention to nominate that person to the office of Auditors has been given other retiring to the Company not less than 14 clear days before the annual general meeting, and the Company auditor shall send a copy of any such notice to the retiring Auditors and shall give notice thereof to the Shareholders not less than seven days before the annual general meeting provided that the above requirement for sending a copy of such notice to the retiring Auditors may be waived by notice in writing by the retiring Auditors to the Secretary.
- All acts done by any person acting as Auditors shall, as regards all persons dealing in good faith with the Company, be valid, notwithstanding that there was some defect in their appointment or that they were at the time of their appointment not qualified for appointment or subsequently became disqualified.
Defect of appointment
NOTICES 180. (a) Except where otherwise expressly stated, any notice or document to be given to or by any person pursuant to these Articles shall be in writing or, to the extent permitted by the Companies Act and the Listing Rules from time to time and subject to this Article, contained in an electronic communication. A notice calling a meeting of the Board need not be in writing. (b) Except where otherwise expressly stated, any notice or document to be given to or by any person pursuant to these Articles (including any corporate communication) may be given, or issued, subject to compliance with the Listing Rules, either by serving it personally on the relevant person; or by sending it through the post in a prepaid envelope or wrapper addressed to such Shareholder at his registered address as appearing in the register; or by delivering or leaving it at that address addressed to the Shareholder or any address supplied by him to the Company for the purpose under Article 180(d); or (other than share certificate) by publishing it by way of advertisement in the Newspapers or other publication and where applicable, in accordance with the requirements of the HK Stock Exchange. In case of joint holders of a share, all notices shall be given to that one of the joint holders whose name stands first in the register and notice so given shall be sufficient notice to all the joint holders. Without limiting the generality of the foregoing but subject to the Companies Act and the Listing Rules, any notice or document may be served or delivered by the Company to any person by electronic means by sending or transmitting it as an electronic communication to the relevant person at such electronic address as he may provide, subject to the Company complying with Cayman Islands law and any other applicable laws, rules and regulations with regard to any requirements for obtaining of consent from such person; or by publishing it on a website or by sending or otherwise making it available to such person through such other means to the extent permitted by the applicable Cayman Islands law, rules and regulations. (c) Any such notice or document may be served or delivered by the Company by reference to the register as it stands at any time not more than fifteen days before the date of service or delivery. No change in the register after that time shall invalidate that service or delivery. Where any notice or document is served or delivered to any person in respect of a share in accordance with these Articles, no person deriving any title or interest in that share shall be entitled to any further service or delivery of that notice or document.
49
Service of notices
(d) Every Shareholder or a person who is entitled to receive notice from the Company under the provisions of the Cayman Islands law or these Articles may register with the Company an electronic address to which notices can be served upon him. (e) Any notice or document required to be sent to or served upon the Company, or upon any officer of the Company, may be sent or served by leaving the same or sending it through the post in a prepaid envelope or wrapper addressed to the Company or to such officer at the Head Office or Registered Office. (f) The Board may from time to time specify the form and manner in which a notice may be given to the Company by electronic means, including one or more addresses for the receipt of an electronic communication, and may prescribe such procedures as they think fit for verifying the authenticity or integrity of any such electronic communication. Any notice may be given to the Company by electronic means only if it is given in accordance with the requirements specified by the Board. 181. (a) Any Shareholder whose registered address is outside the Relevant Territory may notify the Company in writing of an address in the Relevant Territory which for the purpose of service of notice shall be deemed to be his registered address. Where the registered address of the Shareholder is outside the Relevant Territory, notice, if given through the post, shall be sent by prepaid airmail letter where available. (b) Any Shareholder who fails (and, where a Share is held by joint holders, where the first joint holder named on the register fails) to supply his registered address or a correct registered address, or, in case of electronic communications, fails to supply his electronic address or a correct electronic address, to the Company for service of notices and documents on him shall not (and where a Share is held by joint holders, none of the other joint holders whether or not they have supplied a registered address shall) be entitled to service of any notice or documents by the Company and any notice or document which is otherwise required to be served on him may, if the Board in its absolute discretion so elects (and subject to them re-electing otherwise from time to time), be served, in the case of notices, by displaying a copy of such notice conspicuously at the Registered Office and the Head Office or, if the Board sees fit, by publishing or otherwise making available on the Company’s website or by advertisement in the Newspapers, and, in the case of documents, by posting up a notice conspicuously at the Registered Office and the Head Office addressed to such Shareholder which notice shall state the address within the Relevant Territory at which he served in the manner so described which shall be sufficient service as regards Shareholders with no registered or incorrect addresses, provided that nothing in this paragraph (b) shall be construed as requiring the Company to serve any notice or document on any Shareholder with no or an incorrect registered address, or in the case of electronic communication, no or an incorrect electronic address, for the service of notice or document on him or on any Shareholder other than the first named on the Register. (c) If on three consecutive occasions notices or other documents have been sent through electronic means or the post to any Shareholder (or, in the case of joint holders of a share, the first holder named on the register) at his electronic address or registered address but have been returned undelivered, such Shareholder (and, in the case of joint holders of a Share, all other joint holders of the share) shall not thereafter be entitled to receive or be served (save as the Board may elect otherwise pursuant to paragraph (b) of this Article) and shall be deemed to have waived the service of notices and other documents from the Company until he shall have communicated with the Company and supplied in writing a new electronic address or registered address for the service of notices on him.
50
Shareholders out of the Relevant Territory
When notice 182. Any notice or other document, if sent by mail, postage prepaid, shall be deemed to have been served deemed to be or delivered on the day following that on which the letter, envelope, or wrapper containing the same served is put into the post. In proving such service it shall be sufficient to prove that the letter, envelope or wrapper containing the notice or document was properly addressed and put into the post as prepaid mail. Any notice or document not sent by post but left by the Company at a registered address shall be deemed to have been served or delivered on the day it was so left. Any notice or document, if sent by electronic means (including through any relevant system), shall be deemed to have been given on the day following that on which the electronic communication was sent by or on behalf of the Company. Any notice, publication or document served or delivered by the Company by any other means authorized in writing by the Shareholder concerned shall be deemed to have been published, served when the Company has carried out the action it has been authorized to take for that purpose. Any notice, publication or other document published by way of advertisement or on a website shall be deemed to have been published, served or delivered on the day it was so published or it first so appears on the website, unless the Listing Rules specify a different date. In such cases, the deemed date of service shall be as provided or required by the Listing Rules. of 183. A notice or document may be given by the Company to the person entitled to a Share in consequence Service notice to persons of the death, mental disorder, bankruptcy or liquidation of a Shareholder by sending it through entitled on electronic means or the post in a prepaid envelope or wrapper addressed to him by name, or by the death, mental disorder or title of representative of the deceased, the trustee of the bankrupt or the liquidator of the Shareholder, bankruptcy or by any like description, at the electronic address or address, if any, supplied for the purpose by the person claiming to be so entitled, or (until such an electronic address or address has been so supplied) by giving the notice or document in any manner in which the same might have been given if the death, metal disorder, bankruptcy or winding up had not occurred. to 184. Any person who by operation of law, transfer or other means whatsoever shall become entitled to Transferee be bound by any Share shall be bound by every notice in respect of such share which prior to his name and address prior notices being entered on the register shall have been duly served to the person from whom he derives his title to such share.
- Any notice or document delivered or sent through electronic means or by post to, or left at the registered address of any Shareholder in pursuance of these Articles, shall notwithstanding that such Shareholder be then deceased, bankrupt or wound up and whether or not the Company has notice of his death, bankruptcy or winding up, be deemed to have duly served in respect of any registered Shares whether held solely or jointly with other persons by such Shareholder until some other person be registered in his stead as the holder or joint holder thereof, and such service shall for all purposes of these Articles be deemed a sufficient service of such notice or document on his personal representatives and all persons (if any) jointly interested with him in any such Shares.
Notice valid though shareholder deceased, bankrupt
- The signature to any notice or document to be given by the Company may be written or printed.
How notice to be signed
INFORMATION Shareholders 187. No Shareholder (not being a Director) shall be entitled to require discovery of or any information not entitled to respecting any detail of the Company’s trading or any matter which is or may be in the nature of a information trade secret, mystery of trade or secret process which may relate to the conduct of the business of the Company which in the opinion of the Board will be inexpedient in the interests of the Shareholders of the Company to communicate to the public.
WINDING UP App.3 Para 21
- Subject to the Companies Act, a resolution that the Company be wound up by the Court or be wound up voluntarily shall be passed by way of a Special Resolution.
51
Modes of winding up
of 189. If the Company shall be wound up, the surplus assets remaining after payment to all creditors shall Distribution assets in winding up be divided among the Shareholders in proportion to the capital paid up on the Shares held by them respectively, and if such surplus assets shall be insufficient to repay the whole of the paid up capital, they shall be distributed, subject to the rights of any Shares which may be issued on special terms and conditions, so that, as nearly as may be, the losses shall be borne by the Shareholders in proportion to the capital paid on the Shares held by them respectively. may be 190. 190. If the Company shall be wound up (in whatever manner) the liquidator may, with the Assets distributed in specie sanction of a Special Resolution and any other sanction required by the Companies Act, divide among the Shareholders in specie or kind the whole or any part of the assets of the Company whether the assets shall consist of property of one kind or shall consist of properties of different kinds and the liquidator may, for such purpose, set such value as he deems fair upon any one or more class or classes of property to be divided as aforesaid and may determine how such division shall be carried out as between the Shareholders or different classes of Shareholders and the Shareholders within each class. The liquidator may, with the like sanction, vest any part of the assets in trustees upon such trusts for the benefit of Shareholders as the liquidator, with the like sanction, shall think fit, but so that no Shareholder shall be compelled to accept any Shares or other assets upon which there is a liability.
INDEMNITY 191. The Directors, managing directors, alternate Directors, Auditors, Secretary and other officers for the time being of the Company and the trustees (if any) for the time being acting in relation to any of the affairs of the Company, and their respective executors or administrators, shall be indemnified and secured harmless out of the assets of the Company from and against all actions, costs, charges, losses, damages and expenses which they or any of them, their or any of their executors or administrators, shall or may incur or sustain by reason of any act done, concurred in or omitted in or about the execution of their duty or supposed duty in their respective offices or trusts, except such (if any) as they shall incur or sustain through their own fraud or dishonesty, and none of them shall be answerable for the acts, receipts, neglects or defaults of any other of them, or for joining in any receipt for the sake of conformity, or for any bankers or other persons with whom any moneys or effects of the Company shall be lodged or deposited for safe custody, or for the insufficiency or deficiency of any security upon which any moneys of the Company shall be placed out or invested, or for any other loss, misfortune or damage which may arise in the execution of their respective offices or trusts, or in relation thereto, except as the same shall happen by or through their own fraud, dishonest, or recklessness. The Company may take out and pay the premium and other moneys for the maintenance of insurance, bonds and other instruments for the benefit either of the Company or the Directors (and/or other officers) or any of them to indemnify the Company and/or Directors (and/or other officers) named therein for this purpose against any loss, damage, liability and claim which they may suffer or sustain in connection with any breach by the Directors (and/or other officers) or any of them of their duties to the Company.
Indemnity
UNTRACEABLE SHAREHOLDERS Company 192. The Company may exercise the power to cease sending cheques for Dividend entitlements or ceases sending dividend Dividend warrants by post if such cheques or warrants remain uncashed on two consecutive warrants etc. occasions or after the first occasion on which such a cheque or warrant is returned undelivered. may 193. (a) The Company shall have the power to sell, in such manner as the Board thinks fit, any Company sell shares of untraceable Shares of a Shareholder who is untraceable, but no such sale shall be made unless: shareholders
52
(i) during the period of 12 years prior to the date of the advertisements referred to in subparagraph (ii) below (or, if published more than once, the first thereof) at least three Dividends or other distributions in respect of the Shares in question have become payable or been made and no Dividend or other distribution in respect of the Shares during that period has been claimed; (ii) the Company has caused an advertisement to be inserted in the Newspapers of its intention to sell such Shares and a period of three months has elapsed since the date of such advertisement (or, if published more than once, the first thereof); (iii) the Company has not at any time during the said periods of 12 years and three months received any indication of the existence of the holder of such Shares or of a person entitled to such Shares by death, bankruptcy or operation of law; and (iv) the Company has notified the HK Stock Exchange of its intention of such sale. (b) To give effect to any such sale the Board may authorise any person to transfer the said Shares and the instrument of transfer signed or otherwise executed by or on behalf of such person shall be as effective as if it had been executed by the registered holder or the person entitled by transmission to such Shares, and the purchaser shall not be bound to see to the application of the purchase money nor shall his title to the Shares be affected by any irregularity or invalidity in the proceedings relating to the sale. The net proceeds of the sale will belong to the Company and upon receipt by the Company of such proceeds it shall become indebted to the former Shareholder for an amount equal to such net proceeds. Notwithstanding any entries made by the Company in any of its books or otherwise howsoever, no trusts shall be created in respect of such debt and no interest shall be payable in respect of it and the Company shall not be required to account for any money earned from the net proceeds which may be employed in the business of the Company or as it thinks fit. Any sale under this Article shall be valid and effective notwithstanding that the Shareholder holding the Shares sold is dead, bankrupt, wound up or otherwise under any legal disability or incapacity. DESTRUCTION OF DOCUMENTS Destruction of documents
- The Company may destroy: (a) any share certificate which has been cancelled at any time after the expiry of one year from the date of such cancellation; (b) any dividend mandate or any variation or cancellation thereof or any notification of change of name or address at any time after the expiry of two years from the date on which such mandate, variation, cancellation or notification was recorded by the Company (c) any instrument of transfer of Shares which has been registered at any time after the expiry of six years from the date of registration; (d) any other document, on the basis of which any entry in the Register is made, at any time after the expiry of six years from the date on which an entry in the Register was first made in respect of it; and it shall conclusively be presumed in favour of the Company that every Share certificate so destroyed was a valid certificate duly and properly cancelled and that every instrument of transfer so destroyed was a valid and effective instrument duly and properly registered and that every other document destroyed hereunder was a valid and effective document in accordance with the recorded particulars thereof in the books or records of the Company provided always that:
53
(i) the foregoing provisions of this Article shall apply only to the destruction of a document in good faith and without express notice to the Company that the preservation of such document was relevant to a claim; (ii) nothing contained in this Article shall be construed as imposing upon the Company any liability in respect of the destruction of any such document earlier than as aforesaid or in any case where the conditions of proviso (i) above are not fulfilled; and (iii) references in this Article to the destruction of any document include reference to its disposal in any manner. SUBSCRIPTION RIGHT RESERVE 195. The following provisions shall have effect to the extent that they are not prohibited by and are in compliance with the Companies Act: (a) If, so long as any of the rights attaching to any warrants issued by the Company to subscribe for Shares shall remain exercisable, the Company does any act or engages in any transaction which, as a result of any adjustments to the subscription price in accordance with the provisions applicable under the terms and conditions of the warrants, would reduce the subscription price to below the par value of a Share, then the following provisions shall apply: (i) as from the date of such act or transaction the Company shall establish and thereafter (subject as provided in this Article) maintain in accordance with the provisions of this Article a reserve (the “Subscription Right Reserve”) the amount of which shall at no time be less than the sum which for the time being would be required to be capitalised and applied in paying up in full the nominal amount of the additional Shares required to be issued and allotted credited as fully paid pursuant to sub- paragraph (iii) below on the exercise in full of all the subscription rights outstanding and shall apply the Subscription Right Reserve in paying up in full the amount of the shortfall referred to in sub- paragraph (iii) in respect of such additional Shares as and when the same are allotted; (ii) the Subscription Right Reserve shall not be used for any purpose other than that specified above unless all other reserves of the Company (other than the share premium account) have been extinguished and will then only be used to make good losses of the Company if and so far as is required by law; (iii) upon the exercise of all or any of the subscription rights represented by any warrant, the relevant subscription rights shall be exercisable in respect of a nominal amount of Shares equal to the amount in cash which the holder of such warrant is required to pay on exercise of the subscription rights represented thereby (or, as the case may be, the relevant portion thereof in the event of a partial exercise of the subscription rights) and, in addition, there shall be allotted in respect of such subscription rights to the exercising warrant holder, credited as fully paid, such additional nominal amount of Shares as is equal to the shortfall between: (A) the said amount in cash which the holder of such warrant is required to pay on exercise of the subscription rights represented thereby (or, as the case may be, the relevant portion thereof in the event of a partial exercise of the subscription rights); and
54
Subscription right reserve
(B) the nominal amount of Shares in respect of which such subscription rights would have been exercisable having regard to the provisions of the conditions of the warrants, had it been possible for such subscription rights to represent the right to subscribe for Shares at less than par and immediately upon such exercise so much of the sum standing to the credit of the Subscription Right Reserve as is required to pay up in full such additional nominal amount of Shares shall be capitalised and applied in paying up in full such additional nominal amount of Shares which shall forthwith be allotted credited as fully paid to the exercising warrant holder; and (iv) if upon the exercise of the subscription rights represented by any warrant the amount standing to the credit of the Subscription Right Reserve is not sufficient to pay up in full such additional nominal amount of Shares equal to such shortfall as aforesaid to which the exercising warrant holder is entitled, the Board shall apply any profits or reserves then or thereafter becoming available (including, to the extent permitted or not prohibited by law, the share premium account) for such purpose until such additional nominal amount of Shares is paid up and allotted as aforesaid and until then no Dividend or other distribution shall be paid or made on the fully paid Shares then in issue. Pending such payment up and allotment, the exercising warrant holder shall be issued by the Company with a certificate evidencing his right to the allotment of such additional nominal amount of Shares. The rights represented by any such certificate shall be in registered form and shall be transferable in whole or in part in units of one Share in the like manner as the Shares for the time being are transferable, and the Company shall make such arrangements in relation to the maintenance of a register therefor and other matters in relation thereto as the Board may think fit and adequate particulars thereof shall be made known to each relevant exercising warrant holder upon the issue of such certificate. (b) Shares allotted pursuant to the provisions of this Article shall rank pari passu in all respects with the other Shares allotted or which ought to be allotted on the relevant exercise of the subscription rights represented by the warrant concerned. Notwithstanding anything contained in paragraph (a) of this Article, no fraction of any Share shall be allotted on exercise of the subscription rights. (c) The provisions of this Article as to the establishment and maintenance of the Subscription Right Reserve shall not be altered or added to in any way which would vary or abrogate, or which would have the effect of varying or abrogating, the provisions for the benefit of any warrant holder or class of warrant holders under this Article without the sanction of a Special Resolution of such warrant holder(s) or class of warrant holders. (d) A certificate or report by the Auditors as to whether or not the Subscription Right Reserve is required to be established and maintained and if so the amount thereof so required to be established and maintained, as to the purpose for which the Subscription Right Reserve has been used, as to the extent to which it has been used to make good losses of the Company, as to the additional nominal amount of Shares required to be allotted to exercising warrant holders credited as fully paid, and as to any other matter concerning the Subscription Right Reserve shall (in the absence of manifest error) be conclusive and binding upon the Company and all warrant holders and Shareholders.
55
STOCK 196. The following provisions shall have effect at any time and from time to time provided that they are not prohibited by or inconsistent with the Companies Act: (a) The Company may by Ordinary Resolution convert any fully paid Shares into stock, and may from time to time by like resolution reconvert any stock into fully paid Shares of any denomination. (b) The holders of stock may transfer the same or any part thereof in the same manner, and subject to the same regulations as and subject to which the Shares from which the stock arose might prior to conversion have been transferred or as near thereto as circumstances admit, but the Board may from time to time, if it thinks fit, fix the minimum amount of stock transferable and restrict or prohibit the transfer of fractions of that minimum, but so that such minimum shall not exceed the nominal amount of the Shares from which the stock arose. No warrants to bearer shall be issued in respect of any stock. (c) The holders of stock shall, according to the amount of the stock held by them, have the same rights, privileges and advantages as regards Dividends, participation in assets on a winding up, voting at meetings, and other matters, as if they held the Shares from which the stock arose, but no such rights, privileges or advantages (except participation in the Dividends and profits and in the assets on winding up of the Company) shall be conferred by an amount of stock which would not, if existing in Shares, have conferred such rights, privileges or advantages. (d) Such of the provisions of these Articles as are applicable to fully paid Shares shall apply to stock, and the words “Share” and “Shareholder” herein shall include “stock” and “stockholder” and “member”. UNCERTIFICATED SECURITIES AND ELECTRONIC PROCESS 197. The Company shall comply with all applicable laws and regulations, including the Securities and Futures Ordinance and the Securities and Futures (Uncertificated Securities Market) Rules, to facilitate the holding, transfer and registration of its shares or other prescribed securities in uncertificated form through electronic means, including via the UNSRT System or other systems approved by the SFC and the HK Stock Exchange. The Company is authorised to take all reasonably practicable steps to support electronic communication with securities holders, including but not limited to electronic voting, proxy instructions and distribution of corporate action proceeds, and to maintain compatibility with the uncertificated securities market regime. Any provisions in these Articles relating to the issuance, holding or transfer of securities (including shares) or concerning share certificates shall be interpreted to permit compliance with such electronic processes and systems, to the extent permitted by the laws of the Cayman Islands.
56
The board of directors (the “Board”) of Genscript Biotech Corporation (the “Company”) hereby announces that the name of the Company’s principal share registrar and transfer office in the Cayman Islands has been changed from “Harneys Services (Cayman) Limited” to “Ascentium (Cayman) Limited”, and the name of the Company’s registered office in the Cayman Islands has been changed from “Harneys Fiduciary (Cayman) Limited” to “Ascentium (Cayman) Limited”. The address of the Company’s principal share registrar and transfer office and registered office in Cayman Islands remains unchanged. As advised by the Company’s Cayman Islands legal counsel, the change of the name of the registered office provider in the Cayman Islands does not require separate approval of the shareholders of the Company for amendment of the Company’s memorandum and articles of association under the Companies Act (as revised) of the Cayman Islands.
By order of the Board GenScript Biotech Corporation Robin Meng Chairman and Executive Director Hong Kong, 7 September 2026 As at the date of this announcement, the executive Directors are Mr. Jiange Meng (“Mr. Robin Meng”), Dr. Fangliang Zhang (“Dr. Frank Zhang”), Dr. Li Zhu and Ms. Ye Wang (“Ms. Sally Wang”); and the independent non-executive Directors are Dr. Alphonse Galdes, Mr. Yiu Leung Andy Cheung (“Mr. Andy Cheung”), Mr. Jiuan Pan (“Mr. Ethan Pan”), Dr. John Quelch, Dr. Ross Grossman and Dr. Chenyang Shi (“Dr. Victor Shi”).
1
This announcement is made by the board of directors (the “Board”) of Genscript Biotech Corporation (the “Company”, together with its subsidiaries, the “Group”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), and Practice Note 15 (“PN15”) of the Listing Rules. THE PROPOSED SPIN-OFF The Board hereby announces that the Company proposes to spin-off and separately list the shares of Probio Technology Limited (“ProBio”), an indirect non-wholly-owned subsidiary of the Company which operates the Group’s Biologics and Advanced Therapy Contract Research, Development, and Manufacturing Organization services, on the Main Board of the Stock Exchange (the “Proposed Spin-off”). In connection with the Proposed Spin-off, the Company submitted an application to the Stock Exchange in compliance with PN15. On 14 August 2026, the Listing Committee confirmed that the Company may proceed with the Proposed Spin-off. Details of the Proposed Spin-off have yet to be finalized. Upon completion of the Proposed Spinoff, the Company will continue to hold a controlling interest in ProBio, which will remain as a subsidiary of the Company, and its financial results will continue to be consolidated into the financial statements of the Group.
1
GENERAL Pursuant to the requirements under PN15, the Company is required to have due regard to the interests of its existing shareholders by providing them with an assured entitlement to the shares to be issued by ProBio (the “Assured Entitlement”) by way of a preferential application if the Proposed Spin-off proceeds, subject to certain conditions, including the approval of the Stock Exchange and other regulatory authorities for the Proposed Spin-off. The terms of such Assured Entitlement have not been finalized but in any event all the qualifying shareholders of the Company will be treated equally. The Company will make further announcements in this regard as and when appropriate pursuant to the Listing Rules. The Proposed Spin-off, if materialized, will constitute a deemed disposal of the interest in a subsidiary of the Company under Rule 14.29 of the Listing Rules. The Company will comply with the applicable requirements of Chapter 14 of the Listing Rules and the requirements under PN15 as and when appropriate. As the Proposed Spin-off is subject to, among other things, final approval by the Listing Committee, market conditions, and other considerations, the Proposed Spin-off may or may not materialize. Shareholders and other investors are advised to exercise caution when dealing in the securities of the Company. By order of the Board Genscript Biotech Corporation Robin Meng Chairman and Executive Director
Hong Kong, 4 September 2026
As at the date of this announcement, the executive Directors are Mr. Robin Meng, Dr. Frank Zhang, Dr. Li Zhu and Ms. Sally Wang; and the independent non-executive Directors are Dr. Alphonse Galdes, Mr. Andy Cheung, Mr. Ethan Pan, Dr. John Quelch, Dr. Ross Grossman and Dr. Victor Shi.
2
FF301
Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities For the month ended:
31 August 2026
Status: New Submission
To : Hong Kong Exchanges and Clearing Limited Name of Issuer:
Genscript Biotech Corporation
Date Submitted:
03 September 2026
I. Movements in Authorised / Registered Share Capital
- Class of shares
Ordinary shares
Type of shares
Stock code (if listed)
01548
Description
Not applicable
Number of authorised/registered shares Balance at close of preceding month Increase / decrease (-) Balance at close of the month
Listed on the Exchange (Note 1)
Par value
5,000,000,000 USD 0 5,000,000,000 USD Total authorised/registered share capital at the end of the month: USD
Page 1 of 10
Yes
Authorised/registered share capital 0.001 USD
5,000,000
USD
0
0.001 USD
5,000,000 5,000,000
v 1.2.1
FF301
II. Movements in Issued Shares and/or Treasury Shares and Public Float Sufficiency Confirmation
- Class of shares
Ordinary shares
Type of shares
Stock code (if listed)
01548
Description
Not applicable
Number of issued shares (excluding treasury shares) Balance at close of preceding month Increase / decrease (-) Balance at close of the month
Listed on the Exchange (Note 1)
Number of treasury shares
Yes
Total number of issued shares
2,188,831,343
0
11,760,354
0
2,200,591,697
0
2,188,831,343
2,200,591,697
Public float sufficiency confirmation (Note 4) Pursuant to Main Board Rule 13.32D(1) or 19A.28D(1) / GEM Rule 17.37D(1) or 25.21D(1), we hereby confirm that, in relation to the class of shares as set out above, as at the close of the month: ✔ the applicable public float requirement (see below) has been complied with the applicable public float requirement (see below) has not been complied with The applicable minimum public float requirement for the class of shares as set out above pursuant to Main Board Rule 13.32B or 19A.28B / GEM Rule 17.37B or 25.21B (as the case may be) is: Applicable public float threshold
Initial Prescribed Threshold - 25% of the total number of issued shares in the class to which the listed shares belong (excluding treasury shares)
Additional information
Page 2 of 10
v 1.2.1
FF301
III. Details of Movements in Issued Shares and/or Treasury Shares (A). Share Options (under Share Option Schemes of the Issuer)
- Class of shares
Ordinary shares
Type of shares
Stock code (if listed)
01548
Description
Particulars of share option scheme
1).
Number of share options outstanding at close of preceding month
Post-IPO Share Option Scheme
General Meeting approval date (if applicable)
Not applicable
Number of share options outstanding at close of the month
Movement during the month
21,847,294 Exercised - new shares involved
Listed on the Exchange (Note 1)
15,741,452
-6,105,842
Number of treasury Number of new shares shares transferred out of issued during the month treasury during the pursuant thereto (A1) month pursuant thereto (A2)
Yes
The total number of Number of shares which shares which may be may be issued or issued or transferred out transferred out of of treasury upon treasury pursuant exercise of all share thereto as at close of options to be granted the month under the scheme at close of the month
6,105,842
15,741,452
190,403,529
07 December 2015
Increase in issued shares (excluding treasury shares): Decrease in treasury shares: Total funds raised during the month from exercise of options: HKD
Page 3 of 10
6,105,842
Ordinary shares (AA1) Ordinary shares (AA2) 54,758,737
v 1.2.1
FF301 (B). Warrants to Issue Shares of the Issuer
Not applicable
Page 4 of 10
v 1.2.1
FF301 (C). Convertibles (i.e. Convertible into Shares of the Issuer)
Not applicable
Page 5 of 10
v 1.2.1
FF301 (D). Any other Agreements or Arrangements to Issue Shares of the Issuer, including Options (other than Share Option Schemes)
Page 6 of 10
Not applicable
v 1.2.1
FF301 (E). Other Movements in Issued Shares and/or Treasury Shares
- Class of shares
Ordinary shares
Type of shares
Stock code (if listed)
01548
Description
Not applicable
At price (if applicable) Events Currency 1).
Issue of new shares or transfer of treasury shares in respect of share awards granted under a share scheme - new shares involved
HKD
Listed on the Exchange (Note 1)
Date of event (Note 2)
General Meeting approval date (if applicable)
Increase/ decrease (-) in issued shares (excluding treasury shares) during the month pursuant thereto (E1)
20 August 2026
21 June 2024
5,654,512
Yes
Increase/ decrease (-) in treasury shares during the month pursuant thereto (E2)
Number of shares redeemed or repurchased for cancellation but not yet cancelled as at close of the month (Note 3)
Amount 0.00778
Increase/ decrease (-) in issued shares (excluding treasury shares): Increase/ decrease (-) in treasury shares:
Total increase/ decrease (-) in issued shares (excluding treasury shares) during the month (i.e. Total of AA1 to EE1): Total increase/ decrease (-) in treasury shares during the month (i.e. Total of AA2 to EE2):
Page 7 of 10
5,654,512
Ordinary shares (EE1) Ordinary shares (EE2)
11,760,354
Ordinary shares Ordinary shares
v 1.2.1
FF301
IV. Information about Hong Kong Depositary Receipt (HDR)
Not applicable
Page 8 of 10
v 1.2.1
FF301
V. Confirmations
Not applicable
Submitted by:
Jiange MENG
Title:
Director (Director, Secretary or other Duly Authorised Officer)
Page 9 of 10
v 1.2.1
FF301 Notes 1.
The Exchange refers to The Stock Exchange of Hong Kong Limited.
In the case of repurchase of shares (shares repurchased and cancelled) and redemption of shares (shares redeemed and cancelled), "date of event" should be construed as "cancellation date". In the case of repurchase of shares (shares held as treasury shares), "date of event" should be construed as "date on which shares were repurchased and held by the issuer in treasury".
The information is required in the case of repurchase of shares (shares repurchased for cancellation but not yet cancelled) and redemption of shares (shares redeemed but not yet cancelled). Please state the number of shares repurchased or redeemed during the month or in preceding month(s) but pending cancellation as at close of the month as a negative number.
"Initial Prescribed Threshold”, "Alternative Threshold” and "market value" have the meanings ascribed thereto under Main Board Rule 13.32A or 19A.28A / GEM Rule 17.37A or 25.21A. See also Main Board Rule 13.32D(4) or 19A.28D(4) / GEM Rule 17.37D(4) or 25.21D(4) on the basis of the public float disclosure.
Items (i) to (viii) are suggested forms of confirmation. The listed issuer may amend the item(s) that is/are not applicable to meet individual cases. Where the issuer has already made the relevant confirmations in a return published under Main Board Rule 13.25A / GEM Rule 17.27A in relation to the securities issued, or the treasury shares sold or transferred, no further confirmation is required to be made in this return.
“Identical” means in this context: .
the securities are of the same nominal value with the same amount called up or paid up;
.
they are entitled to dividend/interest at the same rate and for the same period, so that at the next ensuing distribution, the dividend/interest payable per unit will amount to exactly the same sum (gross and net); and
.
they carry the same rights as to unrestricted transfer, attendance and voting at meetings and rank pari passu in all other respects.
Page 10 of 10
v 1.2.1
(Equity issuer - changes in issued shares or treasury shares, share buybacks and/or on-market sales of treasury shares) Instrument:
Equity issuer
Name of Issuer:
Genscript Biotech Corporation
Date Submitted:
20 August 2026
Status:
New Submission
Section I must be completed by a listed issuer where there has been a change in its issued shares or treasury shares which is discloseable pursuant to rule 13.25A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Exchange”) (the “Main Board Rules”) or rule 17.27A of the Rules Governing the Listing of Securities on GEM of the Exchange (the “GEM Rules”). Section I
- Class of shares
Ordinary shares
Type of shares
Stock code (if listed)
01548
Description
Listed on the Exchange
Not applicable
Yes
A. Changes in issued shares or treasury shares Changes in issued shares (excluding treasury shares) Events
Opening balance as at (Note 1) 1).
31 July 2026
Issue of new shares or transfer of treasury shares in respect of share awards or options granted to a participant (who is not a director of the issuer) under a share scheme - new shares involved
Changes in treasury shares
As a % of existing number of issued shares (excluding treasury shares) before the relevant event (Note 3)
Number of issued shares (excluding treasury shares)
2,188,831,343 1,138,000
Issue/ selling price per share (Note 4)
Number of treasury shares
0 0.052 %
Total number of issued shares
2,188,831,343 HKD
7.078
Exercise of options pursuant to the Post-IPO share option scheme adopted on 7 December 2015 Date of changes
17 August 2026
Page 1 of 7
v 1.3.0
FF305 2).
Issue of new shares or transfer of treasury shares in respect of share awards or options granted to a participant (who is not a director of the issuer) under a share scheme - new shares involved
784,000
0.0358 %
HKD
10.002
567,000
0.0259 %
HKD
5.003
1,129,000
0.0516 %
HKD
5.393
14,588
0.0007 %
HKD
0.00778
5,639,924
0.2577 %
HKD
0.00778
Exercise of options pursuant to the Post-IPO share option scheme adopted on 7 December 2015 Date of changes 3).
18 August 2026
Issue of new shares or transfer of treasury shares in respect of share awards or options granted to a participant (who is not a director of the issuer) under a share scheme - new shares involved Exercise of options pursuant to the Post-IPO share option scheme adopted on 7 December 2015 Date of changes
4).
19 August 2026
Issue of new shares or transfer of treasury shares in respect of share awards or options granted to a participant (who is not a director of the issuer) under a share scheme - new shares involved Exercise of options pursuant to the Post-IPO share option scheme adopted on 7 December 2015 Date of changes
5).
20 August 2026
Issue of new shares or transfer of treasury shares in respect of share awards or options granted to a director of the issuer under a share scheme - new shares involved Allotment and issue of new shares on 20 August 2026 pursuant to the restricted share award scheme adopted on 23 August 2021 under the general mandate (details of which were disclosed in the announcements of the Company dated 19 November 2024). Date of changes
6).
20 August 2026
Issue of new shares or transfer of treasury shares in respect of share awards or options granted to a participant (who is not a director of the issuer) under a share scheme - new shares involved Allotment and issue of new shares on 20 August 2026 pursuant to the restricted share award scheme adopted on 23 August 2021 under the general mandate (details of which were disclosed in the announcements of the Company dated 24 August 2023, 28 November 2023, 13 June 2024, 8 July 2024, 19 August 2024, 19 November 2024, 11 June 2025 and 4 June 2026). Date of changes
20 August 2026
Closing balance as at (Notes 5 and 6) 20 August 2026
2,198,103,855
Page 2 of 7
0
2,198,103,855
v 1.3.0
FF305
B. Shares redeemed or repurchased for cancellation but not yet cancelled as at the closing balance date (Notes 5 and 6)
Page 3 of 7
Not applicable
v 1.3.0
FF305 Confirmation Pursuant to Main Board Rule 13.25C / GEM Rule 17.27C, we hereby confirm to the best knowledge, information and belief that, in relation to each issue of shares or sale or transfer of treasury shares as set out in Section I, it has been duly authorised by the board of directors of the listed issuer and carried out in compliance with all applicable listing rules, laws and other regulatory requirements and, insofar as applicable: (Note 7) (i)
all money due to the listed issuer in respect of the issue of shares, or sale or transfer of treasury shares has been received by it;
(ii)
all pre-conditions for the listing imposed by the Main Board Rules / GEM Rules under "Qualifications of listing" have been fulfilled;
(iii) all (if any) conditions contained in the formal letter granting listing of and permission to deal in the securities have been fulfilled; (iv) all the securities of each class are in all respects identical (Note 8); (v)
all documents required by the Companies (Winding Up and Miscellaneous Provisions) Ordinance to be filed with the Registrar of Companies have been duly filed and that compliance has been made with all other legal requirements;
(vi) all the definitive documents of title have been delivered/are ready to be delivered/are being prepared and will be delivered in accordance with the terms of issue, sale or transfer; (vii) completion has taken place of the purchase by the issuer of all property shown in the listing document to have been purchased or agreed to be purchased by it and the purchase consideration for all such property has been duly satisfied; and (viii) the trust deed/deed poll relating to the debenture, loan stock, notes or bonds has been completed and executed, and particulars thereof, if so required by law, have been filed with the Registrar of Companies. Notes to Section I: 1.
Please insert the closing balance date of the last Next Day Disclosure Return published pursuant to Main Board Rule 13.25A / GEM Rule 17.27A or Monthly Return pursuant to Main Board Rule 13.25B / GEM Rule 17.27B, whichever is the later.
Please set out all changes in issued shares or treasury shares requiring disclosure pursuant to Main Board Rule 13.25A / GEM Rule 17.27A together with the relevant dates of changes. Each category will need to be disclosed individually with sufficient information to enable the user to identify the relevant category in the listed issuer's Monthly Return. For example, multiple issues of shares as a result of multiple exercises of share options under the same share option scheme or of multiple conversions under the same convertible note must be aggregated and disclosed as one category. However, if the issues resulted from exercises of share options under 2 share option schemes or conversions of 2 convertible notes, these must be disclosed as 2 separate categories.
The percentage change in the number of issued shares (excluding treasury shares) of the listed issuer is to be calculated by reference to the opening balance of the number of issued shares (excluding treasury shares) being disclosed in this Next Day Disclosure Return.
Page 4 of 7
v 1.3.0
FF305 4.
In the case of a share repurchase or redemption, the “issue/ selling price per share” shall be construed as “repurchase price per share” or “redemption price per share”. Where shares have been issued/ sold/ repurchased/ redeemed at more than one price per share, a volume-weighted average price per share should be given.
The closing balance date is the date of the last relevant event being disclosed.
For repurchase or redemption of shares, disclosure is required when the relevant event has occurred (subject to the provisions of Main Board Rules 10.06(4)(a), 13.25A and 13.31 / GEM Rules 13.13(1), 17.27A and 17.35), even if the repurchased or redeemed shares have not yet been cancelled. If repurchased or redeemed shares are to be cancelled upon settlement of such repurchase or redemption after the closing balance date, they shall remain part of the issued shares as at the closing balance date in Part A. Details of these repurchased or redeemed shares shall be disclosed in Part B.
Items (i) to (viii) are suggested forms of confirmation. The listed issuer may amend the item(s) that is/are not applicable to meet individual cases.
“Identical” means in this context:
the securities are of the same nominal value with the same amount called up or paid up;
they are entitled to dividend/interest at the same rate and for the same period, so that at the next ensuing distribution, the dividend/interest payable per unit will amount to exactly the same sum (gross and net); and
they carry the same rights as to unrestricted transfer, attendance and voting at meetings and rank pari passu in all other respects.
Page 5 of 7
v 1.3.0
FF305 Section II must also be completed by a listed issuer where it has made a repurchase of shares which is discloseable under Main Board Rule 10.06(4)(a) / GEM Rule 13.13(1).
Repurchase report
Not applicable
Page 6 of 7
v 1.3.0
FF305 Section III must also be completed by a listed issuer where it has made a sale of treasury shares on the Exchange or any other stock exchange on which the issuer is listed which is discloseable under Main Board Rule 10.06B / GEM Rule 13.14B.
Report of on-market sale of treasury shares
Not applicable
Submitted by: Jiange Meng (Name) Title: Director (Director, Secretary or other Duly Authorised Officer)
Page 7 of 7
v 1.3.0
GenScript Reports 27.3% First-Half 2026 Revenue Growth as AI Drug Discovery Business Doubles
Aug 18, 2026
Adjusted net profit surges 203.3% as Gene-to-Protein generates two-thirds of GenScript Life Science Group revenue
PISCATAWAY, N.J., Aug. 18, 2026 -- GenScript Biotech Corporation (HKEX: 1548) reported first-half revenue of approximately US$404.2 million on a comparable basis, up 27.3% year over year, while adjusted net profit rose 203.3% to approximately US$62.5 million. The results reflect strong growth across its core businesses, improved operating efficiency, and accelerating demand for AI-enabled drug discovery services.

GenScript Biotech Corporation reports 27.3% revenue growth in the first half of 2026.
The AI-enabled drug discovery business doubled year over year and maintained rapid growth for a third consecutive half-year reporting period, driven by demand from AI-focused biotechnology companies and pharmaceutical innovators. Gene-to-Protein accounted for approximately 66% of GenScript Life Science Group revenue and remained the company's primary growth engine.
GenScript's Gene-to-Protein platform combines scientific expertise, automation, and global manufacturing capacity in an integrated workflow spanning discovery, experimental validation, early development, and production support. As AI increases the scale and complexity of drug discovery, these capabilities help customers validate candidates and advance programs with greater speed and reliability.
"Our first-half results reflect strong execution across the portfolio, with our core businesses driving both revenue growth and improved profitability," said Sherry Shao, Rotating CEO of GenScript. "We see significant long-term opportunity as AI reshapes life sciences and increases demand for experimental validation and development services. By expanding our global Gene-to-Protein platform, automation, digital manufacturing, and delivery network, we are strengthening GenScript's role as a critical infrastructure partner for AI-enabled drug discovery."
First-Half 2026 Highlights
GenScript Life Science Group
- Revenue of approximately US$319.0 million, up 28.8%
- Adjusted gross profit of approximately US$184.5 million, up 46.1%
- Adjusted operating profit of approximately US$94.0 million, up 102.8%
- Gene-to-Protein accounted for approximately 66% of segment revenue and remained the primary growth engine
AI-Enabled Drug Discovery
- AI-enabled drug discovery business doubled year over year and maintained rapid growth for a third consecutive half-year reporting period
- Growth reflects deeper engagement with AI drug discovery companies and increasing demand for protein engineering, biologics discovery, and development services, reinforcing GenScript's position as a validation and infrastructure partner within the AI drug discovery ecosystem
ProBio
- Revenue increased 34.2% on a comparable basis to approximately US$61.1 million
- New orders increased 54%
- Adjusted operating loss narrowed 22.5% to US$24.3 million
- Continued order growth and improving operating efficiency support ProBio's expectation of achieving positive adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) by 2027
Bestzyme
- Revenue of approximately US$30.4 million, up 7.4%
- Adjusted gross profit of approximately US$13.0 million, up 14.0%
Integrated Capabilities Support Growth Across the Portfolio
The recovery in global biopharmaceutical research activity and the expanding use of AI are increasing the number and complexity of programs moving from computational design into experimental validation, development, and production. This shift is creating demand for integrated scientific, automation, and manufacturing infrastructure that can support customers across the drug-development workflow.
GenScript connects gene synthesis, protein production, antibody discovery, biologics development, automation, and global manufacturing in a single workflow. This infrastructure enables AI-focused biotechnology companies and pharmaceutical innovators to validate more candidates, identify viable programs, and advance them through early development and production without coordinating multiple service providers.
To support rising demand, GenScript continues to invest across its global discovery and manufacturing network, expanding capacity, shortening turnaround times, and enhancing automation and digital workflows. These investments are improving consistency and scalability as AI-driven customer projects grow increasingly complex.
Across the portfolio, ProBio benefited from growing demand for biologics development and manufacturing services while improving operating performance and building an order base that supports future revenue growth. Bestzyme continues to invest in enzyme engineering and AI-enabled synthetic biology technologies designed to improve research efficiency, reduce production costs, and accelerate new product development.
Outlook
GenScript enters the second half of 2026 with continued momentum across GenScript Life Science Group, ProBio, and Bestzyme, supported by a growing order base across its core businesses.
The company expects higher demand, increased utilization across its global network, and further operating leverage to support continued revenue growth and profitability improvement. Ongoing investment in technology, automation, and capacity is expanding GenScript's ability to support larger and more complex AI-enabled drug discovery programs, while ProBio's growing order base and Bestzyme's enzyme engineering and AI-enabled synthetic biology capabilities provide additional platforms for long-term growth. As adoption expands across these businesses, GenScript expects to deepen customer relationships, strengthen global delivery, and build its position as a critical infrastructure partner supporting next-generation therapeutic and biotechnology innovation.
Additional financial information, including consolidated and segment results, is available in GenScript's First-Half 2026 Results Announcement published on The Stock Exchange of Hong Kong Limited on August 16, 2026, as well as on the GenScript website .
About GenScript
Founded in New Jersey in 2002, GenScript Biotech Corporation supports biotechnology and healthcare innovation through its integrated portfolio of research, development, and manufacturing services. Guided by its mission to Make People and Nature Healthier Through Biotechnology, GenScript has more than 6,100 employees and serves over 200,000 customers across more than 100 countries and regions, including the world's top 20 pharmaceutical companies. For more information, visit www.genscript.com .
Investor and Media Contacts
Investor Relations
Email: [email protected]
Media Contact
Kate Grusich, Senior Corporate Communications Manager
[email protected]
Service & Products
Resource
Tools
About us
Six months ended 30 June 2026 2025 2025
Revenue Gross profit Adjusted net profit Loss after income tax -Profit from GenScript core business -Share of loss from Legend (book basis) -Non-cash equity accounting impact on interest in Legend
Reported/ Underlying
Underlying
Reported
Underlying Basis Change
US$’000 404,216 206,711 62,523 (129,344 ) 25,557 (9,945 )
US$’000 317,413 139,707 20,614 (181,906) 11,792 (106,973)
US$’000 518,773 320,631 177,973 (24,547 ) 169,151 (106,973 )
% 27.3 48.0 203.3 28.9 116.7 90.7
(144,956 )
(86,725)
(86,725 )
(67.1)
(Note 1)
•
During the Reporting Period, the Group’s underlying business achieved robust growth. The revenue of the Group for the Reporting Period was approximately US$404.2 million, representing a YoY increase of 27.3% on an underlying basis.
•
During the Reporting Period, the gross profit of the Group was approximately US$206.7 million, representing a YoY increase of 48.0% on an underlying basis.
•
The adjusted net profit (Note 2) of the Group for the Reporting Period was approximately US$62.5 million, representing a YoY increase of 203.3% on an underlying basis.
•
The Group’s core business recorded a net profit of approximately US$25.6 million for the Reporting Period, representing a YoY increase of 116.7% from approximately US$11.8 million for the Prior Period on an underlying basis. The Group’s “core business” refers to the results of the Group excluding the equity accounting impact from Legend.
1
Taking into account the equity accounting impact from Legend, the Group recorded a net loss of approximately US$129.3 million for the Reporting Period. The equity accounting impact from Legend comprised (i) the share of loss from Legend on a book basis of approximately US$9.9 million, and (ii) non-cash equity accounting impact of approximately US$145.0 million, which consist of the share of amortization and depreciation arising from the fair value adjustments to Legend’s identifiable assets upon Deconsolidation, net of tax of approximately US$88.3 million and the dilution loss on deemed disposal of interests of approximately US$56.7 million. Further details are set out in Note 11 to the interim condensed consolidated financial statements in this announcement. Legend Group turned around from an adjusted net loss of approximately US$17.0 million for the Prior Period to an adjusted net income of approximately US$52.8 million for the Reporting Period (Note 3). Note 1: In this announcement, “underlying basis” refers to the financial figures of the Group excluding the financial impact arising from the license transaction with LaNova pursuant to the License Agreement that was recognised in the Prior Period. As no comparable item was recognised in the Reporting Period, the reported figures are the same as the underlying figures. The Reporting Period performance is compared with the Prior Period on a like-for-like basis using this non-HKFRS presentation. For the reported financial results prepared in accordance with HKFRS Accounting Standards, please refer to the Group’s interim financial information under HKAS 34 set out in this announcement. Note 2: Please refer to the section headed “Management Discussion and Analysis – Financial Review – Adjusted Non-HKFRS Measures” in this announcement. Note 3: For the adjusted net income of Legend Group, please refer to the financial results of Legend Group for the second quarter ended 30 June 2026. The related press release is available on the website of Legend Group at https://investors.legendbiotech.com/press-releases .
2
MANAGEMENT DISCUSSION AND ANALYSIS POSITIONING OF THE COMPANY The Group is a well-recognised biotechnology company. Based on our proprietary DNA synthesis technology and the other technology and know-hows on life-science research and application, we have well established three major platforms including: (i)
GenScript Life Science Group, a life-science services and products platform that offers comprehensive solutions and products to global research communities;
(ii)
ProBio, offering end-to-end CRDMO services from drug discovery to commercialisation with proactive strategies, professional solutions and efficient processes in advanced therapies, antibody and recombinant protein drug, aiming to accelerate drug development for customers; and
(iii)
Bestzyme, an industrial synthetic biology products platform.
These internally developed platforms have collectively demonstrated robust growth, transitioning from R&D to commercial delivery during the Reporting Period. Additionally, the Group holds significant investments in Legend, a fully integrated cell therapy company. The Group’s business operations extend across over 100 countries and regions globally. As of 30 June 2026, our professional workforce comprises 6,135 team members. GenScript Life Science Group, the foundational platform of the Group’s biotechnology infrastructure, provides integrated research services and products that enable biological discovery at global scale. Through proprietary integrated platforms, GenScript Life Science Group delivers a comprehensive suite of solutions spanning DNA synthesis, RNA synthesis, peptide synthesis, protein production, reagent antibody development, and life science instruments and consumables. These capabilities support scientists across pharmaceutical companies, biotechnology firms, and academic institutions accelerating the journey from research ideas to impactful biological discovery. By lowering the barriers of speed, cost, and technical complexity in early-stage research, GenScript Life Science Group plays a critical role in enabling the next generation of biologic medicines and advanced therapies worldwide. ProBio, a subsidiary of the Group, is a well recognised global CRDMO dedicated to empowering biologics and advanced therapy innovators with end-to-end solutions. Our integrated platforms seamlessly combine discovery, development, and manufacturing services, optimizing the development process, shortening timelines, and enhancing the success rate of biologics and advanced therapy projects. ProBio is committed to collaborating with customers in order to shape a healthier future. Bestzyme is a subsidiary of the Group engaged in the industrial enzyme and synbio products. Bestzyme uses advanced protein engineering technology to develop and produce innovative industrial enzymes, and to provide solutions for biofuel, food and beverage, distilling, starch, household care, textile, animal feed industries and functional proteins. We are also exploring new opportunities in synbio products, aiming to unlock new possibilities from both technical and commercial perspectives.
3
BUSINESS REVIEW During the Reporting Period, the external revenue of (i) GenScript Life Science Group, (ii) ProBio, and (iii) Bestzyme accounted for approximately 78.0%, 14.4% and 7.5% of the total revenue of the Group, respectively. The following table sets forth the financial performance of our three business segments during the Reporting Period and the Prior Period:
For the six months ended 30 June 2026
For the six months ended 30 June 2025
GenScript Life Science Group
ProBio
Bestzyme
GenScript Life Science Group
Reported/ Underlying
Reported/ Underlying
Reported/ Underlying
Reported/ Underlying
Underlying
Reported
Reported/ Underlying
US$’000
US$’000
US$’000
US$’000
US$’000
US$’000
US$’000
Revenue Adjusted gross profit
318,979 184,514
61,110 8,315
30,387 13,027
247,639 126,316
45,523 689
246,883 181,613
28,283 11,432
Adjusted selling and distribution expenses
(37,823)
(8,677)
(4,327 )
(34,529)
(6,146 )
(6,146 )
(3,631 )
Adjusted administrative expenses
(26,046)
(17,171)
(4,377 )
(22,999)
(23,334 )
(23,334 )
(3,668 )
Adjusted R&D expenses
(26,023)
(6,709)
(5,613 )
(22,262)
(2,981 )
(2,981 )
(4,693 )
(604)
(20)
(176)
454
454
(21 )
94,018
(24,262 )
(1,290 )
46,350
(31,318 )
149,606
(581 )
(Provision for)/Reversal of impairment of financial assets, net Adjusted operating profit/(loss)
The adjusted cost and expenses exclude the impact of the equity-settled share-based compensation expense.
4
ProBio
Bestzyme
Results Analysis of the Three Business Segments GenScript Life Science Group During the Reporting Period, revenue from GenScript Life Science Group was approximately US$319.0 million, representing an increase of 28.8% as compared with approximately US$247.6 million for the Prior Period. The adjusted gross profit was approximately US$184.5 million, representing an increase of 46.1 % as compared with approximately US$126.3 million for the Prior Period. The adjusted gross profit margin increased to 57.8% from 51.0% for the Prior Period. The adjusted operating profit was approximately US$94.0 million, representing an increase of 102.8% as compared with approximately US$46.4 million for the Prior Period. The notable increase in revenue, adjusted gross profit and adjusted operating profit was mainly attributable to the (i) accelerating demand for integrated gene-to-protein solutions, driven by structural growth in AIdriven drug discovery, (ii) improved profitability through continued investments in automation and digital manufacturing, and (iii) strengthened engagement with global pharmaceutical, biotechnology customers and AI-native customers through enhanced commercial execution, underpinned by a segmented go-tomarket strategy, data-driven customer engagement and integrated solution offerings. Building on the above growth in orders and revenue, the improvement in adjusted gross profit margin benefited from improved capacity utilisation and operating leverage, together with the positive impact of tariff rebates. ProBio During the Reporting Period, revenue from ProBio was approximately US$61.1 million. On an underlying basis, revenue increased by 34.2% YoY. The adjusted gross profit was approximately US$8.3 million, with adjusted gross profit margin improving to 13.6% for the Reporting Period from 1.5% for the Prior Period, while the adjusted operating loss narrowed to approximately US$24.3 million from approximately US$31.3 million for the Prior Period, each on an underlying basis. The increase in revenue and adjusted gross profit, together with the narrowed adjusted operating loss was primarily attributable to the strong recovery in upstream demand across the CRDMO industry, supporting the rapid expansion of biologics, plasmid and mRNA businesses, as well as continued growth in overseas markets. Gross profit margin and operating margin improved as economies of scale began to emerge with higher capacity utilisation and increased volumes, which also contributed to better absorption of depreciation costs. Meanwhile, the continued capacity build-out of the advanced therapy businesses supported our long-term growth potential, with related investments moderating the overall margin improvement to certain extent.
5
Bestzyme During the Reporting Period, revenue from Bestzyme was approximately US$30.4 million, representing an increase of 7.4% as compared with approximately US$28.3 million for the Prior Period. The adjusted gross profit was approximately US$13.0 million, representing an increase of 14.0% as compared with approximately US$11.4 million for the Prior Period. The adjusted gross profit margin increased to 42.9% for the Reporting Period from 40.4% for the Prior Period. The adjusted operating loss increased to approximately US$1.3 million from approximately US$0.6 million for the Prior Period. The increase in revenue and adjusted gross profit was primarily attributable to the (i) continuous growth in sales to key accounts, and (ii) enhanced product performance and improved cost efficiency through R&D innovation. The adjusted operating loss primarily reflected increased R&D investment and strategic expansion into the synthetic biology products field, including initiatives to strengthen the intellectual property portfolio and enhance AI-enabled synthetic biology platform.
FINANCIAL REVIEW For the six months ended 30 June 2026 (Unaudited) Reported/ Underlying US$’000
2025 (Unaudited)
2025 (Unaudited)
Underlying
Reported
US$’000
Underlying Basis Change
Reported Basis Change
US$’000
US$’000
US$’000
Revenue Gross profit Loss after income tax expense Adjusted net profit
404,216 206,711 (129,344) 62,523
317,413 139,707 (181,906) 20,614
518,773 320,631 (24,547) 177,973
86,803 67,004 52,562 41,909
(114,557) (113,920) (104,797) (115,450)
Loss attributable to owners of the Company Loss per share for the period (US cent) -Basic -Diluted
(129,343)
(182,821)
(25,462)
53,478
(103,881)
(5.92) (5.92)
(8.48) (8.48)
(1.18) (2.16)
2.56 2.56
(4.74) (3.76)
208,817 52,219 57,859 38,158
142,255 45,659 58,972 30,460
323,179 45,659 58,972 30,460
66,562 6,560 (1,113) 7,698
(114,362) 6,560 (1,113) 7,698
Adjusted profit and expenses: Gross profit Selling and distribution expenses Administrative expenses R&D expenses
Revenue During the Reporting Period, the Group recorded the revenue of approximately US$404.2 million. On an underlying basis, the Group’s revenue increased by 27.3% YoY, primarily attributable to the (i) sustained industry demand growth for AI-driven drug discovery and antibody drug discovery, accelerating the growth in gene-to-protein businesses, (ii) strong recovery in upstream demand across the CRDMO industry, which led to higher project intake and improved capacity utilization, and (iii) continued expansion of the industrial enzyme business, which contributed to a steady increase in sales during the Reporting Period.
6
Gross Profit During the Reporting Period, the Group recorded a gross profit of approximately US$206.7 million. On an underlying basis, the Group’s gross profit increased by 48.0% YoY, primarily attributable to the expansion of revenue, favorable business mix, improved capacity utilization and ongoing cost efficiency measures. Selling and Distribution Expenses During the Reporting Period, the Group’s selling and distribution expenses increased by 13.7% to approximately US$54.0 million from approximately US$47.5 million for the Prior Period. This is mainly attributable to the (i) continued investment in regional commercial capabilities to support business development and customer engagement in key global markets; and (ii) increased investment in the commercial talent pool through targeted recruitment of experienced sales professionals and enhanced incentive structures. Administrative Expenses During the Reporting Period, the Group’s administrative expenses remained relatively stable at approximately US$63.1 million, broadly in line with the Prior Period. The adjusted administrative expenses decreased by 1.9% YoY. R&D Expenses During the Reporting Period, the Group’s R&D expenses increased by 25.9% to approximately US$39.4 million from approximately US$31.3 million for the Prior Period. This is mainly attributable to the (i) continued R&D efforts to optimise existing processes and technologies, with improvements in production cycle times and operational efficiency, and (ii) exploration of new technology areas and applications to expand the Group’s addressable markets and support future growth. Fair Value Changes of ProBio Preferred Shares On 18 August 2021 (New York time), ProBio Cayman entered into a purchase agreement with certain investors, whereby ProBio Cayman sold 300,000,000 shares of ProBio Series A Preferred Shares and the ProBio Warrant exercisable for up to an aggregate of 189,393,939 ordinary shares of ProBio Cayman, the total proceeds of which were US$150.0 million. Pursuant to the purchase agreement, ProBio Cayman issued the ProBio Warrant to the investors to purchase the ordinary shares of ProBio Cayman at a certain price per share for up to an aggregate amount of US$125.0 million. The ProBio Warrant has expired in accordance with the terms and conditions of the purchase agreement. On 28 April 2025, the ProBio Series A Preferred Shares were purchased by the Company (through a direct wholly-owned subsidiary) pursuant to a share transfer agreement of the same date. Please refer to the announcements of the Company dated 14 May 2021, 7 June 2021, 19 August 2021, 5 September 2021, 28 April 2025 and 7 May 2025 for details. On 17 January 2023, ProBio Cayman entered into a subscription agreement with certain investors (including the Company), pursuant to which ProBio Cayman issued and sold, and the investors purchased an aggregate of 319,998,370 ProBio Series C Preferred Shares for an aggregate consideration of approximately US$224.0 million at the applicable closing. Please refer to the announcements of the Company dated 17 January 2023, 10 February 2023, and 21 April 2023 for details.
7
The ProBio Series A Preferred Shares and the ProBio Series C Preferred Shares are accounted for as financial liabilities measured at fair value with changes through profit or loss in accordance with the relevant HKFRSs. The ProBio Series A Preferred Shares were derecognised after being purchased by the Company. As at 30 June 2026, the fair value of the ProBio Series C Preferred Shares was assessed at approximately US$271.6 million. During the Reporting Period, the Group recorded fair value losses of approximately US$7.2 million were recorded in respect of the ProBio Series C Preferred Shares due to changes in the fair values of these financial liabilities. Financial Liabilities at Amortised Cost On 2 July 2022, ProBio Cayman entered into a subscription agreement with an investor, pursuant to which ProBio Cayman issued and sold, and the investor purchased 57,314,000 ProBio Series B Preferred Shares at an aggregate consideration of approximately US$37.3 million. The transaction was completed on 6 July 2022. Please refer to the announcements of the Company dated 4 July 2022 and 6 July 2022 for details. The ProBio Series B Preferred Shares are accounted for as financial liabilities at amortised cost for liability component and in other reserves for equity component. On 26 May 2023, BSJ Nanjing entered into a capital increase agreement with certain investors, pursuant to which the investors subscribed for the additional registered capital of BSJ Nanjing of RMB37,609,070 (equivalent to approximately US$5.3 million) for a total consideration of RMB250.0 million (equivalent to approximately US$35.2 million) to acquire approximately 10.4168% equity interest in BSJ Nanjing upon the closing. In connection with the BSJ Series A Capital Increase, the investors are entitled to the redemption right pursuant to the shareholder agreement dated 26 May 2023 entered into by, among others, the investors and BSJ Nanjing. Please refer to the announcements of the Company dated 28 May 2023 and 25 June 2023 for details. The BSJ Series A Capital Increase is accounted for as financial liabilities at amortised cost. As at 30 June 2026, the equity component of the ProBio Series B Preferred Shares in other reserves was assessed at approximately US$1.6 million, and the liability component was assessed at approximately US$45.5 million with interest expenses assessed at approximately US$1.4 million during the Reporting Period. The financial liabilities at amortised cost of the BSJ Series A Capital Increase were assessed at approximately US$44.6 million with interest expenses at approximately US$1.4 million during the Reporting Period. Income Tax Expense During the Reporting Period, the Group’s income tax expense decreased by 59.4% to approximately US$9.9 million from approximately US$24.4 million for the Prior Period. The decrease in the income tax expense was primarily due to lower taxable income compared with the Prior Period, which included significant taxable income arising from the license revenue recognised in the Prior Period. Net Loss During the Reporting Period, the net loss of the Group was approximately US$129.3 million, compared with the net loss of approximately US$24.5 million for the Prior Period. On an underlying basis, the Group’s net loss for the Prior Period was approximately US$181.9 million, against which the net loss for the Reporting Period narrowed by 28.9% YoY. The adjusted net profit of the Group was approximately US$62.5 million for the Reporting Period. 8
Reported Basis and Underlying Basis Unless otherwise indicated, the discussions on the YoY changes of the Group’s key financial indicators in this “Financial Review” section are presented on a reported basis. In discussing the YoY changes in the Group’s revenue, gross profit and net loss above, the Company has presented the trends on an underlying basis, which excludes the financial impact of the license transaction with LaNova pursuant to the License Agreement that was recognised in the Prior Period. The Group’s management believes this provides a more comparable view of the Group’s underlying business performance. On a reported basis, the YoY decline in the Group’s revenue and gross profit, as well as the widening of the Group’s net loss, were solely attributable to the absence of the financial impact arising from the aforementioned license transaction during the Reporting Period. Adjusted Non-HKFRS Measures To supplement the Group’s consolidated financial statements, which are prepared in accordance with HKFRS Accounting Standards, the Group presents certain non-HKFRS financial measures, including adjusted gross profit, adjusted operating profit, and adjusted net profit, as additional financial measures that are not required by, or presented in accordance with, HKFRS Accounting Standards. The Group believes that these non-HKFRS financial measures provide additional information to facilitate the understanding and assessment of the Group’s business performance and operating trends. The Group’s management considers that these measures are useful to the shareholders and investors in assessing the Group’s financial performance by excluding the impact of certain items that the Group considers may not be indicative of its underlying operating performance. The presentation of these non-HKFRS financial measures is not intended to be considered in isolation from, or as a substitute for, the financial information prepared and presented in accordance with HKFRS Accounting Standards. Shareholders and potential investors are advised to consider these non-HKFRS financial measures together with the Group’s financial results prepared in accordance with HKFRS Accounting Standards. The non-HKFRS financial measures may not be comparable to similarly titled measures presented by other companies.
9
Adjusted Net Profit For the six months ended 30 June 2026 2025 2025 Reported/ Underlying Reported Underlying US$’000 US$’000 US$’000 Net loss Excluding:
Equity-settled share-based compensation expense, net of tax Impact from acquisition and fair value losses/(gains) of preferred shares Losses on foreign currency forward and option contracts, net of tax Exchange losses/(gains), net of tax Fair value gains of non-current financial assets, net of tax Unrealised finance costs for equity financing activities Share of loss and deemed disposal loss from Legend Group
Adjusted net profit
(129,344)
(181,906)
(24,547)
10,382
8,904
8,904
7,205
(587 )
(587 )
149
11
11
17,978
(1,404 )
(1,404)
(1,532 )
(388 )
(388)
2,784
2,286
2,286
154,901
193,698
193,698
62,523
20,614
177,973
Note: In order to better reflect the key performance of the Group’s current business and operations, the adjusted net profit is calculated on the basis of net loss, excluding: (i) equity-settled share-based compensation expense; (ii) impact from acquisition and fair value changes of preferred shares; (iii) losses on foreign currency forward and option contracts; (iv) exchange gains or losses; (v) fair value gains of noncurrent financial assets, (vi) unrealised finance costs for equity financing activities; and (vii) share of loss and deemed disposal loss from Legend Group. Working Capital and Financial Resources The Group consistently adopted a prudent financial management policy. Fund management, financing and investment activities were all undertaken and monitored by the management of the Company. Given the industry characteristics of the core business of the Group, the emphasis of routine financial control management was placed on the management of working capital, particularly the timely receipts of trade receivables and payment arrangement of trade payables. The capital structure of the Group has been constantly monitored by the Company, which aims to monitor its working capital and financial resources to maintain a solid financial position. The use of any capital instruments (including banking facilities) by each subsidiary is subject to the overall coordination and arrangement of the Company. As at 30 June 2026, the wealth management financial products, time deposits and cash and cash equivalents of the Group amounted to approximately US$810.2 million (as at 31 December 2025: approximately US$812.0 million), and the restricted cash of the Group amounted to approximately US$21.0 million (as at 31 December 2025: approximately US$31.1 million). 10
As at 30 June 2026, the Group had total available unutilised bank facilities of approximately US$1.0 billion (as at 31 December 2025: approximately US$1.0 billion), comprising unutilised general banking facilities of approximately US$523.3 million and unutilised low-risk facilities of approximately US$499.1 million. As at 30 June 2026, the Group’s current ratio (current assets to current liabilities) was approximately 1.5 (as at 31 December 2025: approximately 1.5); and gearing ratio (total liabilities to total assets) was approximately 18.7% (as at 31 December 2025: approximately 18.3%). After considering its current cash and cash flows from operating activities, as well as the credit facilities available to the Group, it is believed that the Group has sufficient capital to fund its future operations and for business expansion and general development purposes. Treasury Policies The Group follows a set of funding and treasury policies to manage its capital resources and prevent risks involved. The Group invests surplus cash in the instruments issued by reputable and large-scale banks and financial institutions, only with reasonable expected return rates and controllable or predictable risks. The Group expects to fund its working capital and other capital requirements from a combination of various sources, including but not limited to necessary banking facilities. To mitigate the risks arising from the volatility of foreign exchange market and its impact on the Group’s operation, in accordance with the principle of risk neutrality, the Group uses proper derivative instruments to hedge foreign currency risks in the ordinary course of business, including foreign currency forward contracts and other related derivatives. Such hedging activities are based on the cashflow forecast by currency and the outlook on and expectation of future exchange rate fluctuations and are subject to the approval of the senior management of the Company. Capital Expenditure During the Reporting Period, the expenditure on the purchase of other intangible assets, primarily software, was approximately US$0.8 million, and the expenditure on the construction and purchase of property, plant and equipment amounted to approximately US$47.7 million. Significant Investments Held, Material Acquisitions and Disposals Significant investments in the material associate As at 30 June 2026, the Group held a significant investment in an associate company, Legend, with a carrying value of approximately US$2.9 billion, representing approximately 60.9% of the total assets of the Group. The Group holds approximately 45.03% equity interest in Legend. During the Reporting Period, the Group recognised the share of loss and deemed disposal loss of the Legend Group of approximately US$154.9 million. Legend Group is principally engaged in the discovery, development, manufacturing and commercialisation of novel cell therapies for oncology and other indications. With Legend Group’s improved operating performance and sustained uptake of its lead product CARVYKTI®, the Group remains optimistic about Legend’s long-term prospects and value creation potential. Details of the financial information of Legend Group are set out in notes 11 to the interim condensed consolidated financial statements in this announcement.
11
Significant investments in the financial assets As at 30 June 2026, significant investments held by the Group are as follows:
Financial assets at fair value through profit or loss Current Wealth management financial products (a) Listed equity investment Non-current Equity and funds investments (b)
Total
As at 30 June 2026 US$’000
As at 31 December 2025 US$’000
378,691 25 378,716
499,683 26 499,709
42,202 42,202
24,039 24,039
420,918
523,748
The current portion of financial assets at fair value through profit or loss mainly comprised wealth management financial products. The majority of the wealth management financial products we purchased during the Reporting Period were issued by banks and financial institutions in Chinese Mainland, Europe, Hong Kong and the U.S., and mainly included non-guaranteed floating-income product, and the money market fund with floating expected return rates ranging from 1.7% to 5.0% per annum and with maturity days between one day and one year. These products did not guarantee the return of principals upon maturity. As at 30 June 2026, we preserved all our invested capital in these products and did not encounter any default by the issuing banks and institutions, and none of our investments were past due or impaired. The Group has redeemed those wealth management financial products at maturation and has no intention of disposal of the investments in the long term. None of our investments had been pledged to secure our borrowings as at 30 June 2026. As part of our treasury management plan, we have purchased wealth management financial products as an auxiliary mean to improve the utilisation of our cash on hand in line with our cashflow forecast. We have made such purchases only when (i) we have surplus funds after we have fully considered the cash requirement of our operations for the future years and allocated accordingly; and (ii) our management has carefully assessed the risks and benefits and decides to make such purchases (including, among others, the availability of certain wealth management financial products which have high liquidity and generate finance income meeting our standards). All of the Group’s investments in wealth management financial products were made in low-risk, liquid and sound products. In addition, any purchase and early redemption of our investments in wealth management financial products shall be reviewed and approved by chief finance officer of the Group or other authorised personnel based on internal approval authority matrix.
12
(a) Information in relation to the wealth management financial products* as at 30 June 2026 are set out as follows: Item Banks/Financial institutions
Product type/description
Original amount RMB or US$
Investment cost US$’000
Fair value as at 30 June 2026 US$’000
CITIC Securities Company Limited
Non-guaranteed floating-income product
RMB162,651,197
23,881
25,084
CITIC Securities Company Limited
Non-guaranteed floating-income product
RMB71,000,000
10,424
10,662
China Merchants Bank
Non-guaranteed floating-income product
RMB100,000,000
14,682
15,243
Shanghai Pudong Development Bank Co., Ltd.
Non-guaranteed floating-income product
RMB100,000,000
14,682
14,951
Shanghai Pudong Development Bank Co., Ltd.
Non-guaranteed floating-income product
RMB160,000,000
23,492
23,497
CITIC Securities Company Limited
Non-guaranteed floating-income product
RMB57,720,000
8,475
8,686
China Merchants Bank
Non-guaranteed floating-income product
RMB100,000,000
14,682
14,692
China Merchants Bank
Non-guaranteed floating-income product
RMB100,000,000
14,682
14,703
China Merchants Bank
Non-guaranteed floating-income product
RMB318,243,009
46,726
47,609
CMB International Asset Management Limited
Money Market Fund
US$25,000,000
25,000
25,046
JPMorgan Distribution Services, Inc.
Money Market Fund
US$118,125,818
118,126
118,472
JPMorgan Chase Bank, N.A Hong Kong Branch
Non-guaranteed floating-income product
US$20,000,000
20,000
20,043
JPMorgan Asset Management (Europe) S.à r.l
Money Market Fund
US$14,800,000
14,800
14,845
CMB International Asset Management Limited
Non-guaranteed floating-income product
US$25,000,000
25,000
25,158
374,652
378,691
Total
- The above wealth management financial products have been already aggregated by issuing bank/financial institution and underlying financial products, with substantially similar products aggregated together.
13
(b) Information in relation to the equity and funds investments as at 30 June 2026 are set out as follows:
Name of investee company/fund Yuanming Prudence SPC – Healthcare Fund I Segregated Portfolio Panacea Venture Healthcare Fund I, L.P. Aima Biotechnology (Nanjing) Co., Ltd.* (艾碼生物科技(南
京)有限公司) Fund A** Fund B** 7G BIOVENTURES I, L.P. AffyXell Therapeutics Co., Ltd. Hanx Biopharmaceuticals (Wuhan) Co., Ltd.* (stock code: 3378)
(翰思艾泰生物醫藥科技 (武漢)股份有限公司) 20n Bio Limited KangaBio Mimulus LLC Total
Principal business or investment scope
Nature of investment
Fund investment
Investment in fund/securities
Fund investment
Investment in fund/securities
Equity investment
Investment in corporation
Fund investment Fund investment Fund investment Equity investment
Investment in fund/securities Investment in fund/securities Investment in fund/securities Investment in corporation
Equity investment
Investment in corporation
Equity investment Equity investment Equity investment
Investment in corporation Investment in corporation Investment in corporation
Number of shares/units/ Percentage of total amount of share capital/units investments owned by the Group held as at 30 June 2026 %
Investment Fair value as at Cost 30 June 2026 US$’000 US$’000
Percentage to the Group’s total assets as at 30 June 2026 %
Unrealised gain/(losses) on fair value changes during the six months ended 30 June 2026 US$’000
486.43
0.28
207
205
0.01
5
Not applicable
5.54
9,384
8,476
0.18
(27)
Not applicable
3.77
1,175
1,688
0.03
Not applicable
31.99
3,952
3,069
0.06
(396)
Not applicable
90.91
3,224
2,414
0.05
(841)
Not applicable
29.56
6,500
6,034
0.13
3
113,637
0.97
810
393
0.01
1,804,020
1.32
2,993
6,582
0.13
2,788
2,586,207
30.15
6,000
6,000
0.13
4,095,767
7.02
7,341
7,341
0.15
60
5.00
41,586
42,202
0.88
1,532
**The Company is subject to strict confidentiality obligations under which the name of the fund cannot be disclosed to any third party. As at the date of this announcement, to the best knowledge of the Company, each of the general partners, limited partners, and their ultimate beneficial owners of Fund A and Fund B is an independent third party who is, to the best of the Directors’ knowledge, information and belief having made all reasonable enquiry, independent of and not connected with the Company and the connected person(s) (as defined in the Listing Rules) of the Company. (Note) Given the value of investment in each financial asset at fair value through profit or loss does not constitute a notifiable transaction of the Company pursuant to Chapter 14 of the Listing Rules, as the applicable percentage ratios (as defined in Rule 14.07 of the Listing Rules), whether on a standalone or aggregate basis, are less than 5.0% of the total assets of the Group as of 30 June 2026, the Company has not prepared any analysis on their prospects.
14
During the Reporting Period, we recorded the net gains on the financial assets at fair value through profit or loss of approximately US$8.5 million. Save as disclosed above, the Group did not hold any other significant investments as at 30 June 2026, nor did it engage in any material acquisitions or disposals of subsidiaries and associated companies during the Reporting Period. Bank loans As at 30 June 2026, the Group had short-term interest-bearing loans from Citibank, HSBC China, China Merchants Bank, Agricultural Bank of China, Bank of China, and China CITIC Bank, respectively, for a total amount of approximately RMB1.2 billion (equivalent to approximately US$175.5 million) with fixed interest rates ranging from 2.1% to 2.11% per annum. These loans were used for the daily operation of subsidiaries located in the Chinese Mainland, of which approximately RMB172.9 million (equivalent to approximately US$25.4 million) is secured by credit. As at 30 June 2026, the Group had short-term interest-bearing loans from China Merchants Bank, Bank of China and Industrial Bank Co., Ltd., for a total amount of approximately RMB120.2 million (equivalent to approximately US$17.7 million) with fixed interest rates ranging from 0.58% to 0.86% per annum. Such loans were derived from the discounting of bank notes. Save as disclosed above, the Group did not have any other outstanding, unpaid bank loans and/or other borrowings. Provision, contingent liabilities and guarantees The Group did not have any material provision, contingent liabilities or guarantees as at 30 June 2026. No material adverse change The Directors confirm that there has been no material adverse changes in the financial or trading position of the Group from the information disclosed under “Management’s Discussion and Analysis” in the 2025 Annual Report and up to the date of this announcement. Charges on group assets As at 30 June 2026, the Group’s bank balances of approximately US$20.9 million were pledged and allocated for various purposes as follows: (i) approximately US$10.8 million as guarantee for certain financial products; (ii) approximately US$7.7 million as security deposits for rentals; (iii) approximately US$1.4 million for bills payable; (iv) approximately US$0.9 million for letters of guarantee; and (v) approximately US$0.1 million for credit card facilities. As at 30 June 2026, the properties acquired by Genscript Jiangsu and ProBio Zhenjiang amounted to approximately RMB220.1 million (equivalent to approximately US$32.3 million) were pledged to an affiliate of the Series B Investor (as defined in the announcement of the Company dated 4 July 2022) of ProBio so as to secure the performance of the redemption obligation of the Company and ProBio Cayman. Please refer to the announcements of the Company dated 29 June 2022 and 4 July 2022 for details. Save as disclosed above, the Group did not have any other material charges over its assets as at 30 June 2026. 15
Significant events after the Reporting Period Since 30 June 2026 and up to the date of this announcement, no subsequent significant events affecting the Group have occurred that would require disclosure under the Listing Rules. Future plans for material investments or capital assets To further solidify GenScript Life Science Group’s position as a critical enabler of next-generation biological discovery, the Group is continuing strategic investments in its gene-to-protein platform. As AI accelerates the pace and scale of drug discovery, GenScript is proactively expanding the capabilities, capacity, and connectivity required to support growing demand from top pharmaceutical, biotech and AI-driven drug discovery companies and platforms. Key capital allocations include the expansion of manufacturing and discovery infrastructure across our sites in the U.S. and Chinese Mainland, alongside accelerated deployment of automation, digitalization, and intelligent workflows. These investments are designed to enhance scalability, accelerate turnaround times, improve service reliability, and drive operational excellence. More importantly, they continue to build and strengthen GenScript’s long-term competitive position within the evolving AI-driven drug discovery ecosystem by providing the infrastructure required to translate biological insights into therapeutic innovation at scale. In the second quarter of 2026, ProBio successfully launched GMP lentiviral vector (LVV) manufacturing capabilities at its New Jersey facility. This milestone reinforces ProBio’s leadership position in the advanced therapy space, while our dual-site strategy—encompassing the Zhenjiang and New Jersey facilities—enables us to deliver flexible and resilient services to global advanced therapy clients. At the Zhenjiang facility, we have invested in a new Biologics Drug Substance suite equipped with 2,000 L single-use bioreactors, which is scheduled for launch in the third quarter of 2026. This addition will provide increased capacity and flexibility to better address rapidly growing global demand. In addition, ProBio plans to expand its discovery laboratory space in the second half of 2026 to accommodate rising discovery project’s needs. Looking forward, ProBio will continue to invest in earlystage T-cell engager (TCE) asset development, leveraging our differentiated CD3 single-domain antibody platform for out-licensing. These initiatives are underpinned by our robust capabilities and comprehensive technology platforms, backed by a proven track record in antibody drug discovery, engineering, and manufacturing. For Bestzyme, the Group plans to further optimise our manufacturing facilities and scale up production capacity in Chinese Mainland. To support future business growth, we will steadily expand enzyme production capacity while establishing new capabilities for innovative products such as sweet protein. Additionally, we are expanding and renovating our laboratories to meet the rising demand from AI driven innovation. The Group also plans to invest in upgrading supply chain and information technology infrastructures as well as other supporting functions to improve operating efficiency and accommodate strong business growth. Save as disclosed above, there was no other specific plan for material investments or capital assets as at 30 June 2026. The Group has sufficient resources in the form of cash and cash equivalents, time deposits and other financial assets to support the planned capital investments.
16
RISK MANAGEMENT Foreign exchange risk The Group conducts business in several countries and regions and transacts in multiple foreign currencies. The Group seeks to limit its exposure to the foreign currency risk by closely monitoring and minimising its cash outflow position of non-U.S. dollars. Since January 2019, the Group has engaged in a series of forward and option contracts, which are usually placed and adjusted quarterly, to manage the Group’s currency risk. The Group may choose not to hedge certain foreign exchange exposures due to immateriality, prohibitive economic cost of hedging particular exposures, or limited availability of appropriate hedging instruments. The Group currently focuses on managing its foreign exchange risk exposure in relation to RMB, aiming to keep such risk at an acceptable level by limiting hedging activities to operational cash flows only. The Group mitigates counterparty risk by executing foreign exchange contracts with only reputable financial institutions and banks. As at 30 June 2026, the Group had outstanding foreign currency forward contracts in respect of U.S. dollar against RMB, with a notional principal amount of approximately US$57.7 million (as at 31 December 2025: Nil). The management of the Company will continue to review the Group’s foreign exchange risk management procedures and will take actions as appropriate to minimise the Group’s exposure whenever necessary. The foreign currency forward contracts are derivatives and are recorded at fair value. The changes in their fair value were recognised in the consolidated statement of profit or loss. All of the foreign currency forward contracts are to be settled within one year. Cash flow and fair value interest rate risk As at 30 June 2026, other than bank balances with variable interest rates and time deposits with fixed interest rates, the Group had financial products of approximately US$374.7 million that were subject to the fair value interest rate risk. The sensitivity analysis for fair value interest rate risk is based on the Group’s exposure to financial assets at the end of the Reporting Period. If the interest rates had been 50 basis points higher or lower with all other variables held constant, our pre-tax loss for the Reporting Period would have been approximately US$0.9 million lower or higher, respectively. The Group is also exposed to the fair value interest rate risk in relation to lease liabilities and fixed-rate bank loans. The Company currently does not enter into any hedging instrument for the fair value interest rate risk. The Directors consider that the risk is insignificant, and therefore no sensitivity analysis on such risk has been prepared. Credit risk The carrying amounts of the Group’s cash and cash equivalents, trade and other receivables and other current assets are most exposed to the credit risk in relation to its financial assets. The Group’s credit risk measures aim to limit its exposure to non-recoverable amounts.
17
In respect of trade and other receivables, individual credit rating is performed on customers and counterparties. These evaluations focus on the counterparty’s business performance, including but not limited to financing activities, financial position, market economic environment and past history of payment punctuality. Prepayment requirements and credit limit are determined based on the credit rating and historical contracting amount, and are reviewed quarterly. Monitoring procedures have been implemented to ensure timely follow-up actions are taken to recover overdue debts. In addition, the Group monthly reviews the recoverable amount of each individual transaction and account’s revenue volume, outstanding balances, long-time past due invoices and payment records to ensure that adequate impairment losses are recognised for any irrecoverable amounts. Risks related to geopolitical factors, international trade agreements, tariffs and import/export regulations and export control and sanctions In recent years, there have been more uncertainties arising from geopolitical factors, including unilateral limitation of market access, renegotiation of international trade agreements, tariffs and export control and sanctions. In order to mitigate these risks, the Group has diversified its global manufacturing footprint and supply chain partners. (i)
Change in tariff and export/import regulations
U.S.-China trade tension remains palpable. Recently, both China and the U.S. imposed new tariffs on goods from the other. If additional burdens or restrictions were imposed on international trade that negatively affect the ability of both countries to import and export goods and services, this may lead to a decline in the supply of materials and the demand for the Group’s services. In order to mitigate this, the Group has diversified and enhanced its global service capabilities. (ii)
Export controls and economic sanctions
As the international trade environment, especially in the U.S. and Europe, becomes increasingly tightened, additional regulatory burdens may be imposed on the Group due to sanctions, import and export controls, and other trade control laws and regulations. We have been closely monitoring such changes in jurisdictions where we operate or have sales, and adjusting and improving our policies to remain compliant and to mitigate potential compliance risks. To mitigate aforesaid risks, effective from 5 February 2025, the Board has established the SubCommittee on Data Security and Geopolitical Resilience as a sub-committee of the Risk Management and ESG Committee for the purpose of, among others, supporting the Board in reviewing the effectiveness of the Company’s risk management in respect of geopolitical risks, data security and privacy risks and other relevant risks. The Group is aware of and has continuously kept monitoring the latest development of the trend and adopted appropriate measures accordingly.
18
PROSPECTS The global biotechnology industry continues to undergo profound transformation and accelerated innovation in the first half of 2026, fueled by breakthroughs in advanced therapies, antibody therapeutics, and AI-driven drug discovery. As therapeutic pipelines expand and biological complexity increases, demand for reliable discovery infrastructure and scalable research platforms continues to grow steadily. AI and machine learning are accelerating drug discovery, optimizing clinical trials, and enabling precision medicine, while co-development models between biotech companies and CRDMOs are fostering collaboration and innovation. Investments in infrastructure, such as plasmid and viral vector production, are enhancing supply chain resilience to meet the rising demand for gene therapies. Furthermore, synthetic biology is unlocking new opportunities in industrial applications, ranging from agriculture to sustainable manufacturing. Despite geopolitical and economic challenges, the biotech industry is expanding its global footprint. With continued scientific achievements and market-driven strategies, 2026 marks another pivotal year for the biotech sector, reinforcing the foundation for longterm growth and innovation. Within this evolving landscape, GenScript Life Science Group is positioned as a critical enabling platform for early-stage biological discovery. Since its establishment in 2002, the Group has supported more than 265,000 customers across over 100 countries, contributing to scientific progress in vaccines, antibody therapeutics, advanced therapies, diagnostics, and agricultural biotechnology. Looking ahead, GenScript Life Science Group will continue to strengthen its leadership through deeper integration of its gene-to-protein platform, expansion of global production capabilities, transition from customized services to standardized product offerings, and sustained investments in automation, AI-driven drug discovery technologies, and digital manufacturing systems. By combining platform integration, operational scale, and a global customer base, GenScript Life Science Group is well positioned to expand its addressable market and reinforce its role as a key infrastructure partner empowering the next generation of life science innovation. Biotech funding continued its recovery across U.S. and European CRDMO markets since 2025. In the first half of 2026, China has further solidified its position as an innovation hub, with increasing collaborations between Chinese biotechnology companies and multinational corporations. The recovery has continued to support our sales in 2026, particularly in the antibody drug CRDMO segment, and we anticipate sustained growth throughout the year. Additionally, 2025 marked a significant year for the CAR-T industry, with the rapid clinical development of in vivo CAR-T technology. This momentum continued into the first half of 2026, with additional clinical data further validating this approach. We are confident that our in vivo CAR-T service offerings will serve as a key driver for our advanced therapy CRDMO business in 2026 and subsequent years. With new capacity now operational in the U.S. and key milestones achieved, ProBio is strategically positioned to capitalize on the continued funding momentum in the industry by strengthening our presence and deepening client partnerships with access to investigator-initiated trials (IIT) in China. Our diversified capabilities and global platform uniquely enable us to navigate regional uncertainties while bolstering our confidence in sustainable growth. After years of dedicated efforts in product optimisation and production efficiency improvements, Bestzyme has emerged as one of the industry’s leading innovators. In addition to our enzyme products, we are developing synthetic biology solutions to explore potential business opportunities in new areas. We believe synthetic biology will serve more industrial applications with health and environmental benefits. With Legend Group’s improved operating performance and sustained uptake of its lead product CARVYKTI®, the Group remains optimistic about Legend’s long-term prospects and value creation potential. 19
EMPLOYEES AND REMUNERATION POLICIES As at 30 June 2026, the Group had a total of 6,135 employees, of which 10.3% were engaged in R&D roles. The Group had entered into employment contracts covering positions, employment conditions and terms, compensation, responsibilities for breach of contractual obligations, and reason for termination with its employees. The remuneration package of the Group’s employees includes basic salary, subsidies, other employee benefits, short-term and long-term incentives, which are determined with reference to their capability, responsibility, performance, and other general factors. During the Reporting Period, the Group’s total expenses (excluding equity-settled share-based compensation expense) on the remuneration of employees (including the Directors and the chief executive of the Company) were approximately US$166.5 million, representing approximately 41.2% of the total revenue of the Group, which was mainly due to that the Group views this as the necessary long-term investment in our talents pool. This investment has demonstrated the Group’s desires and resolutions to continue to strengthen its talent uplifting strategy. This talent uplifting strategy not only involves the recruitment of experienced professional and managerial personnel to fulfill the front-line posts of R&D, commercial and production functions, but also systematically increases the overall salary and benefits packages to sustain the stability of the employees to drive for long-term commitment and performance improvement as well. The Group’s remuneration policy and structure for remuneration of the Directors and senior management of the Group are based on the Group’s operating results, individual performance and comparable market statistics and are reviewed by the Remuneration Committee periodically. The remuneration of the independent non-executive Directors is recommended by the Remuneration Committee and is decided by the Board, while the remuneration of the executive Directors and senior management members of the Group is determined by the Remuneration Committee, having regard to their merit, qualifications and competence, the Group’s operating results and comparable market statistics.
RSU SCHEMES The Company adopted the 2019 RSU Scheme on 22 March 2019 (as amended on 21 June 2024 and 15 December 2025) and the 2021 RSU Scheme on 23 August 2021 (as amended on 26 May 2022, 21 June 2024 and 15 December 2025). During the Reporting Period, no RSUs have been granted under the 2019 RSU Scheme. During the Reporting Period, 14,736,658 RSUs were granted under the 2021 RSU Scheme on 4 June 2026. Please refer to the announcement of the Company dated 4 June 2026 for details. Among 14,736,658 RSUs granted on 4 June 2026, a total of 102,447 RSUs were not accepted by the relevant grantees. Save as disclosed above, no other RSUs have been granted under the 2021 RSU Scheme during the Reporting Period. For details regarding the RSU Schemes adopted by the Company, please refer to the corresponding section of the Company’s interim report for the Reporting Period to be published in due course.
20
DIRECTORS’ INTERESTS IN COMPETING BUSINESS During the Reporting Period, neither the Directors nor any of their close associates had any interests in any business which competed or was likely to compete, either directly or indirectly, with the business of the Group.
SUFFICIENCY OF PUBLIC FLOAT Based on information publicly available to the Company and within the knowledge of the Directors, the Directors confirmed that the Company had maintained a sufficient public float of more than 25% of the Company’s total number of the issued Shares (excluding the Treasury Shares) as required under the Listing Rules during the Reporting Period and up to the date of this announcement.
INTERIM DIVIDEND The Board resolved not to declare any interim dividend for the Reporting Period.
PURCHASE, REDEMPTION OR SALE OF THE LISTED SECURITIES During the Reporting Period, neither the Company nor any of its subsidiaries has purchased, sold or redeemed any of the Company’s listed securities (including sale of the Treasury Shares).
CORPORATE GOVERNANCE PRACTICES The Company is committed to maintaining high standards of corporate governance to safeguard the interests of the Shareholders and to enhance corporate value and accountability. The Company has adopted the CG Code contained in Appendix C1 to the Listing Rules as its own code of corporate governance. The Company has complied with all the applicable code provisions as set out in the CG Code during the Reporting Period and up to the date of this announcement. The Company will continue to review and enhance its corporate governance practices to ensure compliance with the CG Code.
MODEL CODE FOR SECURITIES TRANSACTIONS The Company has adopted its own Code for Securities Transaction on terms no less exacting than the required standard set out in the Model Code as set out in Appendix C3 of the Listing Rules. Specific inquiry has been made to all the Directors and each of the Directors has confirmed that he/she has complied with both the Code for Securities Transaction and the Model Code during the Reporting Period. The Code for Securities Transaction and the Model Code are also applicable to the Company’s relevant employees who are likely to be in possession of unpublished inside information of the Company in respect of their dealings in the Company’s securities. No incidents of non-compliance with the Code for Securities Transaction and the Model Code were noted by the Company during the Reporting Period.
21
AUDIT COMMITTEE The Company has established the Audit Committee. The Audit Committee currently comprises three members, namely Mr. Andy Cheung (chairman), Dr. Alphonse Galdes and Mr. Ethan Pan, all being independent non-executive Directors. The principal duties of the Audit Committee are (i) to review and monitor the Group’s financial reporting system, risk management and internal control systems, (ii) to maintain the relations with the external auditor of the Company, and (iii) to review the financial information of the Group. The Audit Committee has, together with the management and external auditors, reviewed the accounting principles and practices adopted by the Group’s unaudited condensed consolidated interim results for the six months ended 30 June 2026.
REVIEW OF INTERIM RESULTS The Audit Committee has reviewed the unaudited interim results of the Group for the six months ended 30 June 2026 and was of the opinion that such interim results had been prepared in accordance with the relevant accounting standards, laws and regulations, and that adequate disclosures have been made in accordance with the requirements of the Listing Rules.
22
The Board of the Company is pleased to announce the unaudited interim condensed consolidated results of the Group for the six months ended 30 June 2026, together with the comparative figures for the corresponding period in 2025, are as follows:
INTERIM CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS
Notes REVENUE
4
For the six months ended 30 June 2026 2025 (Unaudited) (Unaudited) US$’000 US$’000 404,216
518,773
Cost of sales
(197,505)
(198,142)
Gross profit
206,711
320,631
(414) (54,013) (63,089) (39,442) (7,205)
37,178 (47,509) (63,124) (31,321) (13,783)
(154,901) (58) (6,391)
(193,698) 292 (9,202)
(615)
417
Other income, gains and expenses, net Selling and distribution expenses Administrative expenses R&D expenses Fair value losses of preferred shares Share of losses and deemed disposal loss of associates: Investment in a significant associate Investment in other associates Finance costs (Provision for)/Reversal of impairment of financial assets, net
11
LOSS BEFORE TAX
5
(119,417)
(119)
Income tax expense
7
(9,927)
(24,428)
(129,344)
(24,547)
(129,343) (1)
(25,462) 915
(129,344)
(24,547)
Basic (US cent per share)
(5.92)
(1.18)
Diluted (US cent per share)
(5.92)
(2.16)
LOSS FOR THE PERIOD Attributable to: Owners of the parent Non-controlling interests
4
6
LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT
23
INTERIM CONDENSED COMPREHENSIVE INCOME
CONSOLIDATED
STATEMENT
OF
For the six months ended 30 June 2026 2025 (Unaudited) (Unaudited) US$’000 US$’000 LOSS FOR THE PERIOD
(129,344)
(24,547)
OTHER COMPREHENSIVE INCOME Other comprehensive (loss)/income that may be reclassified to profit or loss in subsequent periods: Share of other comprehensive (loss)/income of associates Reclassification of share of other comprehensive income to profit or loss upon partly deemed disposal of a significant associate Exchange differences on translation of foreign operations
(3,606)
87,419
(1,379) 34,815
4,815
OTHER COMPREHENSIVE INCOME FOR THE PERIOD
29,830
92,234
TOTAL COMPREHENSIVE (LOSS)/INCOME FOR THE PERIOD
(99,514)
67,687
Attributable to: Owners of the parent Non-controlling interests
(99,693) 179
66,742 945
(99,514)
67,687
24
INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION Notes NON-CURRENT ASSETS Property, plant and equipment Advance payments for property, plant and equipment, net Investment properties Right-of-use assets Goodwill Other intangible assets Investments in associates Financial assets at fair value through profit or loss Deferred tax assets Other non-current assets
10
11 12
Total non-current assets CURRENT ASSETS Inventories Contract costs Trade and bills receivables Prepayments, other receivables and other assets Financial assets at fair value through profit or loss Restricted cash Time deposits Cash and cash equivalents
13 12 14 14 14
Total current assets
25
30 June 2026 (Unaudited) US$’000
31 December 2025 (Audited) US$’000
567,438 11,853 4,524 71,570 1,410 13,382 2,944,566 42,202 12,892 3,745
536,774 10,583 4,715 75,918 1,366 13,252 3,086,644 24,039 16,436 4,582
3,673,582
3,774,309
45,250 34,661 156,803 45,860 378,716 21,031 235,194 196,358
39,594 21,954 133,934 40,367 499,709 31,129 169,793 142,488
1,113,873
1,078,968
INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION (CONTINUED) 30 June 2026 (Unaudited) US$’000
31 December 2025 (Audited) US$’000
42,324 137,522 193,185 8,777 8,946 64,431 271,663
36,787 138,288 194,669 9,161 28,691 48,193 264,381
Total current liabilities
726,848
720,170
NET CURRENT ASSETS
387,025
358,798
4,060,607
4,133,107
51,499 12,031 90,069 13,910
55,007 14,011 85,930 13,469
167,509
168,417
3,893,098
3,964,690
2,187 (2,263) 3,887,693 3,887,617
2,185 (3,832) 3,960,978 3,959,331
5,481
5,359
3,893,098
3,964,690
Notes CURRENT LIABILITIES Trade and bills payables Other payables and accruals Interest-bearing bank loans Lease liabilities Tax payable Contract liabilities Financial liabilities at fair value through profit or loss
15 16
17
TOTAL ASSETS LESS CURRENT LIABILITIES NON-CURRENT LIABILITIES Lease liabilities Deferred tax liabilities Financial liabilities at amortised cost Other payables and accruals
16
Total non-current liabilities NET ASSETS EQUITY Share capital Shares held for RSU Schemes Reserves Equity attributable to owners of the parent
18
Non-controlling interests TOTAL EQUITY
26
INTERIM CONDENSED FLOWS
CONSOLIDATED
Note
STATEMENT
OF
CASH
For the six months ended 30 June 2026 2025 (Unaudited) (Unaudited) US$’000 US$’000
Net cash flows generated from operating activities
46,669
232,619
Net cash flows generated from/(used in) investing activities
12,672
(98,645)
Net cash flows (used in)/generated from financing activities
(4,546)
26,403
NET INCREASE IN CASH AND CASH EQUIVALENTS Effect of foreign exchange rate changes, net Cash and cash equivalents at beginning of the period
54,795 (925) 142,488
160,377 839 131,990
196,358
293,206
CASH AND CASH EQUIVALENTS AT END OF THE PERIOD
27
14
NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION
-
CORPORATE INFORMATION The Company was incorporated on 21 May 2015 as an exempted company in the Cayman Islands with limited liability under the Companies Law of the Cayman Islands. The registered office address of the Company is 4th Floor, Harbour Place, 103 South Church Street, George Town, P.O. Box 10240, Grand Cayman KY1-1002, Cayman Islands. The Company is an investment holding company. The Company through its various subsidiaries manufactures and sells products and services, mainly including life-science services and tools, biologics development services and industrial synthetic biology products. The shares were listed on the Main Board of the Stock Exchange since 30 December 2015. In the opinion of the Directors, the ultimate holding company of the Company is GenScript Corporation, which was incorporated in the U.S..
-
BASIS OF PREPARATION 2.1
Basis of preparation
The interim condensed consolidated financial information for the six months ended 30 June 2026 has been prepared in accordance with Hong Kong Accounting Standard (“HKAS”) 34 Interim Financial Reporting. The interim condensed consolidated financial information does not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group’s annual consolidated financial statements for the year ended 31 December 2025. This interim condensed consolidated financial information are presented in United States dollars (“US$”) and all values are rounded to the nearest thousand except when otherwise indicated. 2.2
Changes in accounting policy and disclosures
The accounting policies adopted in the preparation of the interim condensed consolidated financial information are consistent with those applied in the preparation of the Group’s annual consolidated financial statements for the year ended 31 December 2025, except for the adoption of the following amended HKFRS Accounting Standards for the first time for the current period’s financial information. Amendments to HKFRS 9 and HKFRS 7
Amendments to the Classification and Measurement of Financial Instruments
Amendments to HKFRS 9 and HKFRS 7
Contracts Referencing Nature-dependent Electricity
Annual Improvements to HKFRS Accounting Standards – Volume 11
Amendments to HKFRS 1, HKFRS 7, HKFRS 9, HKFRS 10 and HKAS 7
The adoption of above amendments did not have any material effect on the Group’s financial performance and position.
28
OPERATING SEGMENT INFORMATION The segment information for the six months ended 30 June 2026, is as follows: Life-science services and products (Unaudited) US$’000
Biologics Industrial development synthetic biology services products (Unaudited) (Unaudited) US$’000 US$’000
Operation unit (Unaudited) US$’000
Eliminations (Unaudited) US$’000
Total (Unaudited) US$’000
Segment revenue Sales to external customers
315,218
58,028
30,387
583
404,216
Intersegment sales
3,761
3,082
32,590
(39,433)
Total segment revenue
318,979
61,110
30,387
33,173
(39,433)
404,216
Segment cost of sales
(135,486)
(53,849)
(17,386)
(29,191)
38,407
(197,505)
Segment gross profit
183,493
7,261
13,001
3,982
(1,026)
206,711
(485)
1,343
3,617
(3,840)
(1,049)
(414)
(39,283)
(8,929)
(4,346)
(1,530)
75
(54,013)
(28,005)
(17,615)
(4,488)
(13,204)
223
(63,089)
(27,079)
(6,852)
(5,642)
(466)
597
(39,442)
(15,459)
8,336
(82)
(7,205)
Finance costs
(2,739)
(2,611)
(2,339)
1,298
(6,391)
Share of losses and deemed disposal loss of associates: Investment in a significant associate Investment in other associates Provision for impairment of financial assets, net
(154,901)
(154,901)
(164)
106
(58)
(604)
(20)
(16)
25
(615)
Profit/(Loss) before tax
88,037
(43,010)
(633)
(163,872)
61
(119,417)
Other income, gains and expenses, net Selling and distribution expenses Administrative expenses R&D expenses Fair value (losses)/gains of preferred shares
29
The segment information for the six months ended 30 June 2025, is as follows: Life-science services and products (Unaudited) US$’000
Biologics development services (Unaudited) US$’000
Industrial synthetic biology products (Unaudited) US$’000
Operation unit (Unaudited) US$’000
Eliminations (Unaudited) US$’000
Total (Unaudited) US$’000
Segment revenue Sales to external customers
245,050
244,047
28,283
1,393
518,773
Intersegment sales
2,589
2,836
29,719
(35,144)
Total segment revenue
247,639
246,883
28,283
31,112
(35,144)
518,773
Segment cost of sales
(122,595)
(66,539)
(16,853)
(26,477)
34,322
(198,142)
Segment gross profit
125,044
180,344
11,430
4,635
(822)
320,631
(7)
4,205
1,683
17,406
13,891
37,178
(35,894)
(6,473)
(3,642)
(1,641)
141
(47,509)
(24,355)
(23,159)
(3,691)
(12,460)
541
(63,124)
(22,876)
(3,095)
(4,721)
(997)
368
(31,321)
(20,126)
20,713
(14,370)
(13,783)
(2,996)
(1,643)
(5,319)
756
(9,202)
(193,698)
(193,698)
Other income, gains and expenses, net Selling and distribution expenses Administrative expenses R&D expenses Fair value (losses)/gains of preferred shares Finance costs Share of losses and deemed disposal loss of associates: Investment in a significant associate Investment in other associates (Provision for)/Reversal of impairment of financial assets, net
338
(46)
292
(176)
454
(21)
128
32
417
Profit/(Loss) before tax
41,736
129,154
(267)
(171,279)
537
(119)
30
- REVENUE, OTHER INCOME, GAINS AND EXPENSES, NET An analysis of revenue, other income, gains and expenses, net is as follows: For the six months ended 30 June 2026 2025 (Unaudited) (Unaudited) US$’000 US$’000 Revenue from contracts with customers Revenue from other sources: Gross rental income from operating leases Others
Other income, gains and expenses, net Foreign exchange differences, net Gains on financial assets at fair value through profit or loss, net Interest income Subsidies Management service income Losses of foreign currency forward and option contracts, net Unrealised gains on acquisition of preferred shares Others
31
403,628
518,059
465 123
690 24
404,216
518,773
(21,511) 8,454 7,922 4,297 474 (175) 125
1,680 8,225 8,626 3,615 456 (14 ) 14,370 220
(414)
37,178
- LOSS BEFORE TAX The Group’s loss before tax from operations is arrived at after charging/(crediting): For the six months ended 30 June 2026 2025 (Unaudited) (Unaudited) US$’000 US$’000 Cost of services and products Depreciation of property, plant and equipment Depreciation of investment properties Depreciation of right-of-use assets Amortisation of other intangible assets Provision for/(Reversal of) impairment of financial assets, net Write-down of inventories and contract costs to net realisable value
111,042 33,040 44 6,006 1,330 615 341
124,370 28,543 47 5,057 1,245 (417) 587
Employee benefit expenses (including directors’ and chief executives’ remuneration): Wages and salaries Pension scheme contributions (defined contribution schemes) Equity-settled share-based compensation expense Less: Amount capitalised
155,867 10,658 10,431 (17)
132,790 10,163 9,575 (164)
176,939
152,364
860 (1,532) 21,511
22 (388) (1,680)
Loss on disposal of property, plant and equipment Fair value gains on non-current financial assets Foreign exchange differences, net
32
- FINANCE COSTS For the six months ended 30 June 2026 2025 (Unaudited) (Unaudited) US$’000 US$’000 Interest on financial liabilities measured at amortised cost Interest on bank loans Interest on lease liabilities Interest accrued on other payables
2,784 2,078 1,529
2,286 1,616 1,636 3,664
6,391
9,202
- INCOME TAX EXPENSE For the six months ended 30 June 2026 2025 (Unaudited) (Unaudited) US$’000 US$’000 Current — Chinese Mainland Current — the U.S. Current — Others Deferred income tax expense
7,889 1,490 (623) 1,171
6,085 (61) 1,560 16,844
Total tax charge for the period
9,927
24,428
- DIVIDENDS The Board of directors resolved not to declare any dividend for the six months ended 30 June 2026 (for the six months ended 30 June 2025: Nil).
33
- LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT The calculation of the basic loss per share amounts is based on the loss for the Reporting Period attributable to ordinary equity holders of the parent, and the weighted average number of ordinary shares of 2,183,409,040 (for the six months ended 30 June 2025: 2,154,852,609) in issue during the Reporting Period. The calculation of the diluted loss per share amount is based on the loss for the period attributable to ordinary equity holders of the parent. The weighted average number of ordinary shares used in the calculation is the number of ordinary shares in issue during the period, as used in the basic loss per share calculation, and the weighted average number of ordinary shares assumed to have been issued at no consideration on the deemed exercise of all dilutive potential ordinary shares into ordinary shares. The diluted loss per share is the same as the basic loss per share for the period ended 30 June 2026. This is because the preferred shares issued by a subsidiary, as well as the share options and restricted shares units of the Company, were anti-dilutive effect. The calculations of basic and diluted loss per share are based on: For the six months ended 30 June 2026 2025 (Unaudited) (Unaudited) US$’000 US$’000 Loss Loss attributable to ordinary equity holders of the parent, used in basic calculation Dilution effect arising from preferred shares issued by a subsidiary Loss attributable to ordinary equity holders of the parent, used in diluted calculation
(129,343)
(25,462 )
(21,080 )
(129,343)
(46,542 )
Number of shares For the six months ended 30 June 2026 2025 (Unaudited) (Unaudited) Shares Weighted average number of ordinary shares in issue during the period Effect of shares repurchased
2,185,337,993 (1,928,953)
2,157,984,701 (3,132,092)
Weighted average number of ordinary shares in issue during the period used in the basic loss per share calculation
2,183,409,040
2,154,852,609
Effect of dilution – adjustments for share options and awarded shares
1,221,941
Weighted average number of ordinary shares in issue during the period used in the diluted loss per share calculation
2,183,409,040
2,156,074,550
34
- PROPERTY, PLANT AND EQUIPMENT Total US$’000 As at 1 January 2025 (Audited) Additions Depreciation Disposal Exchange realignment
518,001 71,407 (60,477) (1,424) 9,267
As at 31 December 2025 and 1 January 2026 (Audited) Additions Depreciation Disposal Exchange realignment
536,774 50,919 (33,040) (1,215) 14,000
As at 30 June 2026 (Unaudited)
567,438
As at 30 June 2026, properties amounted to approximately US$32,313,000 (31 December 2025: approximately US$31,774,000) were pledged to an affiliate of the Series B Investor of ProBio Cayman as security for the redemption obligation of the Company and ProBio Cayman.
- INVESTMENTS IN ASSOCIATES 30 June 2026 (Unaudited) US$’000
31 December 2025 (Audited) US$’000
Investment in a significant associate Investments in other associates Less: Impairment loss provided
3,314,762 27,875 (398,071)
3,454,161 30,554 (398,071)
Net carrying amount
2,944,566
3,086,644
Legend Group is a global, commercial-stage biotechnology company developing and manufacturing novel therapies whose shares are listed by way of ADS on the Nasdaq Global Select Market in the U.S., and it is regarded as a significant associate and a strategic investment of the Group.
35
The following tables illustrate the summarised financial information in respect of Legend Group subject for appropriate adjustments made in order to account, for example, identifiable intangible assets based on the fair values at the Deconsolidation Date, and adjusted for any differences in accounting policies and reconciled to the carrying amount of the Group’s investment in Legend Group. 30 June 2026 (Unaudited) US$’000
31 December 2025 (Audited) US$’000
Non-current assets (Note) Current assets Current liabilities Non-current liabilities (Note)
5,957,528 1,227,400 403,600 921,395
6,148,434 1,247,100 636,400 939,053
Total identifiable net assets at fair value
5,859,933
5,820,081
Reconciliation to the Group’s interest in the associate: Proportion of the Group’s ownership Group’s share of identifiable net assets of Legend Group Equity method goodwill
45.03% 2,638,509 676,253
47.18% 2,745,635 708,526
Impairment loss provided
(398,071)
(398,071)
Carrying amount of the investment in Legend Group
2,916,691
3,056,090
For the six months ended 2026 2025 US$’000 US$’000 (Unaudited) (Unaudited) Financial results of Legend Group during the period: Revenue
692,600
450,111
Loss for the period, net of tax Other comprehensive loss, net of tax Total comprehensive loss
(21,100) (800) (21,900)
(226,296) 184,929 (41,367)
Subsequent amortisation and depreciation of fair value adjustment to Legend Group’s identifiable assets at the Deconsolidation Date, net of tax (Note)
(187,719)
(146,585)
Total
(209,619)
(187,952)
Note: The differences with Legend Group’s financial information are fair value adjustments to Legend Group’s identifiable assets as at the Deconsolidation Date, along with the associated tax impact. Subsequent amortisation and depreciation of these fair value adjustments have been incorporated into the Company’s equity accounting in subsequent periods.
36
The following table illustrates the movement of the carrying amount of the Company’s investment in Legend Group: Total US$’000 As at 31 December 2024 and 1 January 2025 (Audited) Share of loss from Legend Group’s loss for the year Share of subsequent amortisation and depreciation of fair value adjustments to Legend Group’s identifiable assets at the Deconsolidation Date, net of tax Loss on deemed disposal of interests during the year Share of other comprehensive income Share of the change in other reserves Impairment loss
3,653,932 (140,453)
As at 31 December 2025 and 1 January 2026 (Audited) Share of loss from Legend Group’s loss for the period Share of subsequent amortisation and depreciation of fair value adjustments to Legend Group’s identifiable assets at the Deconsolidation Date, net of tax Loss on deemed disposal of interests during the period Reclassification of share of other comprehensive income to profit or loss upon partly deemed disposal Share of other comprehensive loss Share of the change in other reserves
3,056,090 (9,945)
As at 30 June 2026 (Unaudited)
2,916,691
(156,471) (23,476) 90,078 30,551 (398,071)
(88,254) (56,702) (1,379) (353) 17,234
The following table illustrates the aggregate financial information of the Group’s associates that are not individually material: For the six months ended 30 June 2026 2025 (Unaudited) (Unaudited) US$’000 US$’000 Share of the associates’ (losses)/profits for the period Share of the associates’ total comprehensive (losses)/income
37
(58) (3,311)
292 292
- FINANCIAL ASSETS AT FAIR VALUE THROUGH PROFIT OR LOSS 30 June 2026 (Unaudited) US$’000
31 December 2025 (Audited) US$’000
378,691 25
499,683 26
378,716
499,709
42,202
24,039
42,202
24,039
30 June 2026 (Unaudited) US$’000
31 December 2025 (Audited) US$’000
Trade receivables Bills receivable
165,696 4,439 170,135
142,926 3,711 146,637
Impairment of trade receivables
(13,332)
(12,703)
156,803
133,934
Current Investments in financial products Listed equity investment
Non-current Equity and funds investments
- TRADE AND BILLS RECEIVABLES
An ageing analysis of the gross carrying amount of trade receivables as at the end of the Reporting Period, based on the invoice date, is as follows:
Within 3 months 3 to 6 months 6 to 12 months Over 1 year
38
30 June 2026 (Unaudited) US$’000
31 December 2025 (Audited) US$’000
117,537 22,498 9,633 16,028
101,342 15,881 9,821 15,882
165,696
142,926
- CASH AND BANK BALANCES 30 June 2026 (Unaudited) US$’000
31 December 2025 (Audited) US$’000
452,583
343,410
21,031
31,129
Current portion
235,194
169,793
Cash and cash equivalents
196,358
142,488
30 June 2026 (Unaudited) US$’000
31 December 2025 (Audited) US$’000
41,070 1,254
36,787
42,324
36,787
Cash and bank balances Less: Restricted cash Non-pledged time deposits:
- TRADE AND BILLS PAYABLES
Trade payables Bills payable
An ageing analysis of the trade payables as at the end of the Reporting Period, based on invoice date, is as follows:
Within 3 months 3 to 6 months 6 to 12 months Over 1 year
39
30 June 2026 (Unaudited) US$’000
31 December 2025 (Audited) US$’000
37,611 1,227 504 1,728
33,848 857 536 1,546
41,070
36,787
- OTHER PAYABLES AND ACCRUALS 30 June 2026 (Unaudited) US$’000
31 December 2025 (Audited) US$’000
47,822 36,251 23,237 7,848 2,184 20,180
55,009 33,951 21,153 6,934 2,126 19,115
137,522
138,288
12,619 1,291
12,173 1,296
13,910
13,469
Current Accrued payroll and welfare Payables for purchases of property, plant and equipment Accrued expenses Other tax payables Subsidies Other payables
Non-current Subsidies Others
- FINANCIAL LIABILITIES AT FAIR VALUE THROUGH PROFIT OR LOSS
ProBio Series C Preferred Shares Foreign currency forward contracts
30 June 2026 (Unaudited) US$’000
31 December 2025 (Audited) US$’000
271,586
264,381
77
271,663
264,381
The movements of the above preferred shares are set out below: Total US$’000 As at 1 January 2026 (Audited) Fair value changes
264,381 7,205
As at 30 June 2026 (Unaudited)
271,586
As at 1 January 2025 (Audited) Acquired by the Group’s subsidiary Fair value changes
473,732 (239,512) 30,161
As at 31 December 2025 (Audited)
264,381
40
- SHARE CAPITAL 30 June 2026 (Unaudited) US$’000
31 December 2025 (Audited) US$’000
Shares Authorised: Ordinary shares of US$0.001 each
5,000
5,000
Issued and fully paid: Ordinary shares of US$0.001 each
2,187
2,185
A summary of movements in the Company’s number of shares in issue and share capital is as follows:
As at 1 January 2026 (Audited) Exercise of share options and restricted share units As at 30 June 2026 (Unaudited)
41
Number of shares in issue
Share capital US$’000
2,184,705,170
2,185
2,155,839
2
2,186,861,009
2,187
PUBLICATION OF THE UNAUDITED INTERIM CONDENSED CONSOLIDATED RESULTS AND INTERIM REPORT FOR THE REPORTING PERIOD ON THE WEBSITES OF THE STOCK EXCHANGE AND THE COMPANY This unaudited interim condensed consolidated results announcement for the Reporting Period is published on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.genscript.com), and the interim report for the Reporting Period containing all the information required by the Listing Rules will be published on the respective websites of the Stock Exchange and the Company in due course.
ACKNOWLEDGEMENT The steady development of the Group has always been trusted and supported by the Shareholders, investors and business partners of the Company as well as the loyalty of our staff members. On behalf of the Board, I express my heartfelt gratitude.
DEFINITIONS “2019 RSU Scheme”
the restricted share unit scheme of the Company adopted on 22 March 2019 and subsequently amended on 21 June 2024 and 15 December 2025;
“2021 RSU Scheme”
the restricted share unit scheme of the Company adopted on 23 August 2021 and subsequently amended on 26 May 2022, 21 June 2024 and 15 December 2025;
“2025 Annual Report”
the annual report of the Company for the year ended 31 December 2025;
“ADS”
American Depositary Shares;
“AI”
Artificial intelligence;
“Andy Cheung”
Mr. Yiu Leung Andy Cheung, an independent non-executive Director;
“Audit Committee”
the audit committee of the Board;
“Bestzyme”
Bestzyme Biotech Corporation, an exempted company incorporated under the laws of the Cayman Islands with limited liability and a direct wholly-owned subsidiary of the Company;
“Board”
the board of Directors;
“BSJ Nanjing”
Nanjing Bestzyme Bioengineering Co., Ltd.* (南京百斯傑生物工程有限公司), an indirect non-wholly owned subsidiary of the Company;
“BSJ Series A Capital Increase”
a capital increase of RMB37,609,070 of BSJ Nanjing pursuant to a capital increase agreement dated 26 May 2023 entered into among BSJ Nanjing and certain investors;
“CAR-T”
chimeric antigen receptor T-cell;
“CG Code”
the Corporate Governance Code as contained in Appendix C1 to the Listing Rules;
“cilta-cel”
ciltacabtagene autoleucel; 42
“Code for Securities Transaction”
the Code for Securities Transaction by Directors and Specified Individuals adopted by the Company;
“Company” or “GenScript”
Genscript Biotech Corporation, an exempted company incorporated under the laws of the Cayman Islands with limited liability;
“CRDMO”
contract research, development and manufacturing organisation;
“Deconsolidation”
the deconsolidation of Legend Group from the Company on 18 October 2024 and was reclassified as an associate thereafter;
“Deconsolidation Date”
18 October 2024, the date when Legend Group was deconsolidated from the Company and was reclassified as an associate thereafter;
“Director(s) ”
the director(s) of the Company;
“DNA”
deoxyribonucleic acid;
“Ethan Pan”
Mr. Jiuan Pan, an independent non-executive Director;
“GenScript Life Science Group”
the life-science services and products segment of the Group;
“GMP”
Good Manufacturing Practice;
“Group”
the Company together with its subsidiaries;
“HKFRS”
Hong Kong Financial Reporting Standards;
“Hong Kong”
the Hong Kong Special Administrative Region of the PRC;
“Frank Zhang”
Dr. Fangliang Zhang, an executive Director;
“Janssen”
Janssen Biotech, Inc.;
“LaNova”
LaNova Medicines Ltd.;
43
“Legend” or “Legend Biotech”
Legend Biotech Corporation, an associate of the Company, whose shares are listed by way of ADS on the NASDAQ Global Select Market in the U.S.;
“Legend Group”
Legend together with its subsidiaries;
"License Agreement"
a restated and amended license agreement dated 12 November 2024 entered into between Nanjing ProBio Biotech Co., Limited* (南京蓬勃生物科技有限公司) and LaNova in connection with the sublicense of anti-PD-1 single domain antibody;
“Listing Rules”
the Rules Governing the Listing of Securities on the Stock Exchange as amended or supplemented from time to time;
“Model Code”
the Model Code for Securities Transactions by Directors of Listed Issuers contained in Appendix C3 to the Listing Rules;
“PRC”, “China” or “Chinese Mainland”
the People’s Republic of China, for the purpose of this announcement, excluding Hong Kong, the Macau Special Administrative Region and Taiwan;
“Prior Period”
six months ended 30 June 2025;
“ProBio” or “ProBio Cayman”
Probio Technology Limited, an exempted company incorporated in the Cayman Islands with limited liability and a non-wholly owned subsidiary of the Company;
"ProBio Series A Preferred Shares"
the series A preferred shares of ProBio Cayman;
“ProBio Series B Preferred Shares”
the series B preferred shares of ProBio Cayman;
“ProBio Series C Preferred Shares”
the series C preferred shares of ProBio Cayman;
“ProBio Warrant”
a warrant issued by ProBio Cayman exercisable for up to an aggregate of 189,393,939 ordinary shares of ProBio Cayman;
“ProBio Zhenjiang”
Zhenjiang ProBio Biotech Co., Ltd.* (鎮江蓬勃生物科技有限公司), a nonwholly owned subsidiary of the Company;
“Genscript Jiangsu”
Jiangsu GenScript Biotech Co., Ltd.* ( 江蘇金斯瑞生物科技有限公司 ), a wholly-owned subsidiary of the Company;
“R&D”
research and development;
“Remuneration Committee”
the remuneration committee of the Board;
“Reporting Period”
six months ended 30 June 2026;
“RNA”
Ribonucleic acid;
“Robin Meng”
Mr. Jiange Meng, the chairman of the Board and an executive Director;
44
“RSU(s) ”
any restricted share unit(s) representing the same number of Shares that have been or may be granted by the Company to pursuant to the RSU Schemes which have been or may be vested in the form of Shares issued or otherwise transferred by the Company and/or trust to selected participants;
“RSU Schemes”
collectively, the 2019 RSU Scheme and the 2021 RSU Scheme;
“Sally Wang”
Ms. Ye Wang, an executive Director;
“Share(s) ”
the ordinary share(s) in the share capital of the Company with a par value of US$0.001 each;
“Shareholder(s) ”
holder(s) of the Shares;
“Stock Exchange”
The Stock Exchange of Hong Kong Limited;
“Treasury Shares”
has the meaning ascribed to it under the Listing Rules as amended from time to time;
“U.S. ”
the United States of America;
“US$”
U.S. dollar;
“Victor Shi”
Dr. Chenyang Shi, an independent non-executive Director;
“YoY”
year-over-year; and
“%”
per cent.
By order of the Board Genscript Biotech Corporation Robin Meng Chairman and Executive Director Hong Kong, 16 August 2026 As at the date of this announcement, the executive Directors are Mr. Robin Meng, Dr. Frank Zhang, Dr. Li Zhu and Ms. Sally Wang; and the independent non-executive Directors are Dr. Alphonse Galdes, Mr. Andy Cheung, Mr. Ethan Pan, Dr. John Quelch, Dr. Ross Grossman and Dr. Victor Shi.
45
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding Genscript Biotech Corporation
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| MCH | 0.51% | 76,000 | $ 118.525K | Jun 30, 2026 |
| AVEE | 0.23% | 78,000 | $ 297.876K | Nov 16, 2026 |
| AVEM | 0.10% | 6,736,000 | $ 25.724M | Nov 16, 2026 |
| AVSE | 0.10% | 54,000 | $ 206.222K | Nov 16, 2026 |
| DFEM | 0.09% | 2,014,000 | $ 8.174M | Nov 12, 2026 |
| AVES | 0.05% | 195,000 | $ 744.69K | Nov 16, 2026 |
| DFAE | 0.05% | 1,076,000 | $ 4.367M | Nov 12, 2026 |
| DFAX | 0.04% | 1,162,000 | $ 4.716M | Nov 12, 2026 |